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CHAPTER 1: INTRODUCTION TO
PROTEIN FOLDING AND STRATEGIES TO DISULFIDE BOND FORMATION IN
NEUROACTIVE PEPTIDES.

1.1 Disulfide Bonds in Proteins and peptides
In both proteins and peptides, disulfide bonds are formed as a reversible covalent
bond between the side chain thiol groups of two cysteine residues. The cysteine amino
acid residue is the only amino acid capable of forming disulfide bonds, and thus it become
a unique residue among the proteinogenic amino acids.1 Disulfide bonds enforce
conformational constraints and stabilize the tertiary structure of peptides.2 In addition,
disulfide bonds prevent proteins from aggregation and subsequent degradation by cellular
proteases, thus increasing their half-life.3,4 The formation of disulfide bonds is a key posttranslational modification in the folding and assembly of the extracellular domains of many
membranes and secreted proteins.5,6,7
Most classes of extracellular proteins and peptides, including hormones,
neurotransmitters, growth factors, toxins and enzyme inhibitors often have several
disulfide bonds.8 In nature, disulfide bonds are common in bacteria, microalgae, plant and
animal peptide toxins.9 Disulfide-rich mini-proteins derived from plants are known as
cyclotides, which consist of 28-37 residues and display a cysteine knot motif composed
of three disulfide bonds.10,11 Cyclotides are exceptionally stable and serve a range of
natural bioactivities such as antiviral and antimicrobial behaviors, which make them
potential therapeutics.12,13,14,15 The poisonous and venomous animals such as spiders,
snakes, scorpions, shellfish, cone snails produce complex venom cocktails with
thousands of unique bioactive compounds.16,17 The disulfide-rich compact architectures
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of these venoms make them resistant to extreme pH conditions and stable to high
temperatures and organic solvents.18,19 In addition, these disulfide-rich peptides have
high binding affinity and specificity towards their cognate receptors, which make animal
toxins extremely valuable pharmacological tools.20,21,22
Conus peptides are natural peptides with sufficiently complex and diverse disulfide
bond patterns in their structure. Hence, in this study, among all toxins, conotoxins were
chosen as excellent model system to study disulfide bond formation in peptides.
1.2 Conotoxins as Source of Disulfide-Rich Mini-peptides
Conotoxins are neurotoxic peptides isolated from venom of Conus marine snails.23
They are mini-proteins consisting of 10 – 50 amino acid residues and typically have one
or more disulfide linkages. Over 500 different species of cone snails have been identified
and majority of them are carnivorous predatory sea snails and marine gastropod molluscs
that use venom-based strategy to capture their prey.24 All of the cone snails are
venomous and produce conotoxins of 20 – 200 extremely complex components
composed of modified peptides.25 The exact composition of conotoxins varied widely
from one species of cone snail to another; a rough estimate of the conotoxin diversity is
that ~ 50,000 different peptides.26 Generation of such a huge diversity of conotoxin is
based on specific target macromolecules, mainly ion channels or receptors, and target
animals, such as prey, predator or competitor. The huge diversity of conotoxins also
evolved from various hyper mutations of the primary amino acid sequence, different
cysteine patterns and disulfide scaffolds27,28 (Figure 1.1).
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Figure 1.1 Different cysteine patterns and disulfide scaffolds in conotoxins
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Conotoxins have well-defined, compact structures, stabilized by different patterns of
disulfide bonds. For two disulfide-bond conotoxins, either a ribbon or globular shape is
more prominent.29 For three disulfide-bond conotoxins, the structure varies from a
globular shape to compact, cage-like structures.

4
Moreover, diversity of disulfide-bond mediated structural frameworks improve the
stability, potency and selectivity of conotoxins.30,31 Many of these conotoxins modulate
the activity of ion channels. The action of conotoxins is fast, which can immobilize the
injected prey by affecting its nervous system to cause massive membrane depolarization
followed by an irreversible neuromuscular block.32 This effect results from simultaneous
inhibition of voltage-gated sodium and potassium channels.33 This phenomena indicates
the potential of conotoxins as inhibitors for specific ion channels (voltage-gated Na+, K+
and Ca2+ ion channels) and receptors (serotonin, acetylcholine) with high affinities and
selectivities.
The conotoxins have been divided into a number of major classes based on their
cysteine frameworks and physiologically relevant target (Table 1.1).34 The high selectivity
of conotoxins facilitates discrimination of closely related molecular isoforms of members
of a particular ion channel family. For example, µ-conotoxins, which targets tissue specific
sodium ion channel, inhibit voltage-sensitive sodium ion channels in muscles, with only
minimum binding to neuronal sodium channel.35 Some conotoxins show species-specific
binding, where they have the ability to bind to same site of receptors, but produce different
results. For example, d-conotoxin such as conotoxin SVIA from Conus striatus bind with
high affinity to voltage-independent sodium channels, and in contrast, Conus
purpurascens which produce d-conotoxin such as conotoxin PVIA have specific binding
to voltage-sensitive channel.36
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Table 1.1 Diversity conotoxins and their molecular targets
Conotoxins

Primary sequence

Molecular targets

A-superfamily
α-GI

ECCNPACGRHYSC#

nAChRs

α-ImI

GCCSDPRCAWRC#

nAChRs

α-SI

ICCNPACGPKYSC#

nAChRs

NGVCCGYKLCHOC

NET

T-superfamily
χ-MrIA
M-superfamily
µ-GIIA

RDCCTOOKKCKDRQCKOQRCCA#

VGSCs

µ-PIIA

ZRLCCGFOKSCRSRQCKOHRCC#

VGSCs

µ-SmIIIA

ZRCCNGRRGCSSRWCRDHSRCC#

VGSCs

µ-SIIIA

ZNCCNGGCSSKWCRDHARCC#

VGSCs

µM-RIIIK

LOSCCSLNLRLCOVOACKRNOCCT

VGKCs

ω-MVIIA

CKGKCAKCSRLMYDCCTGSCRSGKC#

VGCCs

ω-MVIIC

CKGKGAPCRKTMYDCCSGSCGRRGKC#

VGCCs

ω-GVIA

CKSOGSSCSOTSYNCCRSCNOOYTKRCY#

VGCCs

µ-Ο-MrVIB

ACSKKWEYCIVPILGFVYCCPGLICGPFVCV

VGSCs

δ-SVIE

EASSSGGTFCGIHPGLCCSEFCFLWCITFID

VGSCs

δ-PVIA

EACYAPGTFCGIKPGGLCCSEFCLPGVCFG#

VGSCs

δ-TxVIA

CKQSGEMCNLLDQNCCDGYCIVLVCT

VGSCs

O-superfamily

nAChRs - nicotinic acetylicholine receptors, VGSCs - voltage-gated sodium channels, VGCCs - voltage-gated
calcium channels, VGKCS - voltage-gated potassium chennels, NET - norepinephrine transporter, O hydroxyproline, Z - puroglutamatae, # - Amidated C-terminal,
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There are thousands of conotoxin-mediated selective bindings toward ion
channels and receptors, which make conotoxins extremely valuable tools in biomedical
research. The venom produced from Conus magus have shown promising activity as a
non-addictive pain reliever 1000 times as powerful as morphine.37 Furthermore, conotoxin
AVCI from Conus victoriae has excellent potential for treating post-surgical and
neuropathic pain, even accelerating recovery from nerve injury.38 The first venom-derived
painkiller, Ziconotide, was approved by the U.S. Food and Drug Administration in 2004
under the name “Prialt”. It is an w-conotoxin and acts by blocking calcium channels on
the surface of the nerve cells that transmit the pain signal. Ziconotide can interfere with
the transmission of pain signals within the spine, which aids to relieve pain.29 There are
many venom-based drugs in clinical and preclinical trials, which have potential in
treatment of Alzheimer’s disease, Parkinson’s disease and epilepsy.39
1.3 Disulfide Bonds and Protein Folding
The mechanism by which the small, disulfide-rich peptides form their native
disulfide bonds remain far from understood, and how these mini-proteins fold in vivo is
one of the key unsolved problems in the field.40 This is mainly due the challenges in
identification and characterization of folding intermediates that are only very transiently
present. However, majority of detailed in vitro folding studies have been done using model
peptides such as BPTI,41,42 Hirudin43 and RNase A44,45 These extensive studies have
provided interesting insights for folding mechanism of disulfide-rich peptides. It was
observed that most of the information needed to specify three-dimensional structure of a
protein is encoded in its primary amino acid sequence and disulfide bonds greatly
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influence the thermodynamics of protein folding process.46 Generally accepted method
by which the disulfide bonds stabilize the native conformation of a protein is lowering the
entropy of the unfolded form and making it less favorable compared to the folded form.47
This process of protein folding can be seen as a folding funnel (Figure 1.2).48
Figure 1.2 Schematic overview of folding funnels for BPTI and Hirudin-like proteins

The folding process begins from a reduced, high energy, unfolded ensemble and the
protein molecules work their way down a funnel of decreasing energy. For proteins such
as BPTI, a limited number of native-like intermediates adopt protein conformation towards
the native structure ((a). Figure 1.2). Hirudin-like proteins fold through an initial stage of
disulfide bond formation, process known as packing, followed by the reshuffling of
scrambled isomers to form the native protein ((b). Figure 1.2). Disulfide bonds in proteins
are formed by two thiol exchange reactions (Scheme 1.1). First, the ionized thiolate form
reacts with one of the sulfur atoms in the redox reagent to form a mixed disulfide bond
between the protein and redox reagent. Then, the remaining thiol anion in the protein
attacks the mixed disulfide to form the oxidized protein.49

8
Scheme 1.1 Thiol-disulfide exchange reaction between a protein and a redox reagent
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The kinetics of protein folding are greatly affected by the location of disulfide bond relative
to the folding nucleus. When disulfide bonds are in or near the folding nucleus, it can
accelerate the folding process, whereas when disulfide bonds are far away from the
folding nucleus, the folding process can decelerate up to three order of magnitude.50 In
addition, accessibility, proximity and reactivity of the thiol groups and disulfide bonds
influence the formation of disulfide bonds.51
Disulfide bond formation is one of the major rate-limiting steps in protein folding in
vivo. Therefore, protein folding catalysts called oxidoreductases are required to form
disulfide bonds in vivo. Oxidoreductases are consist of catalytic disulfides at the active
site and these disulfides are serve as the oxidant for disulfide formation. The reduced
form facilitates the reduction or isomerization of disulfide bonds. In addition,
oxidoreductases accelerate oxidative folding by eliminating misfolding in protein folding.52
Formation of disulfide bonds in the bacterial periplasm has been extensively studied over
past decades.53 Those studies reveal that disulfide bonds in the periplasm of Escherichia
coli are introduced by the Dsb family of proteins. The family includes DsbA and DsbB,
which are involved in disulfide bond formation, and DsbC and DsbD, which are involved
in disulfide bond isomerization.54 In eukaryotic cells, disulfide bond formation occurs in
the lumen of the endoplasmic reticulum (ER) and two proteins, protein disulfide isomerase
(PDI) and EroIp, are primarily responsible for controlling the process of oxidative folding.
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These folding catalysts reduce and shuffle non-native disulfide bonds at early stages of
folding to avoid misfolding.55 As mentioned earlier, there is little known about the in vivo
folding of small, disulfide-rich proteins, hence more future research should be focused on
analyzing disulfide-mediated folding processes under physiological conditions.
With the attractive potential of conotoxin-like small, disulfide rich-proteins as
valuable tools in pharmacological and biological studies, there is a huge need for isolation
and/or synthesis of these bioactive molecules. As mentioned earlier in this chapter, the
marine snails produce relativity small quantities of the toxins, and they are a complex
mixture of thousands of bioactive compounds. Therefore, isolation of each interested
bioactive compound is very difficult and the amount recovered after lengthy isolation
protocol is not sufficient for those experimental studies. Moreover, production of these
disulfide-rich bioactive peptides by recombinant methods using suitable host organisms
is very challenging. The major obstacles are low expression rates, high susceptibility for
degradation by the host cell proteases and a significant toxicity for the host organism.56
In order to access these disulfide-rich mini-proteins in large quantities, many methods
have been developed to perform chemical synthesis of these bioactive molecules.
1.4 Chemical Synthesis of Disulfide-Rich Mini-proteins
The in vitro studies of protein folding have given information to develop suitable
strategies to chemically access disulfide-rich mini proteins. From Anfinsen’s in vitro
studies, it is accepted that an intrinsic folding code in primary amino acid sequence of a
protein determines its correct folding pattern.41 This implies that as long as we can
synthesize the correct primary amino acid sequence, generation of the native 3D structure
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of protein is possible with suitable folding methods. This concept opened up a huge area
of chemical synthesis of proteins and several methods have been developed to access
disulfide-rich mini-proteins.
The first chemical synthesis of conotoxins were carried out in early to mid 1980s
and since then, at least a hundred of conotoxins have been synthesized.57,58,59,60 The
primary amino acid sequence is made either by Fmoc or Boc chemistry with thiol
protected cysteines using several thiol-protecting groups (Table 1.2). There are several
methods used to synthesize disulfide-rich peptides and these methods can be
categorized into three broad sections based on how the linear peptide or reagents are
used in the synthetic process; either in solution or on a solid support. They are namely 1)
solution-phase oxidation 2) on-resin oxidation and 3) oxidation via solid-supported
oxidants. When performing each of these strategies, a special attention needed to be
taken to optimize variables in the folding reaction, such as peptide concentration,
temperature, folding time, folding additives and solvents to increase the folding
efficiency.61,62,63
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Table 1.2 The most common thiol protecting groups used in peptide synthesis
Protecting Group

Stability

Structure

Removal

TFA, Ag(I), base, RSCl

HF (0 ºC),Tl(Ii),
Ph2SO/MeSiCl3

4-methoxybenzyl (Mob)

TFA, base, RSCl, I2

HF (0 ºC), Ag(I), Hg(II),
Tl(III), Ph2SO/MeSiCl3

tert-butyl (tBu)

TFA, HF (0 ºC),
Ag(I), I2

HF (0 ºC), Hg(II), RSCl,
Ph2SO/MeSiCl3

TFA, HF (0 ºC), base

I2, Ag(I), Hg(II), RSCl,
Tl(III), Ph2SO/MeSiCl3

TFA, HF (partial), base,
RSCl

RSH, Bu3P,
(HOOC-CH2-CH2)P

HF

RSH, Bu3P,
(HOOC-CH2-CH2)P

base, nucleophiles

dil.TFA/scavenger, I2,
Ag(I), Hg(II), TI(III), RSCl

base, nucleophiles

dil.TFA/scavenger, I2,
Ag(I), Hg(II), TI(III)

base, nucleophiles

dil.TFA/scavenger, I2,
TI(III)

base, nucleophiles

dil.TFA/scavenger, I2,
TI(III)

4-methylbenzyl (Bzl(4-Me))

MeO

O
Acetamidomethyl (Acm)

N
H

tert-butylsulfanyl (StBu)

S

N

S

3-nitro-2-pyridylsulfanyl (Npys)
NO2

triphenylmethyl, trityl (Trt)

4-methoxytrityl (Mmt)

MeO

MeO

OMe

2,4,6-trimethyoxybenzyl (Tmob)
OMe

9H-xanthen-9-yl (Xan)
O
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1.4.1 Solution-Phase Synthesis of Disulfide-Rich Peptides
Solution-phase oxidation is the most common method to form intramolecular
disulfide bonds in peptides.51,52,64,65,66 The linear synthesis of the peptide is assembled
via solid phase peptide synthesis (SPPS), and the peptide folding is performed after
cleavage of the linear peptide from the resin. Solution-phase disulfide bond formation
requires highly dilute conditions such as 20 – 50 µM concentrations of peptide solution.
In solution, there is a competition between intramolecular disulfide bond formation and
intermolecular disulfide bond formation. At higher peptide concentrations, the effective
concentration of intermolecular thiol becomes relatively higher, which facilitates
dimerization and oligomerization of the peptide and lowers the folding yields.67 Numerous
oxidants have been exployed to perform solution-phase peptide folding.68 Common
examples of such oxidants are, glutathione, cysteine, cystamine, DMSO, trans-1,2-bis(2mercaptoacetamido)cyclohexane (BMC) and molecular oxygen. Glutathione-based redox
buffers are common in solution-phase disulfide bond formation methods as they are
hypothesized to better reflect oxidation pathways in vivo.69,70 The folding efficiency and
extent of oxidation are influenced by the ratio of GS-SG to GSH.71 Dilute dimethyl
sulfoxide with final concentration of 5 – 10% is another common oxidant, often requiring
longer folding times.72 The major drawback of DMSO oxidation is the difficulty of removal
of excess DMSO from the folded product. Molecular oxygen is also used to form disulfide
bonds in peptides and oxygen is drawn from either air or oxygen atmosphere for the
folding process. Oxygen-mediated peptide folding method relies on low levels of oxygen
dissolved in solution. Thus, the method is relatively slow.67 When performing multistep
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folding procedures in solution-phase, in addition to the final product, the intermediate
products from each step usually need to be purified before the next step. Multiple
purification steps can diminish the final yield of the folded peptide.
1.4.2 On-resin Synthesis of Disulfide-Rich Peptides
High dilution conditions in solution-phase folding protocols introduce problems with
larger scale and high throughput folding. To avoid this issue, peptide disulfide bond
formation can be performed on solid support, requiring less solvent. After the linear
synthesis of the target peptide on resin, the folding procedures are carried out while the
peptide is still attached to the resin. The reagents are easily filtered out after the synthesis
and the resulting folded product can be cleaved form the resin and purified. Therefore,
this method does not need time-consuming and wasteful purification steps. When
disulfide is formed on a resin with medium to low loading, a phenomenon called pseudodilution73 is generated within the reaction core, which ensure that the molecule of peptide
is isolated. This favors intramolecular disulfide bond formation over intermolecular
disulfide bond formation, minimizing formation of dimers and oligomers as by products.
Several methods have been developed to form disulfide bonds in resin-bound peptides
using suitable cysteine protecting groups and reagents, which are compatible with resinbased reaction conditions. Few of them are summarized in Scheme 1.2. One of the
traditional approaches to access disulfide bonds on resin is the iodine oxidation. On-resin
peptides with Trt, Acm or Mmt protected cysteines (1.1.A) are treated with excess
iodine.74,75
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Scheme 1.2 Known methods for on-resin disulfide formation
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This is a convenient method to form on-resin disulfide linkages, but it cannot always be
employed as peptides containing Met or Trp amino acids are prone to oxidation and
peptides on TGT and CTC resins can be cleaved under iodine oxidation condition.76 In
addition to iodine oxidation, Tl(tfa)3 can be used on peptides 1.1.C with Acm protected
cysteine to directly yield the product with desired disulfide bond. This approach is not
orthogonal to other cysteine protecting groups or acid-labile side chain protecting groups,
and it can induce cleavage of peptides from TGT and CTC resins.77 On-resin oxidation of
free thiols, 1.1.B, can be achieved using either N-chlorosuccinimide78 or acidic DMSO
(HX = HCl or HOAc).79 Cysteines with benzyl derived protecting groups, 1.1.D, need 2step process to form disulfide bonds. First, low concentration of TFA is used to the remove
benzyl group, and then, the resulting free thiols are oxidized with CCl4/TFA to form
corresponding disulfide bond. This method is not compatible with Cys(Mmt), Cys(Trt) or
TGT and CTC resins as TFA can cause cysteine deprotection and/or peptide cleavage.
The multistep approach with StBu and Mmt protected cysteines, 1.1.E, was developed to
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improve the purity of peptides.80 The disulfide bond formation takes place based on the
sequence of two disulfide exchange reactions and no oxidizing agent is needed. First, the
on-resin peptide is treated with mercaptoethanol to remove StBu group by reduction to
expose free thiols. Then, the peptide undergoes first disulfide exchange reaction when
treated with excess DTNP to activate the free thiol with 5-Npys group. Deprotection of
Cys(Mmt) group initiates second disulfide exchange reaction, where the nucleophilic
attack of free thiol on the resin-bound 5-Npys-activated hetero disulfide leads to the
desired folded product. This approach is very effective and widely used. The reaction can
also be carried out under microwave heating to decrease the reaction time.81 Current
limitations in on-resin disulfide bond formation are often poor yield recovery cause by
undesired polymerization or disulfide interaction with the resin.82
1.4.3 Disulfide Bond Formation via Solid-Supported Oxidants
Another solution for the issues associated with high dilution conditions in solutionphase disulfide bond formation is use of solid-supported oxidants. A variety of solidsupported oxidants have been explored using different types of polymers/resins such as
hydrocarbon-based resins,83 agarose-bound folding chaperones,84 PEG-PS, Sephadex,
controlled pore glass85 and cross-linked ethoxylate acrylate resin (CLEAR)86 (Figure 1.3).
As in on-resin disulfide bond formation, the low loading of the resin takes advantage of
the pseudo-dilution effect and favors the intramolecular disulfide bond formation. In
addition, the reagent can be easily filtered off upon completion of disulfide bond formation.
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Figure 1.3 Soild-supported oxidants for disulfide bond formation in peptides
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Polymer-bound version of Ellman’s reagent (1.2.A) can be made by linking the oxidant to
a polymer matrix through a lysine residue.86 When a solution of reduced peptide is treated
with solid-supported Ellman’s reagent, the reduced peptide is temporarily immobilized on
to the solid-supported disulfide, generating a peptide – resin disulfide intermediate that is
released again upon intramolecular disulfide-bond formation. The Clear resin preloaded
with Ellman’s reagent called Clear-OX69 has been successfully utilized in the synthesis of
many conotoxins.66,87 The drawback of this method is lower yield of recovery due to the
covalent trapping of the peptide within the resin.
The solid-supported Met sulfoxide (1.2.B), which is known as Oxyfold, can be
readily prepared on aminopoly(ethylene glycol)polyacrylamide (PEGA) resin by
methionine N-carboxyanhydride polymerization initiated by free amine groups on the
resin.88 The disulfide formation of resin-bound Met sulfoxide is analogous to DMSO
oxidation, and therefore, it can be used as a substitute of DMSO. As mentioned earlier,
the major drawback of DMSO oxidation is the difficulty in removal of excess DMSO from
the oxidized product. The resin-bound Met sulfoxide does not have this disadvantage as
it can be removed by simple filtration. The efficiency of the resin-bound Met sulfoxide can
be increased by generating longer Met sulfoxide chains, which increases the number of
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Met sulfoxide groups per gram of resin.73 Besides the longer reaction time, the resinbound Met sulfoxide oxidation shows quantitative formation of the disulfide bonds with no
dimer formation, and hence, it can be used to get high yields for more complex or valuable
peptide sequences.89
N-chlorosuccinimide can also be immobilized on the versatile poly(ethylene
glycol)-based ChemMatrix resin (1.2.C). The resin-bound NCS can be used in either
aqueous or organic media and have shown efficient reactivity to form disulfide bonds on
peptides.90
1.4.4 Thermodynamically controlled Folding Strategy for Disulfide Bond Formation in
Peptides
The classic work of Anfinsen and co-workers towards in vitro protein folding41
inspired the development of a thermodynamically controlled oxidative folding strategy to
access disulfide-rich bioactive mini-proteins. This approach involves random oxidation,
reduction and reshuffling of the fully deprotected peptide to the native isomer (scheme
1.3). Disulfide bond formation is performed mainly in solution phase and all the cysteine
groups are usually protected with a single protecting group during the SPPS. Common
folding conditions include slightly alkaline aqueous or aqueous/organic buffers, such as
GSH/GSSG buffer. In addition, DMSO-promoted oxidation is done frequently. Most
recently, Clear-OX was successfully used in the oxidative folding of three disulfidebridged conotoxins such as µ-SIIIA, µ-KIIIA, w-GVIA.72 As the name implies, disulfide
bond connectivity in this method is not controlled by reagents. Therefore, the final yield
and disulfide connectivity is highly dependent on the encoded structure information built-
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in the primary amino acid sequence and thermodynamic stability of the native
conformation.91,92,93
Scheme 1.3 Thermodynamically controlled disulfide bond formation
SPG

SPG
H

Peptide
SPG

SPG

Peptide cleavage
and
total deprotection
SH

SH
H

OH

Peptide
SH

SH

Disulfide bond formation
(Oxidation)

S

S
H

OH

Peptide
S

S

This can result in many non-native or misfolded products in addition to the native product.
Although the method requires only one purification step, separation of the native product
from all the non-native products is very challenging. Despite its disadvantages, this is still
the most commonly use approach to access peptides, especially when the native
configuration is substantially thermodynamically favored.
1.4.5 Regioselective Folding Strategy for Disulfide Bond Formation in Peptides
The regioselective folding approach is a step-by-step process to form multiple
disulfide bonds in desired pattern. The strategy is based on selective deprotection and
oxidation of each cysteine pair in the peptide. As this is a step-wise process, reshuffling
of disulfide bonds can take place by the breakage of disulfide bonds that already formed.
Hence, exposure to alkaline conditions, thiols and other nucleophiles and lengthy reaction
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times should be avoided to prevent competitive disulfide-bond disproportionation, which
can lower the product recovery. Most importantly, regioselective folding strategies require
careful planning and designing of the synthetic route by analyzing the orthogonal behavior
of cysteine protecting groups. Regioselective disulfide bond formation can be conducted
either in solution phase, after the peptide been cleaved from the resin, or solid phase,
while the peptide is still attached to the resin.
1.4.5.1 In-Solution Regioselective Disulfide Bond Formation in Peptides
Nishiuchi and Sakakibara demonstrated the use of Acm protected cysteine in
combination with Trt protected cysteine to form disulfide bonds in a-conotoxin GI using
Boc chemistry (Scheme 1. 4).94 Since then, Acm group has been widely used in the
synthesis of disulfide bonds in peptides. As Acm group is resistant to TFA or HF cleavage,
the linear peptide can be cleaved form the resin together with all other protecting groups
without affecting the Acm group. In the synthesis of a-conotoxin GI, the resulting free
thiols from HF cleavage were oxidized by mild oxidant, ferricyanide, to form the first
disulfide bond. The second disulfide bond formation was then achieved after Acm group
removal and oxidation by iodine oxidation.
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Scheme 1.4 Regioselective folding strategy for synthesis of α-GI
using Cys(Acm) and Cys(Meb)
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The utility of S-Acm protection strategy to synthesize conotoxins containing three disulfide
bonds has also been explored. A semi-directed method was used to synthesize wconotoxin MVIID using Acm group in combination with Trt group to protect pairs of
cysteine residues (Scheme 1.5.A).95 During the resin cleavage all the protecting groups
get cleaved except for the Acm group, forming two pairs of reduced cysteine residues.
Upon treatment with air, the reduced peptide undergoes a random oxidation to form first
two disulfide bonds. This step gave predominantly a single isomer which reflects the
efficiency of the synthetic design. The second disulfide linkage was formed by
simultaneous Acm group removal and oxidation using iodine-mediated oxidation
condition.
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Scheme 1.5 A. Semi-directed folding strategy for synthesis of ω-MVIID using Cys(Acm) and Cys(Trt)
B. Regioselective folding strategy for synthesis of ω-MVIIA using Cys(Acm), Cys(Mob)
and Cys(Trt)
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The synthesis of w-conotoxin MVIIA, which is a three disulfide bond containing peptide,
has been done in a more selective approach using Acm, Mob and Trt protected
cysteines.96 It allows a step-by-step oxidation by selective deprotection and oxidation of
each pair of cysteine groups. First, selective Cys(Trt) deprotection was achieved together
with total deprotection by TFA treatment. Then, air oxidation was performed to oxidize the
free thiols to access the first disulfide bond. Iodine oxidation ensures selective cleavage
of Acm and oxidation to introduce the second disulfide bond in the peptide. The fully

22
folded peptide was completed by deprotection of Cys(Mob) to get the reduced cysteines
followed by DMSO oxidation of free thiols.
A method was reported in which DTNP was used to remove several commercially
available protecting groups.97 In the regioselective synthesis of apamin, no Acm
protection was applied, StBu and tBu groups were used to protect cysteine residues
(Scheme 1.6). DTNP was used to deprotect both StBu and tBu groups, and the selectivity
of one group removal over the other was achieved by the presence or absence of
thioanisole in the reaction solution. As StBu group was found to be stable in DTNP
reaction condition without thioanisole, Cys(tBu) deprotection was done first using DTNP
in absence of thioanisol.
Scheme 1.6 Regioselective DTNP-mediated strategy for synthesis of apamin using
Cys(tBu) and Cys(StBu)
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A bis-Npys-protected peptide was made upon removal of tBu group with DTNP, addition
of DTT facilitated the first disulfide bond formation instantaneously. After purifying the
mono-cyclic peptide, it was subjected to the same reaction condition, but with thioanisole,
to deprotect Cys(StBu) and form second disulfide bond in the target peptide.
Although most of the regioselective folding approaches have multiple disulfide
formation steps with a distinct set of reagents for each step, one-pot regioselective
method has been developed to synthesize a-conotoxin SI.98 (Scheme 1.7). In this onepot regioselective approach, combination of Meb and tBu protected cysteines were used,
and synthesis was designed based on the difference temperature dependence of these
groups towards DMSO / TFA / anisole oxidation.
Scheme 1.7 Regioselective in-solution folding strategy for synthesis of α-SI
using Cys(Meb) and Cys(tBu)
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At room temperature, tBu protected cysteines rapidly get converted to the corresponding
disulfide bond without affecting Meb group removal. Subsequent heating of the same
reaction solution facilitates the deprotection and oxidation of Cys(Meb) groups to form the
second disulfide bond.
1.4.5.2 On-resin Regioselective Disulfide Bond Formation in Peptides
As an on-resin strategy, the regioselective disulfide formation is done while the
peptide is still attached to the resin. The specific methods of on-resin disulfide formation
(see Section 1.4.2) can be combined carefully, based on their orthogonality towards other
excising cysteine protecting groups, to control formation of each disulfide bond in the
peptide. One of the examples is use of Cys(Fm) in combination with Cys(Acm) to
synthesize a-conotoxin GI using Boc chemistry (Scheme 1.8).99
Scheme 1.8 Regioselective on-resin folding strategy for synthesis of α-GI
using Cys(Acm) and Cys(Fm)
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In this synthetic route, piperidine in DMF was used to base-labile Fm group and iodinemediated oxidation was used for simultaneous Acm removal and oxidation. Final peptide
cleavage and side group deprotection has to be done using HF condition. This step is
challenging as disulfide bonds are found to be unstable under highly acidic condition.
Therefore, careful selection of scavengers is critical for isolation of the native isomer in
good yields.
Fmoc chemistry can be carried out as an alternative method to avoid HF conditions
in the synthesis of disulfide bonds. Two different approaches have been reported to
synthesize a-conotoxin GI by Fmoc chemistry (Scheme 1.9). The first approach (Scheme
1.9.A) was done using Tmob group in combination with Acm group for cysteine
protection.100 The challenging step in this protocol is deprotection of Cys(Tmob) residue,
as it requires TFA conditions, which can affect the peptide cleavage from resin. Therefore,
this step needs to be run carefully to avoid peptide loss. The resulting free thiols can be
oxidized with CCl4-Et3N in NMP to form the first disulfide bond without Acm group
removal. Second disulfide bond formation can be done by oxidation of Acm group with
TI(TFA)3 in DMF in presence of anisole as the scavenger. In the second approach
(Scheme 1.9.B), the orthogonal combination of Acm and Xan group was used to obtain
a selective disulfide bond formation.101 The deprotection and selective disulfide bond
formation conditions were similar to that of approach A in Scheme 1.9. These methods
illustrate the utility of orthogonal combination of Acm group with various other cysteine
protecting groups to access multiple disulfide bonds on resin.
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Scheme 1.9 Regioselective on-resin folding strategy for synthesis of α-SI using; A. Cys(Acm) and Cys(Fm)
B. Cys(Acm) and Cys(Xan)
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regioselective disulfide bond formation.79 Regioselective synthesis of a-conotoxin SI is
reported utilizing NCS as only oxidant to form disulfide bonds (Scheme 1.10.A).
Orthogonal combination of STmp and Mmt groups were chosen as cysteine protecting
group for the synthesis, which is an example for an on-resin regioselective synthesis
without Acm group protection. A solution of 2 equivalents NCS in DMF was needed for
each oxidation step and each disulfide formation was completed in 15 min.
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Scheme 1.10 A. Regioselective on-resin folding strategy for synthesis of α-SI using Cys(STmp) and
Cys(Mmt) B. Regioselective on-resin folding strategy for synthesis of α-MII using Cys(StBu),
Cys(Mmt) and Cys(Acm)
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A microwave-assisted on-resin regioselective disulfide formation method was reported for
the synthesis of a-conotoxin MII102 (Scheme 1.10.B). This is a displacement method that
can be used to form the first intramolecular disulfide bond in a regioselective scheme to
access peptides with two disulfide bonds. For this method, three cysteine protecting
groups were used, StBu, Mmt and Acm, and two of them were facilitated the displacement
process to access first disulfide bond. 30% Mercaptoethanol in DMF was used to remove
the StBu group under microwave heating. Upon addition of excess DTNP to the resulting
on-resin peptide, reaction between the free thiol from StBu removal and DTNP forms an
activated 5-Npys cysteine group. Removal of highly acid sensitive Mmt group under
microwave heating facilitates the nucleophilic attack of free thiol on to the activated
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cysteine to form the first disulfide bond by releasing one molecule of 5-nitropyridine-2thione. Neither the deprotection conditions nor activation process in this displacement
step affects the Cys(Acm) group in the peptide. The second disulfide formation was
achieved by traditional on-resin Acm removal and oxidation via iodine oxidation. The
significance of this method is reduction in the time required for disulfide bond formation,
which highlights the power of microwave heating in combination with a displacement
method.
1.4.5.3 On-Resin Oxidants for Regioselective Disulfide Bond Formation in Peptides
As described in section 1.4.3, there a several on-resin oxidants available for
formation of disulfide bonds in peptides. Commercially available Clear-OX resin has been
successfully applied in regioselective two-step disulfide formation procedure to access aconotoxin GI (Scheme 1.11).84 Both Xan and Acm groups were used to protect cysteine
residues selectively and standard free thiol oxidation methods have been replaced by
Clear-OX oxidation to form the first disulfide bond.
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Scheme 1.11 Regioselective on-resin folding strategy for synthesis of α-GI using
solid supported oxidant (Clear-OX)
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1.5 Objective of the Project
Cysteine-rich peptides, including plant derived protease inhibitors, defensins from
both vertebrates and invertebrates and neurotoxins from spiders, scorpions and mollusks,
demonstrate high potency and good target specificity, making them useful tool
compounds in biomedical and pharmaceutical research. The importance of these
peptides is not limited to exclusively to therapeutic peptides. They can also be used in
other applications such as bioconjugation,103 b-sheet stabilization,104 siRNA delivery,105
increasing in vivo stability,106 stabilization of peptide-based nanocarriers, and peptide
backbone linkers.107,108 Due to their small size, chemical synthesis has been the method
of choice to access these bioactive targets in large quantities. Although several strategies
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have been developed to synthesize cysteine-rich mini-proteins, a convenient and
straightforward preparation of the native disulfide bond connectivity in these peptides still
needed to be investigated. The goal of this dissertation is to further explore cysteine
protecting groups with effective deprotection conditions and develop efficient methods for
on-resin regioselective disulfide bond formation to access disulfide-rich bioactive
peptides.
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CHAPTER 2: DIRECT Pd-MEDIATED ON-RESIN DISULFIDE BOND FORMATION
FROM ALLOCAM PROTECTED PEPTIDES

2.1 Introduction
The preparation of disulfide bonds in bioactive peptide is currently limited by the
lengthy nature of solution-phase folding procedures. On-resin approach for disulfide bond
formation is advantageous as it avoids multiple purification steps and reaction
manipulations associated with solution-phase protocols. In addition, it favors
intramolecular disulfide bond formation.74 Much effort has been devoted to the
development of new cysteine protecting groups to improve the available toolbox to access
disulfide-rich bioactive peptides. Although some of these groups are selective in their
cleavage, several have practical limitations preventing their widespread use. In this
chapter, we are reintroducing Allocam group as cysteine protecting group with novel Pdmediated deprotection-oxidation method to form on-resin disulfide bonds in peptides.
2.2 Allyloxycarbonylaminomethyl as Cysteine Protecting Group
Kunz and coworkers are the pioneers who introduced the allyl (All) and
Allyloxycarbonyl (Alloc) protecting groups (Figure 1.1) in to the fields of peptide
synthesis.109,110 The groups became increasingly popular due to their orthogonality with
the widely used Boc chemistry and Fmoc chemistry in peptide synthesis.111 They can be
selectively cleaved under mild condition by catalytic p-allyl palladium chemistry which
involves combination of a palladium catalyst and a nucleophilic species as an allyl group
scavenger.112 These groups have been used for a-amino and a-carboxy groups and
various side chain reactive functionalities such as carboxylic groups of aspartic acid and
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glutamic acid,113,114 phenolic groups of tyrosine,115 nitrogen functions of lysine116 or
indole.117 However, neither the allyl nor the Alloc groups are suitable for thiol group
protection in cysteine residues. The allyl thioesters are not cleaved by palladium and can
undergo intermolecular nucleophilic attack by neighboring a-amino function under basic
conditions of Fmoc removal or even during coupling processes.114
As

an

alternative

group

for

allyl-based

cysteine

protection,

the

allyloxycarbonylaminomethyl (Allocam, Figure 1.1) group was introduced by Loffet and
co-workers.118,119 It is stable in the basic conditions of Fmoc deprotection but only
marginally stable under acidic conditions.
Figure 2.1 Structure of Allyl, Alloc and Allocam groups
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Allocam protected thiols can be cleaved by palladium-catalyzed hydrostannolysis with
Bu3SnH. A nucleophilic species should be in a reaction medium to trap the p-allyl entity
before any rearrangements take place. Examples of such scavengers are N,N’dimethybarbituric acid (NDMBA),120 N-trimethylsilylamines121 and phenylsilane.122 In
early studies of Allocam deprotection, it was found that the deprotection reaction stops at
initial stage as a result of catalyst poisoning. The system of PdCl2(PPh3)2/Bu3SnH /AcOH
was found as the best deprotection conditions to get rapid and complete removal of
Allocam. The success of the procedure may be due to the combination of very high rate
of the palladium catalyzed hydrostannolytic cleavage and presence of acetic acid, which
prevent the catalytic poisoning.120 However, 5-10% of allyl thioether formation was
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observed during reaction. In addition, the hydrostannolytic procedure give a mixture of
the thiol, its tributylstannyl salt and minor amount of disulfide (Scheme 2.1).
Scheme 2.1 Reported cleavage and oxidation condition for Allocam
RSH + AcOSnBu3
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RS SR
2.1.C
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Therefore, isolation of the deprotected product is difficult. In order to characterize the
product, the solvent and most of the acetic acid were evaporated and the crude reaction
mixture was treated with iodine until persistence of I2 coloration. Reaction with iodine
convert all thiols and their tin salts into disulfide. Theses disulfides were then purified from
the side-products (catalyst and tin compounds) by appropriate extractive procedures
followed by chromatographic purification.120 The acid lability of Allocam group, use of
Bu3SnH as an allyl scavenger, and the observation of significant amounts of S-allylated
side products in the deprotection process have limited the general use of Allocam group.
To improve the acid stability of Allocam group, two new protecting group, Fsam and
Fnam, were introduced by substitution of an electron-withdrawing group on the carbonate
nitrogen (Figure 2.2).123,124 Both Fnam and Fsam are completely stable to basic and
acidic conditions used in both Boc and Fmoc based peptide synthesis and can be
selectively cleaved by palladium-catalyzed allylic cleavage in the presence of
nucleophiles (Scheme 2.2).124,125
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Figure 2.2 Structure of Fsam and Fnam groups
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However, in the deprotection process, they require additional acidic treatment to convert
intermediate 2.2.A to the free thiol 2.2.B.
Scheme 2.2 Reported cleavage and oxidation condition for Fnam
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The reported deprotection methods for Allocam, Fnam and Fsam groups result the
reduced cysteine and a separate oxidation step need to be performed to access disulfide
bond 2.1.C.
2.3 Synthesis of Fmoc-Cys(Allocam)-OH
Loffet and co-workers have reported synthesis of Allocam protected thiols.120 The
reported synthesis cannot be reproduced and hence, we developed an alternative
approach starting from commercially available allyl chloroformate (Scheme 2.3). First,
ammonia was bubbled through a solution of allyl chloroformate (2.3.A) to access the
intermediate carbamate in 95% yield. Then, it was treated with paraformaldehyde and
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Ba(OH)2, which generated hydroxymethyl carbamate (2.3.B) in 48% yield. Next, the
hydroxymethyl group was activated with trimethylsilyl chloride and addition of FmocCys(H)-OtBu produced fully protected cysteine (2.3.C) in 70% yield. Finally, the t-Bu ester
was removed with 30% TFA to produce Fmoc-Cys(Allocam)-OH (2.3.D) in 99% yield.
Scheme 2.3 Synthesis of Fmoc-Cys(Allocam)-OH
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This approach can be used to synthesize Fmoc-Cys(Allocam)-OH in larger scale with
good yields.
2.4 Optimization of Solid Phase Peptide Synthesis (SPPS) using Fmoc-Cys(Allocam)-OH
With a convenient protocol to synthesize Fmoc-Cys(Allocam)-OH in hand, we
wanted to develop new deprotection conditions and reintroduce Allocam group for
cysteine protection in peptide synthesis. First, compatibility of Allocam as cysteine
protecting group in Fmoc-SPPS process was evaluated. For the studies, a model peptide
derived from the first 9 amino acid residues of islet amylod polypeptide was selected
(IAPP1-9, Figure 2.3). The main reason for the selection of IAPP1-9 as the model peptide
was its higher potential in formation of a disulfide linkage between the two cysteine
residues without any secondary structures.125,126 In addition, linear synthesis of a peptide
with 9 amino acid residues can be done relatively shorter period of time.
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Figure 2.3 Structure of Islet amyloid polypeptide and the model peptide
37
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S
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H

KCNTATCAT OH
S

S

Model Peptide (IAPP1-9)

Initial SPPS was done on TGT resin using HATU as the coupling agent and DIPEA as
the base under microwave heating. Single coupling step was sufficient enough to
incorporate Fmoc-Cys(Allocam)-OH successfully into the linear IAPP1-9 sequence.
Allocam group is stable to the TGT resin cleavage condition, TFE:AcOH:DCM (1:1:3).
Moreover, Fmoc-Cys(Allocam)-OH is compatible with SPPS on CTC, Wang and Rink
amide resins. When cleaving peptides from Wang and Rink amide resins, the Allocam
group get cleaved with 95% TFA condition. In order to cleave peptides from Wang and
Rick amide resins, without affecting Allocam removal, a cleavage solution of 30% TFA in
DCM in presence of a scavenger can be used.
2.5 Palladium-Mediated On-Resin Disulfide Formation in Peptides using Allocam
Protected cysteines
As mentioned in section 2.2, removal of Allocam group can be done selectively via
p-allyl palladium chemistry. We envisioned a combination of palladium mediated Allocam
cleavage and in situ oxidation to access disulfide bonds in a single step (Scheme 2.4). If
a Pd(II) pre-catalyst 2.4.A is employed to the process, first, in situ reduction would convert
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Pd(II) to Pd(0). Then, Pd(0) complex 2.4.B coordinates to the p-allyl system in Allocam
protected thiol 2.4.C and generate the system 2.4.D.
Scheme 2.4. Postulated catalytic cycle for deprotection of Allocam
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Next, oxidative addition of Pd(0) complex leads to cationic p-allyl Pd(II) species 2.4.E and
intermediate 2.4.F. The intermediate 2.4.F can undergo decarboxylation to release an
equivalent of formimine, and liberates the thiol. The p-allyl Pd(II) species 2.4.E undergoes
nucleophilic attack to turn over the catalyst (2.4.G then 2.4.B) and release the allylated
nucleophile. In presence of an oxidant, the thiol can undergo in situ oxidation to form a
disulfide bond.
In Albericio and co-workers’ study of cleavage conditions for an allyl aspartate,
they observed undesired disulfide bond formation when a mixture of DMSO, AcOH, and
NMM was used in combination with Pd(PPh3)3 complex.127 These conditions were taken
as the starting point for our investigation and the model peptide IAPP1–9 was subjected to
different Pd complexes with various solvent systems and additives (Table 2.1). First, 5
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equivalents of Pd(PPh3)4 in a DMSO/THF solvent mixture was used in presence of 3%
NMM and 5% AcOH (entry 1). A mixture of unreacted starting peptide (2.5.B), desired
disulfide (2.5.C), and the mono-Allocam version of the starting peptide was observed after
2 hours. When the amount of NMM was increased, an increment in the conversion of
disulfide was observed. In addition, ∼1% mono-S-allylated product was observed along
with the mono-Allocam side product (entry 2). With 7 equivalent Pd(PPh3)4, the desired
disulfide was observed as the major product (80% conversion) in addition to the minor
amounts of mono-Allocam, reduced, and mono- and bis-allylation products (entry 3).
Next, the Pd(0) source was switched to Pd(II) complexes due to the practical difficulties
in handling air sensitive Pd(0) complexes. When Pd(dppf)Cl2·CH2Cl2 was used in
presence of regular DMSO-AcOH-NMM solvent system, the reaction was completely shut
down and no disulfide bond formation was observed (entry 4). However, repeating this
reaction in the presence of 20 equivalent of phenylsilane resulted in nearly complete
conversion to the desired disulfide bond, and most importantly, with no S-allylation by
products (entry 5). Beside Pd(dppf)Cl2·CH2Cl2, Pd(OAc)2 was used as the Pd(II) complex
for this reaction. In the presence of 7 equivalent of Pd(OAc)2, 10% NMM, and 5% AcOH
in DMSO, about <5% starting material was observed within 2 hours as well as a small
amount of mono-Allocam peptide (entry 6). Lowering the loading to 5 equivalent and
increasing the reaction time to 4 hours led to complete disulfide formation with no side
products (entry 7). However, further reduction in the loading of Pd(OAc)2 to only 1
equivalent resulted insignificantly reduced conversion and increased side product
formation (entry 8). Therefore, the loading of Pd(OAc)2 was slightly increased to 1.5
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equivalent (entry 9), and a nearly complete conversion was observed. When less NMM
was used the reaction can be pushed towards a 100% conversion of the desired product
(entry 10).
Table 2.1 On-resin deprotection/oxidation optimization for model peptide (IAPP1-9)
tBu
tBu tBu
Boc Trt
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Pd(OAc)2
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2
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aUnless

otherwise noted, reaction was performed using 10 mg of TGT resin (loading 0.2
mmol/g) and 250 µL total volume (all liquids). LCMS analysis is performed directly on crude
peptide following removal of solvents from resin cleavage. b NovaSyn PEG-PS copolymer
resin with TGT linker, preloaded with Fmoc-Thr(OtBu). c Aminomethyl ChemMatrix Resin
manually functionalized with TGT linker. d 20 equiv PhSiH3 added. e Ratio determined by
integration of relevant peaks in mass spectra. f 1 Allocam remaining. g 2 Free thiols. h 1 SAllyl. i 2 S-Allyls.

These were taken as the optimized conditions for the NovaSynTGT resin. As PEG resins
have superior swelling properties relative to polystyrene resins,128,129,130 we wanted to
evaluate the reaction conditions on ChemMatrix resin. After linear synthesis of the model
peptide IAPP1-9 on ChemMatrix resin, the reaction was performed with lower loadings of
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Pd(OAc)2 (entries 11 and 12). Upon exposure to 0.75 or 1.0 equiv Pd(OAc)2, only 11 or
50% conversion was observed after 4 h. However, under the previously optimized
conditions, complete conversion was observed after 2 h instead of 4 h (entry 13). Overall,
we were delighted with the low loadings of palladium needed for the transformation.131
Addition of a Pd scavenger to the rinsing procedure prevents any detectable
contamination of the cleaved products. Most importantly, neither partially deprotected nor
S-allylated products were observed with the optimized Allocam deprotection-oxidation
conditions.
Moreover, we were interested in understanding the mechanism of Pd-DMSO
mediated simultaneous Allocam removal and oxidation. To evaluate the function of each
component in the reaction system and to understand how each component affects
reactivity of the reaction, a set optimization were done. In the optimization process
reactions were done by removing each component from the optimized condition at a time
to evaluate the role of the component in deprotection-oxidation process. In addition,
components such as NMM and AcOH were replaced by ionic NH4OAc to understand the
mechanism of action. Further details are needed to conclude the mechanism of PdDMSO mediated simultaneous Allocam cleavage-oxidation and the investigations are still
ongoing in our lab
2.6 Synthesis of Oxytocin using Allocam Protected Cysteine
With optimized conditions in hand, we wanted to utilize this direct, on-resin
disulfide bond formation method to form disulfide bond in oxytocin.132,133,134,135 Oxytocin
is a neurotransmitter which has 9 amino acid residues and one disulfide bond. Carboxy-
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oxytocin was synthesized in order to facilitate analysis of the disulfide bond forming
reaction. Linear synthesis of the peptide 2.6.A was done on a TGT-linked ChemMatrix
resin via Fmoc-SPPS. The resulting fully protected peptide was subjected to Pd-DMSO
mediated simultaneous Allocam cleavage and oxidation conditions (Table 2.2). First, the
optimized conditions for IAPP1-9 was used and only ~80% conversion of the product 2.6.C
was observed after 6 hours (Entry 1). Then, Pd(OAc)2 loading was increased to 3.0
equivalent and it facilitated a complete conversion of folded peptide 2.X.B (Entry 2). The
resulting folded peptide was cleaved from the resin followed by side chain protecting
groups deprotection.
Table 2.2 Reaction optimization for on-resin folding of caboxy-oxytocin
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Fully deprotected carboxy-oxytocin was purified via RP-HPLC and 32% isolated yield was
obtained.
2.7 Summary
In this study, Allocam group was reintroduced to the field of peptide synthesis as
a cysteine protecting group with novel Pd-mediated deprotection-oxidation method to
form disulfide bonds on resin. This is a one-pot approach, which avoids solution-phase
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manipulations of the peptide and minimizes the number of time consuming purification
steps. No special equipment is needed and the reaction can be done with bench-stable
reagents. Reaction conditions were optimized for no trace of Pd or S-allylated byproducts.
The utility of the method was demonstrated by solid phase synthesis and folding of the
carboxy-oxytocin, which consist of single disulfide bond. This method can be broadly
applied in the synthesis of more complex targets with multi-disulfide bonds. Detailed
investigations into the mechanism of Pd-DMSO mediated simultaneous Allocam removal
and oxidation are still ongoing.
2.8 Materials and Methods
2.8.1 General Information
Unless otherwise specified, all commercially available reagents were purchased from
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF,
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial
solvent purification system (2 columns of alumina) and used without further drying.
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL,
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room
temperature. All yields refer to chromatographically and spectroscopically pure products.
All HPLC analyses and purifications were performed on a Custom Reverse Phase
Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle
between analytical and semi-preparative columns. This instrument has a photodiode
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array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O)
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific
Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based
on the final loading.
Fmoc-SPPS General Information. Solid-phase peptide synthesis was executed on a
Biotage Isolera+ semi-automated synthesizer with microwave heating.
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL)
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The
solvent was then removed over 1 m followed by two DMF washes (DMF was added
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of
solvent (over 2 m)).
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv)
in DMF was made immediately prior to addition to the reaction vial containing the
resin. Once the solution was added, the suspension was heated to 75 ºC (except for
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed
with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m).
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•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF.
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF
washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200
RPM for 1 m, solvent removal was at a rate of 2 m).
•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times.
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL).
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the
lyophilizer overnight for drying.
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF
(5 x 3 mL).
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed
based on amount of Fmoc group.
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min,
the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF
was added to it and allowed to vortex in the peptide synthesizer at room temperature for
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10 min. The resulting filtrate was collected to the same tube and the deprotected resin
was washed with DMF (4 x 1.75 ml).
Sample preparation for UV analysis – From the collected ”deprotection solution” above,
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF.
The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF
blank using a UV spectrometer with 1 cm cuvette.
2.8.2 Experimental Procedures and Spectroscopic Data
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Synthesis of IAPP1-9 (2.5.A). The standard Fmoc-SPPS protocol described was used to
synthesize IAPP1-9 on preloaded TGT resin 2.5.A’ using a semi-automated peptide
synthesizer, in a 10-mL reaction vial. First, the resin was swelled followed by deprotection.
Then, each amino acid was added accordingly followed by coupling and deprotection
steps. Finally, the resin + peptide was washed with DCM and Methanol. To analyze the
peptide, 10 mg of the resin was subjected to 300 µL of the cleavage mixture (1:1:3
TFE:AcOH:DCM) for 30 min. The filtrates were collected, concentrated and analyzed by
RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow
rate of 1 mL/min with 40-80% MeCN/H2O gradient for 60 minutes. m/z ES calc’d for
Allocam IAPP (2.5.A) [(C80H121N13O20S2)+1]+: 1648.83; observed: 1649.60; m/z ES calc’d
for [(C70H105N11O16S2 + 2)/2]+: 824.92; observed: 825.30.
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Linear IAPP1-9 (2.5.A) [M+1]+
Linear IAPP1-9 (2.5.A) [(M+2)/2]+
PDA, 190 nm

Figure 2.4 Analytical Column PDA for linear IAPP1-9 2.5.A; Gradient: 40-80% MeCN/H2O + 1% HCOOH
over 60 min. Retention time 27.26 min

Figure 2.5 ES-MS spectrum for linear IAPP1-9 2.5.A
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General Procedure for Allocam Cleavage/Oxidation for IAPP1-9 (Table 2.1). IAPP1-9
on the stated resin (10 mg, 2.0 µmol) was swelled in DMF (800 µL) on the Biotage Isolera+
synthesizer. After removing excess DMF, the cartridge was removed from the synthesizer
and capped on the bottom. A solution of the stated catalyst in 5% AcOH/DMSO
solution (250 µL) was added, and then the stated amount of PhSiH3 (if relevant)
and NMM were added. The cartridge was capped on the top, attached to a
magnetic stirbar retriever using a rubber band (see image), and agitated for the
stated amount of time under an atmosphere of ambient air. The reaction was filtered then
transferred back to the synthesizer, where it was washed successively: 1) 750 µL of DMF
was added and vortexed 2 min, then filtered (3 total times), 2) 750 µL of CH2Cl2 was
added and vortexed 2 min, then filtered (3 total times), 3) 800 µL of 0.2 M sodium
diethyldithiocarbamate in DMF was added and vortexed 15 min, then filtered (3 total
times). *Note: resin changes from dark orange/brownish to yellowish/tan. 4) 750 µL of
DMF was added and vortexed 2 min, then filtered (5 total times), 5) 750 µL of CH2Cl2 was
added and vortexed 2 min. The resin was then subjected to a cleavage mixture of
TFE:AcOH:DCM (1:1:3, 300 µ ) for 3 x 15 min (not on synthesizer). The filtrates were
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collected and concentrated with a stream of nitrogen gas. The concentrated solution was
analyzed directly (with no lyophilization) by analytical HPLC-MS using a Hypersil GOLD
column (5 µL, 150 x 4.6 mm) at a flow rate of 1 mL/min with 20–80% MeCN/H2O gradient
for 60 min. The possible expected masses are:
m/z ES calc’d for Allocam IAPP (2.5.A) [(C80H121N13O20S2)+1]+: 1648.83; observed: 1649.60; m/z
ES calc’d for [(C70H105N11O16S2 + 2)/2]+: 824.92; observed: 825.30.
m/z ES calc’d for IAPP Disulfide (2.5.B) [(C70H105N11O16S2)+1]+: 1420.72; observed: 1421.05; m/z
ES calc’d for [(C70H105N11O16S2 + 2)/2]+: 710.86; observed: 711.100.
m/z ES calc’d for 1-Allocam (2.5.C) [(C70H105N11O16S2)+1]+: 1535.78; observed: 1535.00; m/z ES
calc’d for [(C70H105N11O16S2 + 2)/2]+: 768.39; observed: 767.85.
m/z ES calc’d for free thiols (2.5.D) [(C70H105N11O16S2)+1]+: 1422.73; observed: 1422.25; m/z ES
calc’d for [(C70H105N11O16S2 + 2)/2]+: 711.86; observed: 712.10.
m/z ES calc’d for 1 allyl (2.5.E) [(C70H105N11O16S2)+1]+: 1462.77; observed: 1463.15; m/z ES calc’d
for [(C70H105N11O16S2 + 2)/2]+: 731.88; observed: 732.20.
m/z ES calc’d for 2 allyls (2.5.F) [(C70H105N11O16S2)+1]+: 1502.80; observed: 1502.25; m/z ES
calc’d for [(C70H105N11O16S2 + 2)/2]+: 751.90; observed: 752.15.
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Table 2.1, entry 1. The general procedure was followed. The relevant quantities are:
Pd(PPh3)4 (11.6 mg, 10 µmol), NMM (6.3 µL, 58 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 2 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.6 Analytical Column PDA for determination of conversion; Table 2.1. Entry 1.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 2. The general procedure was followed. The relevant quantities are:
Pd(PPh3)4 (11.6 mg, 10 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 2 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+

PDA, 214 nm

Figure 2.7 Analytical Column PDA for determination of conversion; Table 2.1. Entry 2.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 3. The general procedure was followed. The relevant quantities are:
Pd(PPh3)4 (16.2 mg, 14 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 2 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.8 Analytical Column PDA for determination of conversion; Table 2.1. Entry 3.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 4. The general procedure was followed. The relevant quantities are:
Pd(dppf)Cl2 (11.4 mg, 14 µmol), NMM (25 µL, 227 µmol). The reaction mixture was
agitated in a closed vial at room temperature for 2 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.9 Analytical Column PDA for determination of conversion; Table 2.1. Entry 4.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.

53
Table 2.1, entry 5. The general procedure was followed. The relevant quantities are:
Pd(PPh3)4 (11.4 mg, 14 µmol), PhSiH3 (5 µL, 40 µmol), NMM (25 µL, 227 µmol). The
reaction mixture was agitated in a closed vial at room temperature for 2 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.10 Analytical Column PDA for determination of conversion; Table 2.1. Entry 5.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 6. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (3.1 mg, 14 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 2 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.11 Analytical Column PDA for determination of conversion; Table 2.1. Entry 6.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 7. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (2.2 mg, 10 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 4 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.12 Analytical Column PDA for determination of conversion; Table 2.1. Entry 7.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 8. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (0.45 mg, 2 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 4 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.13 Analytical Column PDA for determination of conversion; Table 2.1. Entry 8.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 9. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (0.67 mg, 3 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 4 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.14 Analytical Column PDA for determination of conversion; Table 2.1. Entry 9.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 10. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 4 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.15 Analytical Column PDA for determination of conversion; Table 2.1. Entry 10.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 11. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (0.34 mg, 1.5 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was
agitated in a closed vial at room temperature for 4 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.16 Analytical Column PDA for determination of conversion; Table 2.1. Entry 11.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 12. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (0.45 mg, 2 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 4 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+
PDA, 214 nm

Figure 2.17 Analytical Column PDA for determination of conversion; Table 2.1. Entry 12.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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Table 2.1, entry 13. The general procedure was followed. The relevant quantities are:
Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated
in a closed vial at room temperature for 2 hours.

Starting peptide (2.5.B) [M+1]+
Starting peptide-1Allocam (2.5.D) [M+1]+
Oxidized Pdt (2.5.C) [M+1]+
Isotope of Oxi Pdt (2.5.D) [M+1]+
1 S-Allyl (2.5.E) [M+1]+
2 S-Allyl (2.5.F) [M+1]+

PDA, 214 nm

Figure 2.18 Analytical Column PDA for determination of conversion; Table 2.1. Entry 13.
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min.
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H 2N

CM

Aminomethyl
ChemMatrix Resin

Fmoc Gly

TGT

Fmoc-G-TGT
ChemMatrix Resin

TGT-ChemMatrix Resin. The coupling of 4-(diphenylhydroxy methyl)benzoic acid on to
the Aminomethyl ChemMatrix resin was done using the semi-automated peptide
synthesizer, in a 10-mL reaction vial. The general procedure was followed. The relevant
quantities are: Aminomethyl ChemMatrix resin (200 mg, 0.112 mmol), 4-(diphenylhydroxy
methyl)benzoic acid (170.4 mg, 0.56 mmol), HATU (212.9 mg, 0.56 mmol), and DIPEA
(195 µl, 1.12 mmol). After the coupling, the reaction vial with the resin was taken out from
the synthesizer and 25% acetic anhydride in DMF (3 mL) was added. It was agitated for
5 min and then DIPEA (30 µl, 0.168 mmol) was added and agitated for another 30 min.
After the reaction, the solution was removed and the resin was rinsed with DMF 4 times.
Next, 1M NaOH (3 mL) was added to the resin and agitated for 12 h. At the end of the
reaction, the solution was removed followed by 4 DMF washes. To the resulting resin in
a close-sealed vial, 2% SOCl2 in DCM (3 mL) was added and agitated for 12 h. Finally,
the solution was removed and the resin was rinsed with DCM 5 times and 2% DIPEA in
DCM 3 times.
Fmoc-Gly-TGT-ChemMatrix. The resin was swelled in DMF and a solution of the desired
Fmoc-Gly-OH (5 equiv) with DIPEA (6 equiv) in DMF was added. Then the resulting
reaction vial was agitated at RT for 12 h. After the reaction, the solution was drained out
and the resin was rinsed with DMF, DCM and MeOH (3 times each). Finally, the resin
was dried in the lyophilizer for 12 h.
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tBu
Trt
Trt

SPPS
Fmoc Gly

TGT

H

S
2.6.A’

9

CYIQNCPLG

TGT

S Allocam
Allocam
2.6.A

Synthesis of Linear Oxytocin (2.6.A). The standard Fmoc-SPPS protocol described
was used to synthesize linear peptide 2.6.A on Fmoc-Gly-TGT-Chemmatric resin 2.6.A’
using a semi-automated peptide synthesizer, in a 10-mL reaction vial. First, the resin was
swelled followed by deprotection. Then, each amino acid was added accordingly followed
by coupling and deprotection steps. Finally, the resin + peptide was washed with DCM
and Methanol. To analyze the peptide, 10 mg of the resin was subjected to 300 µL of the
cleavage mixture (1:1:3 TFE:AcOH:DCM)

for 30 min. The filtrates were collected,

concentrated and analyzed by RP-HPLC-MS using an analytical Phenomenex column at
a flow rate of 1 mL/min with 5-95% MeCN/H2O gradient for 30 minutes. Final loading:
0.13 mmol/g. m/z ES calc’d for linear peptide 2.6.A [(C95H117N13O17S2)+1]+: 1777.18;
observed: 1776.95.

Linear peptide (2.6.A); [M+1]+
PDA 214 nm

Figure 2.19 Analytical Column PDA for linear carboxy-oxytocin 2.6.A; Gradient: 2-95% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 14.92 min
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Figure 2.20 ES-MS spectrum for linear carboxy-oxytocin 2.6.A at retention time 14.92 min
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Trt
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Allocam
2.6.A

tBu
Trt
Trt

1) 3.0 equiv. Pd(OAc)2,
DMSO-AcOH-NMM, 6 h
2) TFE:AcOH:CH2Cl2
(1:1:3), 3 x 1 h

H

9

CYIQNCPLG OH H
S

S Allocam
Allocam
2.6.B

tBu
Trt
Trt

9

CYIQNCPLG OH
S

S
2.6.C

Optimized Conditions for On-Resin Folding of Oxytocin-OH (2.6.A ® 2.6.C). The
IAPP standard protocol was followed. The relevant quantities are: Pd(OAc)2 (1.34 mg, 6
µmol, 3 equiv), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated in a closed
vial at room temperature for 6 hours. The resin was then subjected to a cleavage mixture
of TFE:AcOH:DCM (1:1:3, 300 µ ) for 3 x 1 h. The resin was then subjected to a cleavage
mixture of TFE:AcOH:DCM (1:1:3, 300 µ ) for 3 x 1 h. The filtrates were collected and
analyzed directly (with no lyophilization) by analytical HPLC-MS using a Phenomenex
column (5 µL, 250 x 4.6 mm) at a flow rate of 1 mL/min with 50–90% MeCN/H2O gradient
for 30 min. The side chain protecting groups were then cleaved with 95:2.5:2.5
TFA:TIPS:H2O,, the peptide was crashed out with cold ether, redissolved in 1:1 MeCN/H-
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2O,

and lyophilized. The resulting white solid was purified on a Hypersil GOLD column (5

µL, 150 x 10 mm) at a flow rate 5 mL/min with 10–50% MeCN/H2O gradient for 30 min.
The purified product was analyzed by analytical HPLC-MS using a Phenomenex column
(5 µL, 250 x 4.6 mm) at a flow rate of 1 mL/min with 10–50% MeCN/H2O gradient for 30
min. m/z ES calc’d for carboxy-oxytocin [(C43H66N12O12S2)+1]+: 1007.19; observed:
1008.25.

Starting peptide (2.6.B) [M+1]+
Starting peptide-1Allocam [M+1]+
Oxidized Pdt (2.6.C) [M+1]+
Isotope of Oxi Pdt [M+1]+
1 S-Allyl [M+1]+
2 S-Allyl [M+1]+
PDA, 214 nm

Figure 2.21 Analytical Column PDA for crude carboxy-oxytocin 2.6.C. Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 17.67 min
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Carboxy-oxytocin [M+1]+
PDA, 214 nm

Figure 2.22 Analytical Column PDA for pure carboxy-oxytocin 2.6.C. Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 17.67 min

(+) Scan

(-) Scan

Figure 2.23 ES-MS spectrum for pure carboxy-oxytocin 2.6.C at retention time 17.67 min
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CHAPTER 3: ASSESSING ALLOCAM:
ON-RESIN SYNTHESIS AND CONTROLLED FOLDING OF a-CONOTOXIN LvIA

3.1 Introduction
Conotoxins are a group of neuroactive peptides with multiple disulfide linkages
and have considerable potential as both therapeutics and biochemical probes.136,137 The
synthesis of conotoxins would enable both biological studies and evaluation of both the
ion-gated and ligand-gated structures as lead target for therapeutics.138,139 The success
in synthesis of oxytocin using Allocam-protected cysteine led us to discover the potential
of our Pd0/II - DMSO based Allocam cleavage-oxidation strategy to generate two disulfide
linkages in peptides with their desired pattern. This chapter details two on-resin synthetic
approaches to access a4/7-conotoxin LvIA using Allocam in combination with other
cysteine protecting groups.
3.2 a4/7-Conotoxin LvIA
3.2.1 a4/7-Conotoxin LvIA: Structure and Bioactivity
a4/7-conotoxin LvIA is a C-terminally amidated mini-peptide from C. lividus with
16 amino acid residues. It is the first a-conotoxin isolated from C. lividus and has 4
cysteine residues, resulting two disulfide bridges with constrained conformation.140 These
disulfide bridges lie between Cys2-Cys8 and Cys3-Cys16 (Figure 3.1). The first loop or
bridge contains 4 amino acid residues, and the second loop consists of 7 amino acid
residues.
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Figure 3.1 A. Structure of α4/7-conotoxin LvIA B. Graphical represtation of α4/7-conotoxin LvIA structure
S

S
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S
S

S
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S

NH2

S

Being an a-conotoxin, a4/7-conotoxin LvIA has unique selectivity on nicotinic
acetylcholine receptors (nAChRs) subtypes and mainly block mammalian neuronal
nAChRs.141 Neuronal nAChRs consists of combinations of a (a2-a10) and b (b2-b4)
subunits and exit as a complex family of heteromeric and homooligomeric pentameric
proteins.142 These subtypes are important in normal physiology and in a wide range of
disease states such as pain, addiction, Alzheimer’s disease, myasthenia gravis,
schizophrenia, epilepsy, and breast and lung carcinoma.143,144 a-conotoxins are valuable
tools for identifying and probing the composition and roles of nAChR subtypes.145
Interestingly, a4/7-conotoxins have the ability to discriminate between diverse neuronal
a-b nAChR subunit combinations. a4/7-conotoxin LvIA is selective for the a3b2 nAChR,
and it is the first a-conotoxin that blocks human a3b2 with high selectivity over a6b2*
nAChRs.146 The receptor residues involved in its binding have been identified, and an
analog has been generated that selectively targets a3b2 and a3b6 nAChRs. This analog
also facilitated the identification of a3b4* receptors as the major subtype present in human
adrenal chromafinn cells.147
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3.2.2 a4/7-Conotoxin LvIA: Published Chemical Synthesis
Walker and co-workers have reported a solution phase chemical synthesis of a4/7Conotoxin LvIA (Scheme 3.1).148 In their synthesis protocol, they used Trt and Acm
groups to protect cysteine thiols. After linear synthesis of the peptide 3.1.A using FmocSPPS on rink amide resin, the peptide was removed from the resin and purified. The first
disulfide bond was formed in solution using 20 mM potassium ferricyanide in a Tris buffer
(pH 7.5). The resulting monocyclic peptide 3.1.C was purified by RP-HPLC before the
next folding step. Then, a simultaneous Acm group removal and oxidation was done using
iodine oxidation to close the second disulfide linkage. To perform iodine oxidation, they
dripped

the

monocyclic

peptide

and

HPLC

eluent

into

a

solution

of

iodine:H2O:trifluroacetic acid (78:2:20 by volume) and used ascorbic acid diluted 20-fold
with 0.1% TFA to quench the reaction. Finally, a third purification step had to be performed
using RP-HPLC to get a pure bicyclic product 3.1.D.
Scheme 3.1 Published in-solution synthesis of α4/7-conotoxin LvIA
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The above synthetic process contains total of three purifications steps, which consume
more time and diminish the yield. In addition, there are two in-solution manipulations of
the peptide, which introduces possibility of solubility and/or aggregation issues.
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3.3 Orthogonality of Other Cysteine Protecting Groups Towards Pd-based Allocam
removal
In order to access two disulfide systems like a4/7-conotoxin LvIA, in addition to
Allocam group, another cysteine protecting group is needed for the regioselective
synthesis. The suitable candidate must have stability towards Pd0/II - DMSO based
cleavage-oxidation condition. Therefore, the orthogonality of common cysteine protecting
groups such as Trt, Acm, Mmt and tBu towards Pd-based Allocam removal condition was
evaluated using the model peptide IAPP1-9 (Table 3.1)
Table 3.1 Stability of cysteine protecting groups towards Pd-based Allocam removal condition
tBu
tBu tBu
Boc Trt
9

H

KCNTATCAT

TGT

1) 1.5 equiv Pd(OAc)2
DMSO - 5% AcOH - 3% NMM, 4 h

tBu
tBu tBu
tBu Trt
H

KCNTATCAT

2) TFE:AcOH:DCM (1:1:3), 30 min
SPG

tBu
tBu tBu
Boc Trt

9

S

SPG

3.2.A

S
3.2.B

:

9

OH H

KCNTATCAT OH
SPG

SPG

3.2.C

3.2.C

Entry

PG

3.2.B

1.

Trt

00

100

2.

Mmt

20

80

3.

Acm

90

10

4.

tBu

00

100

Four batches of the model peptide IAPP1-9 were made using Cys(Trt), Cys(Mmt),
Cys(Acm) and Cys(tBu). Each peptide was subjected to the optimized Pd0/II - DMSO
based Allocam removal condition discussed in Chapter 2. Peptides with Trt and tBu
protected cysteines remained unreacted (entry 1 and entry 4) while peptide with Mmt and
Acm protected cysteines gave 20% (entry 2) and 90% (entry 3) of the expected oxidized
product 3.2.B respectively, compared to the starting peptide . This experiment concluded
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that both Cys(Trt) and Cys(tBu) are stable to the Pd0/II - DMSO based cleavage-oxidation
condition and both Cys(Mmt) and Cys(Acm) groups can be cleaved during the Allocam
removal process.
3.4 Stability of Allocam Group Towards Other On-Resin oxidants
After evaluating the orthogonality of other cysteine protecting groups towards Pdbased Allocam removal condition, next, the stability of Allocam group towards other onresin oxidants was examined. Iodine149 and NCS150 are commonly used oxidants for onresin disulfide formation. Therefore, the model peptide IAPP1-9 with Allocam protected
cysteines was subjected to iodine and NCS oxidation condition separately (Scheme 3.2).
Scheme 3.2 IAPP1-9 under A. I2 oxidation and B. NCS oxidation condition
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It was observed that Allocam is not stable under both iodine and NCS oxidation
conditions. The model peptide 3.3.A on Wang resin was subjected to general iodinemediated oxidation conditions (Scheme 3.2.A). Interestingly, simultaneous Allocam
cleavage and oxidation was observed. With Albericio conditions79, 2 equivalents of NCS
in DMF for 15 min (Scheme 3.2.B), 50% conversion of the oxidized product 3.3.B’ was
observed.
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3.5 On-Resin Synthesis of a4/7-Conotoxin LvIA
3.5.1 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on CTC Resin
Considering results from both the experiments discussed in sections 3.1 and 3.2,
our first attempt for on-resin synthesis of a4/7-conotoxin LvIA was use of Trt group as the
second cysteine protecting group along with Cys(Allocam). In the synthesis procedure,
simultaneous removal of Allocam and oxidation followed by Trt group removal and
oxidation using I2 in DCM can be done to obtain the two disulfide linkages selectively
(Scheme 3.3). Stability of Trt group towards Pd0/II - DMSO based cleavage-oxidation
condition allowed us to use it for the second disulfide bond formation. But, it cannot be
used to form the first disulfide linkage since Allocam group is unstable to I2 oxidation.
Scheme 3.3 On-Resin Synthesis of α4/7—Conotoxin LvIA using Cys(Allocam)
and Cys(Trt)
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To evaluate feasibility of the proposed synthesis, linear synthesis of the peptide with
Cys(Allocam) and Cys(Trt) was done on CTC resin. Although C-terminal end of a4/7conotoxin LvIA is an amide, CTC resin, which gives C-terminal carboxylic acid after
peptide cleavage, was used to facilitate analysis of the reaction. CTC resin cleavage
requires mild acid condition such as TFE:AcOH:DCM (1:1:8), which results peptides with
side chain protecting groups including Cys(Allocam) and Cys(Trt). This helps in reaction
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optimization for each step of the synthesis. Reactions were monitored via analytical RPHPLC-MS. The ratio of starting material to product was monitored and optimization was
done until complete disappearance of the starting material in the system.
First, optimization of step one was done, which is Allocam removal and oxidation
using Pd0/II - DMSO based cleavage-oxidation condition (Table 3.2).
Table 3.2 Optimization for Pd-mediated Allocam cleavage and oxidation
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The linear peptide 3.5.A was subjected to the optimized Pd0/II - DMSO based Allocam
cleavage condition for IAPP 1-9 described on chapter 2. A ratio of 80:20, the desired folded
product 3.5.B and the starting peptide 3.5.C was observed (entry 1). When the reaction
time was increased from 4 hours to 6 hours, keeping equivalents of Pd the same, the
reaction can be pushed towards 100% conversion of the product with desired disulfide
bond 3.5.B (entry 2). After optimizing the first step of the synthesis, the reaction was
scaled up and the resulting solid supported peptide 3.5.D was forward to the second step.
Traditional I2 oxidation was done using 8 equivalents of iodine in DCM to form the second
disulfide bond. Here, Trt group removal and oxidation occur in a single step (Scheme
3.4).
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Scheme 3.4 I2 oxidation for second disulfide formation
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After each step, the resin was washed thoroughly to remove all the reagents used. The
final peptide was cleaved from the resin using TFA:AcOH:DCM (1:1:8) mixture and all the
remaining side chain protecting groups were cleaved with 95% TFA to obtain fully
deprotected carboxy-a4/7-conotoxin LvIA 3.5.E with desired folding pattern. This
illustrated the potential of orthogonal combination of Allocam and Trt groups for cysteine
protection to form on-resin selective disulfide bonds to access carboxy-a4/7-conotoxin
LvIA.
3.5.2 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on MeDbz-GChemMatrix Resin
With the optimized conditions on hand, we wanted to synthesize a4/7-conotoxin
LvIA on a resin which gives C-terminal carboxamide after cleavage. Our first choice was
rink amide resin. Due to the failure in linear synthesis of the peptide on rink amide resin,
we had to select another suitable resin for the synthesis. This problem let to development
of a novel method for C-terminal modification of peptides,151,152,153 while we employed as
shown in Figure 3.2. ChemMatrix resin with MeDbz linker154,155,156 (Figure 3.2.A) was
employed to synthesize a4/7-conotoxin LvIA. Peptides on MeDbz linker found to be
cleaved with a balloon of NH3, after activating the linker, to achieve peptide
carboxamide.152
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Figure 3.2 A. Structure of MeDbz linker-Gly-ChemMatrix Resin B. Graphical representation of
MeDbz linker-Gly-ChemMatrix Resin
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When peptides are cleaved from MeDbz linker, the N-terminal needs to be protected to
prevent acylation during linker activation.153 On the other hand, for Pd-mediated Allocam
removal process, the N-terminal of the peptide should be free in order to use less Pd
loading.157 Therefore, in the synthesis of a4/7-conotoxin LvIA on MeDbz linker-GChemMatrix resin, an additional step needed to be done to protect N-terminal of the
peptide before cleavage from the resin (Scheme 3.5).
Scheme 3.5 On-Resin Synthesis of α4/7-Conotoxin LvIA on MeDbz-G-ChemMatrix Resin
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After success in the linear synthesis of the peptide 3.6.A on MeDbz-G-ChemMatrix resin,
it was first subjected to optimized Pd0/II - DMSO based Allocam cleavage condition to form
on-resin peptide 3.6.B with first S-S bond. With 1.5 equivalences of Pd in DMSO-AcOHNMM solvent system for 6 hours, 100% of the desired product 3.6.B was obtained as
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expected. The mono-cyclic peptide 3.6.B was then exposed to I2 oxidation for 1 hour to
form the second S-S bond 3.6.C. Before cleaving the peptide from resin, Boc protection
was done to the N-teminal using (Boc)2O in DCM along with DIPEA as the base. Next,
MeDbz linker was activated with 4-nitrophenyl chloroformate followed by bubbling NH3 in
to a solution of peptide in DMF to result Boc-protected and side chain protected peptide
3.6.E. Finally, 95% TFA cleavage was done to obtain fully deprotected peptide 3.6.F with
desired disulfide bonds. All the steps in the synthesis proceeded as expected except the
last step, the Boc group proved resistant to acidic cleavage. Even though the final product
was subjected to 95% TFA for longer exposer time, Boc group deprotection was
unsuccessful.
3.5.3 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on Rink Amide
Resin
After several attempts, we were able to optimize Fmoc-SPPS condition for the
linear synthesis of a4/7-conotoxin LvIA with Cys(Allocam) and Cys(Trt) on rink amide
resin. This led us to evaluate all the optimized on-resin folding steps on rink amide resin
and synthesize a4/7-conotoxin LvIA with carboxyamide functionality (Scheme 3.6). First,
the linear peptide 3.7.A was subjected to the optimized Pd0/II - DMSO mediated Allocam
cleavage condition for CTC resin. The reaction didn’t go to completion with 1.5 equivalent
of Pd(OAc)2 loading. The reaction was repeated with 3.0 equivalent of Pd(OAc)2 loading
for 6 hours and complete disappearance of starting peptide was observed along with the
product 3.7.B with desired disulfide bond. Next, the resulting solid supported mono cyclic
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peptide 3.7.C was subjected to traditional I2 oxidation to obtain the second disulfide bond
3.7.D.
Scheme 3.6 On-Resin Synthesis of α4/7—Conotoxin LvIA using Cys(Allocam)
and Cys(Trt) on Rink Amide Resin
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Treatment of 95% TFA followed by RP-HPLC purification gave the fully deprotected a4/7conotoxin LvIA 3.7.E in ~1% isolated yield.
3.5.4 Synthesis of a4/7-Conotoxin LvIA using Cys(StBu), Cys(Mmt) and Cys(Allocam) on
Rink Amide Resin
After accessing a4/7-conotoxin LvIA with Cys(Allocam) and Cys(Trt), where
simultaneous Allocam removal and oxidation followed by Trt group removal and oxidation
was done on solid support, we wanted to evaluate the utility of Pd-based Allocam removal
and oxidation method to generate a second S-S bond selectively in mono cyclic peptides.
To form the first disulfide linkage, the method reported by Tung and co-workers was
selected.81 According to their method, StBu and Mmt was used as cysteine protecting
groups, which facilitate on-resin disulfide bond formation without an oxidant. As the first
step, the Cys(StBu) deprotection can be done using 20% mrecaptoethanol in DMF and
the resulting free SH 3.8.B can be activated with 10-fold excess of DTNP in DCM to form
5-Npys-activated disulfide 3.8.C. Removal of Mmt group with mild TFA condition in
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presence of TIPS facilitates the disulfide bond formation in the peptide 3.8.D. After
formation of first disulfide bond, our Pd-based simultaneous removal of Allocam and
oxidation method can be done to form the second disulfide bond (3.8.E) (Scheme 3.7).
Scheme 3.7 On-Resin Synthesis of α4/7-Conotoxin LvIA with Cys(StBu), Cys(Mmt)
and Cys(Allocam)
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Linear synthesis of a4/7-conotoxin LvIA with Cys(StBu), Cys(Mmt) and Cys(Allocam) was
successfully done using optimized Fmoc-SPPS conditions. Optimization of each step was
then begun starting with thiol exchange of the StBu group (Table 3.3). Linear a4/7conotoxin LvIA on rink amide resin 3.8.A was first subjected to 20% mercaptoethanol at
room temperature for different time intervals. In 3 hours, it gave 40% conversion of the
desired product 3.8.F (entry 1). When increase the time to 6 hours, 80% product
conversion was observed (entry 2). More than 95% of product was observed when the
reaction run for 12 hours (entry 3). Grøtli and co-workers have reported microwave
conditions for StBu – Mmt mediated on-resin non-oxidative disulfide bond formation
strategy.82
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Table 3.3 Reaction optimization for Cys(StBu) deprotection
SH

SH

16

H
SMmt SStBu
tBu tBu
tBu

SAllocam

16

H

GCCSHPACNVDHPEIC

GCCSHPACNVDHPEIC

RA

Trt Trt Trt
SAllocam
SAllocam

NH2

SAllocam

3.8.F

1) X% HSCH2CH2OH in DMF, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min

SStBu

SH

16

H

GCCSHPACNVDHPEIC

NH2

3.8.A
SAllocam

SAllocam

3.8.G
:

Entry

X%

Temperature

time (h)

3.8.F

1.

20

R.T.

3

40

2.

20

R.T.

6

80

20

3.

20

R.T.

12

>95

<5

4.

30

60 ºC, MW

2

>95

<5

5.

30

60 ºC, MW

3

>98

<2

3.8.G
60

For Cys(StBu) deprotection, they used microwave heating at 60 ºC with 30%
mercaptoethanol. In order to lower the reaction time for Cys(StBU) deprotection, a
reaction with 30% mercaptoethanol at 60 ºC under microwave heating was set up for 2
hours. This reaction gave 95% conversion of product (entry 4), while heating for 3 hours
gave more than 98% of product conversion (entry 5). Therefore, it was concluded that
30% mercaptoethanol at 60 ºC under microwave heating for 3 hours is the optimal
Cys(StBu) deprotection condition for the substrate 3.8.A.
According to Tung and co-workers’ displacement method for on-resin disulfide
bond formation, the resulting free SH, after Cys(StBu) deprotection, needs to be activated
using 10-fold excess of DTNP in DCM. Optimization for DTNP activation was done for
Cys(StBu) deprotected peptide 3.8.B. In terms of monitoring the reaction, we analyzed
ratio of the desired folded product 3.8.H and the fully reduced product 3.8.I. If the reaction
goes to 100% conversion, only desired folded product 3.8.H should be observed in MS
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after 95% TFA cleavage. Partially activated resins give mixture of folded and reduced
products since, only peptides with 5-Npys-activated thiol group facilitates disulfide bond
formation. First, reactions were done at room temperature for different time intervals
(Table 3.4). Reactions which run for 1 hour (entry 1) and 3 hour (entry 2) time intervals
gave about 50% and 65% of folded product respectively while 6 hour reaction (entry 3)
gave 100% folded product, indicating all the thiol groups on the resin have been activated
with 5-Npys group.
Table 3.4 Reaction optimization for activation of free thiol using DTNP
S

S
16

H
SMmt SH
tBu tBu
tBu

SAllocam

16

H

GCCSHPACNVDHPEIC

GCCSHPACNVDHPEIC

RA

Trt Trt Trt
SAllocam
SAllocam

1) 10 equiv DTNP in DCM, t1 h

NH2

SAllocam

3.8.H

2) TFA:TIPS:H2O (95:2.5:2.5), 30 min

SH

SH
16

H

GCCSHPACNVDHPEIC

NH2

3.8.B
SAllocam

SAllocam

3.8.I
:

Entry

Temperature

time (h)

3.8.H

1.

R.T.

1

50

50

2.

R.T.

3

65

35

3.

R.T.

6

100

00

4.

60 ºC, MW

1

100

00

3.8.I

In addition, microwave condition was tried similar to Grøtli and co-workers have reported
in their studies. Under microwave heating at 60 ºC, 100% activation of free SH from DTNP
can be achieved within an hour (entry 4). When scaling up the reaction, microwave
conditions didn’t give consistent results. Hence, we concluded 6 hour room temperature
conditions as the optimal conditions for this reaction.
According to the synthetic procedure, next step is to remove Mmt group using mild
TFA condition to facilitate S-S bond formation. Although commonly used Cys(Mmt)

81
cleavage condition is 1% TFA in DCM, in our system, Mmt group is found to be not labile
to such mild TFA condition. Therefore, reaction optimization had to be done to Mmt group
removal and a4/7-conotoxin LvIA was synthesized on CTC resin as the substrate for the
optimization. After the success in linear synthesis of a4/7-conotoxin LvIA on CTC, the
peptide 3.8.J was subjected to various percentages of TFA solutions in DCM with 5%
TIPS for different time intervals (Table 3.5).
Table 3.5 Reaction optimization for Cys(Mmt) deprotection
SH
tBu
H

OH

Trt Trt Trt
SAllocam
SAllocam

16

GCCSHPACNVDHPEIC

16

GCCSHPACNVDHPEIC

SMmt SStBu
tBu tBu
tBu
H

SStBu
tBu tBu

CTC

3.8.K

X% TFA: 5% TIPS: in DCM

SMmt SStBu
tBu tBu
tBu

t min

Trt Trt Trt
SAllocam
SAllocam

16

H

GCCSHPACNVDHPEIC

3.8.J

OH

Trt Trt Trt
SAllocam
SAllocam
3.8.L
Entry

X%

1.

2

30

2.

2

60

3.

3

15

4.

4

10

5.

4

5

6.

5

5

time (min)

3.8.K

:

3.8.L

As CTC resin is sensitive to mild acidic conditions, the peptide cleavage can also be
achieved in the same TFA condition as the reaction condition. The resulting peptides are
immediately precipitated using cold diethyl ether, centrifuged, the ether layer was
decanted, resulting precipitate was dissolved in 1:1 MeCN:H2O and analyzed by MS
directly for 100% product 3.8.K peaks. With increased TFA concentration, Cys(Mmt)
removal can be seen in shorter period of time. In order to have a minimal percentage of
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TFA to remove Mmt group, 3% TFA condition was selected as the optimal reaction
condition for this substrate (entry 3). For peptides with 5-Npys-activated disulfide group,
3% TFA treatment was done for 2 x 15 min to ensure total Mmt group cleavage and it
was then subjected to DCM wash for 3 x 30 min until no yellow color in the washings. As
the byproduct 5-nitropyridine-2-thione has an absorbance at 386 nm,14 disappearance of
yellow color in the washings indicates completion of disulfide bond formation. In addition,
Ellman’s reagent was used to analyze unreacted free thiol groups in the system. These
steps led to the first folding of a4/7-conotoxin LvIA. The resulting peptide was then
subjected to Pd-DMSO Allocam removal condition to obtain the second folding of the
peptide (Table 3.6). For an incomplete reaction, in addition to the desired peptide 3.8.M,
starting peptide with both Allocam group on, 3.8.N, and starting peptides with partial
Allocam cleavage, 3.8.O, were observed by MS. Therefore, when monitoring the reaction
for completion, all the above structures were evaluated. Optimization was started with
previously optimized conditions for caboxy-a4/7-conotoxin LvIA. With 1.5 equivalences
of Pd(OAc)2 at room temperature for 6 hours, reaction didn’t go to completion as expected
(enrty 1). Neither increased time nor increased Pd loading at room temperature pushed
the reaction for 100% product conversion (entry 2 – entry 4). Assuming additional energy
might improve reactivity of the reaction, microwave heating was applied to the system
(entry 5 – entry 9). Various Pd loadings and reaction times were tried, but none of them
led to complete disappearance of starting material in MS. In addition to the Pd-based
Allocam removal condition, NCS oxidation condition was also used to achieve a complete
conversion of the desired product. Different equivalencies of NCS and reaction times
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were tried (Table 3.7), and no complete conversion of the reaction was observed.
Interestingly, in most of these reaction conditions tried, major substrate observed was the
peptide with one Allocam cleavage 3.8.O.
Table 3.6 Reaction optimization for Pd-based Allocam removal and oxidation
S

S
tBu tBu

tBu
H

16

RA

GCCSHPACNVDHPEIC

Trt Trt Trt
SAllocam
SAllocam
3.8.D
1) X equiv Pd(OAc)2
DMSO - 5% AcOH - 3% NMM, T ºC, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 x 30 min
S

S

S

NH2

GCCSHPACNVDHPEIC

S

SAllocam

16

H

GCCSHPACNVDHPEIC

SAllocam

GCCSHPACNVDHPEIC
S

3.8.N

NH2
S

S
3.8.M

S

S
16

S

H

16

H

GCCSHPACNVDHPEIC

NH2

GCCSHPACNVDHPEIC

SH

SAllocam
SH

SH

NH2

SAllocam

SH

16

H

S

S

16

H

3.8.O

3.8.P
: 3.8.N

:

:

Entry

X equiv.

Temperature

time (h)

3.8.M

1.

1.5

R.T.

6

05

00

95

00

2.

1.5

R.T.

12

n.d.

n.d.

n.d.

n.d.

3.

3.0

R.T.

6

05

00

95

00

4.

7.0

R.T.

6

15

00

85

00

5.

3.0

60 ºC MW

6

55

00

45

00

6.

3.0, 1.5

60 ºC MW

6, 3

n.d.

n.d.

n.d.

n.d.

7.

3.0

60 ºC MW

7

50

00

50

00

8.

3.0

60 ºC MW

6

45

00

55

00

9.

5.0

60 ºC MW

6

20

00

80

00

3.8.O

3.8.P

NH2
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Table 3.7 Reaction optimization for NCS-mediated Allocam removal and oxidation
: 3.8.N

: 3.8.O

:

Entry

X equiv.

1.

5.0

6

02

00

95

00

2.

5.0

10

60

00

40

00

3.

7.0

6

85

00

15

00

time (h)

3.8.M

3.8.P

The results of these reactions indicate that removal of one of the Allocam groups’ is
difficult. If we analyze the peptide structure, one of the Allocam protected cysteines is
closer to the resin and sterically more hindered. Due to the fact Cys16(Allocam) is closer
to the resin, deprotection might be challenging.
3.5.5 Synthesis of a4/7-Conotoxin LvIA using Cys(StBu), Cys(Mmt) and Cys(Allocam) on
Rink Amide Linker-GGG-ChemMatrix Resin
In order to overcome the challenge of terminal Cys16(Allocam) removal we
hypothesized that the steric hindrance around the peptide needed to be minimized.
Therefore, we endeavor to increase the distance between the resin and the peptide by
introducing a long linker in between them (Figure 3.3).
Figure 3.3 A. Structure of RA linker-Gly—Gly-Gly-ChemMatrix Resin
B. Graphical representation of RA linker-Gly-Gly-Gly-ChemMatrix Resin
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Fmoc—Rink amide linker-Gly-Gly-Gly-ChemMatric Resin

The linker (A. Figure 3.3) was synthesized successfully on ChemMatrix resin and then,
linear synthesis of the peptide 3.9.A was done, using optimized Fmoc-SPPS conditions,
on the linker. Thereafter, reaction conditions for each step was evaluated. First, the
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peptide 3.9.A was subjected to microwave assisted optimized Cys(StBu) deprotection
conditions described in section 3.6 (Table 3.8). With 3 hours, a total deprotection was
observed as expected (entry 1). In chapter 02, we evaluated that PEG based ChemMatrix
resin can proceed reactions faster than polystyrene based resins due to their superior
swelling power. Therefore, we set up reactions with lower reaction times leaving
microwave heating conditions the same. Interestingly, complete StBu removal was
observed in 1.5 hours for our new system (entry 2).
Table 3.8 Reaction optimization for Cys(StBu) deprotection
SMmt SStBu
tBu tBu
tBu

16

H

GCCSHPACNVDHPEIC

RA Linker

CM

GGG

Trt Trt Trt
SAllocam
SAllocam
3.9.A
1) 30% HSCH2CH2OH in DMF
60 ºC MW, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
SH

SH

SStBu

SH
16

H

GCCSHPACNVDHPEIC

16

NH2

H

GCCSHPACNVDHPEIC

SAllocam

SAllocam

SAllocam

3.9.B

NH2

SAllocam

3.9.C
Entry

:

time (h)

3.9.B

1.

3

100

00

2.

1.5

100

00

3.

1

95

05

3.9.C

After StBu removal, the resulting free SH needed to be activated by DTNP. The reaction
optimization was done for the peptide 3.9.D with 10 equivalences of DTNP in DCM for
different time intervals (Table 3.9). Even though it took 6 hours for the peptide on rink
amide resin to get fully activated, for the same peptide on rink amide linker-Gly-Gly-Gly
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ChemMatrix resin, it only took 1 hour (entry 3). Remarkably, the reaction time dropped
drastically for this reaction.
Table 3.9 Reaction optimization for Activation of free thiol using DTNP
SMmt SH
tBu tBu
tBu

16

H

GCCSHPACNVDHPEIC

RA Linker

CM

GGG

Trt Trt Trt
SAllocam
SAllocam
3.9.D
1) 10 equiv DTNP in DCM, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min

S

S

SH

SH
16

H

GCCSHPACNVDHPEIC

16

NH2

H

GCCSHPACNVDHPEIC

SAllocam

SAllocam

SAllocam

3.9.E

NH2

SAllocam

3.9.F
:

Entry

time (h)

3.9.E

1.

6

100

00

2.

3

100

00

3.

1

100

00

3.9.F

After activating the free thiol group on the peptide, Mmt removal needed to be done to
form the first disulfide bond after release of Npys group. In section 3.6, the selected
condition for Mmt removal was 3% TFA in DCM for 15 min. Due to a significant peptide
cleavage observed with longer exposer time, we switched the condition for shorter time
by using 5% TFA in DCM for 5 x 1 min. After TFA treatment, the resin was allowed to
agitate with DCM wash an hour to ensure complete displacement of 5-Npys group.
Additionally, DCM wash for 3 x 30 min was done until no yellow color was observed in
the washings. Furthermore, absence of free thiol groups was tested with Ellman’s reagent
to confirm complete folding of first S-S bond.
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Table 3.10 Reaction optimization for Allocam removal and oxidation
S

S
tBu tBu

tBu
H

16

RA Linker

GCCSHPACNVDHPEIC

CM

GGG

Trt Trt Trt
SAllocam
SAllocam
3.9.G
1) Reaction condition, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 x 30 min
S

S

S

S

GCCSHPACNVDHPEIC
SAllocam

NH2

16

H

SAllocam

GCCSHPACNVDHPEIC

3.9.I

NH2
S

S

S
3.9.H

SAllocam

S

S
16

S

H

16

H

NH2

GCCSHPACNVDHPEIC
SH

16

H

S

S

16

H

GCCSHPACNVDHPEIC

GCCSHPACNVDHPEIC

NH2

NH2
SH

SAllocam
SH

SH

3.9.J

3.9.K
: 3.9.I

Entry

Rxn condition

time (h)

1.

3.0 equiv Pd(OAc)2
DMSO-5%AcOH-3%NMM

6

>95

(7)

00

2.

5.0 equiv NCS in DMF

6

>99

(n.d.)

3.

5.0 equiv I2 in DCM

6

50

4.

8.0 equiv I2 in DCM

6

>99

3.9.H (Yield%)

(18)

:

3.9.J

: 3.9.K

<5

00

00

<1

00

00

00

50

00

<1

00

Three different procedures were tried simultaneously to form the second on-resin disulfide
bond (Table 3.10). Previously optimized Pd-DMSO Allocam removal and oxidation
condition gave about 95% conversion of desired product with 7% overall yield and
significantly less partial Allocam cleavage substrate 3.9.J (entry 1). The NCS condition
also worked well for the new design where about 98% conversion was achieved with 5.0
equivalences of NCS in 6 hours reaction time (entry 2). This is a great improvement from
what we observed in section 3.6. For the first time, we tried iodine condition for Allocam
removal and oxidation. With 5.0 equivalences of iodine in DCM for 6 hours, about 50%
oxidized product formation was observed (entry 3). When increase the iodine loading from
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5.0 to 8.0 equivalences the reaction went to 100% conversion of the product with desired
S-S pattern in 18% overall yield (entry 4).
3.5.6 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on Rink Amide
Linker-GGG-ChemMatrix Resin
After the success in the synthesis of a-Conotoxin LvIA on Rink amide linker-GGGChemMatrix resin (see section 3.5.5), we wanted to revisit the synthesis protocol
discussed in section 3.5.3 on Rink amide linker-GGG-ChemMatrix resin.
Scheme 3.8 Synthesis of of α4/7—Conotoxin LvIA using Cys(Allocam)
and Cys(Trt) on Rink Amide Linker-GGG-ChemMatrix Resin
SAllocam
SAllocam
tBu tBu
tBu
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H
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S
H
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Trt
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Trt Trt STrt
3.10.B
1) 5 equiv I2 in DCM, 90 min
2) TFA:TIPS:H2O (95:2.5:2.5), 2 h
S

S

16

H

GCCSHPACNVDHPEIC
S

NH2

S
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The linear synthesis of the peptide was done using Cys(Allocam) and Cys(Trt) on Rink
amide linker-GGG-ChemMatrix resin and the optimized conditions for each step were
rerun for the new system (Scheme 3.8). Similar to what we observed in section 3.5.5, an
increment in the reaction rates was observed. First disulfide bond formation can be
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obtained in 3 hours with 3.0 equivalent of Pd(OAc)2 in DMSO-AcOH-NMM solvent
system, which required 6 hours for rink amide resin without the linker. An iodine oxidation
was done to achieve the formation of second disulfide bond. Final TFA cleavage was
done to access the fully deprotected a-Conotoxin LvIA, 3.10.C with desired disulfide
bonds.
3.6 Summary
In this chapter, we demonstrated the utility of Allocam group to access a4/7-conotoxin
LvIA in combination with other cysteine protecting groups such as Trt, StBu and Mmt.
Two routes were introduced based on position of the Allocam protected cysteines and
selection of compatible other cysteine protecting groups for each of the synthetic routes.
The linear synthesis of the a4/7-conotoxin LvIA and its reactivity towards folding were
improved by using a three glycine linker in between the resin and the peptide. In addition
to Pd-DMSO based simultaneous on-resin Allocam removal and oxidation condition, both
I2 oxidation and NCS oxidation can be used in on-resin Allocam removal and oxidation.
Among the three deprotection-oxidation conditions, I2 mediated simultaneous Allocam
removal and oxidation gave the highest yield for selective on-resin synthesis of a4/7conotoxin LvIA. The utility of Allocam group can be extended to synthesize peptides with
more than two disulfide bonds by careful selection of orthogonally compatible other
cysteine protecting groups.
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3.6 Materials and methods
3.6.1 General Information
Unless otherwise specified, all commercially available reagents were purchased from
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF,
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial
solvent purification system (2 columns of alumina) and used without further drying.
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL,
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room
temperature. All yields refer to chromatographically and spectroscopically pure products.
All HPLC analyses and purifications were performed on a Custom Reverse Phase
Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle
between analytical and semi-preparative columns. This instrument has a photodiode
array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O)
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific
Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based
on the final loading.
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SPPS General Information. Solid-phase peptide synthesis was executed on a Biotage
Isolera+ semi-automated synthesizer with microwave heating.
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL)
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The
solvent was then removed over 1 m followed by two DMF washes (DMF was added
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of
solvent (over 2 m)).
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv)
in DMF was made immediately prior to addition to the reaction vial containing the
resin. Once the solution was added, the suspension was heated to 75 ºC (except for
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed
with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m).
•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF.
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF
washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200
RPM for 1 m, solvent removal was at a rate of 2 m).
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•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times.
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL).
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the
lyophilizer overnight for drying.
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF
(5 x 3 mL).
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed
based on amount of Fmoc group.
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min,
the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF
was added to it and allowed to vortex in the peptide synthesizer at room temperature for
10 min. The resulting filtrate was collected to the same tube and the deprotected resin
was washed with DMF (4 x 1.75 ml).
Sample preparation for UV analysis – From the collected ”deprotection solution” above,
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF.
The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF
blank using a UV spectrometer with 1 cm cuvette.
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General Procedure for Pd-DMSO Cleavage/Oxidation. The peptide on the stated resin
(10 mg) was swelled in DMF at room temperature for 30 minutes. After removing excess
DMF, the cartridge was capped on the bottom. A solution of Pd(OAc)2 in 5% AcOH/DMSO
solution was added, and then the stated amount of NMM was added. The cartridge was
capped on the top, attached to a magnetic stirbar retriever using a rubber band, and
agitated for the stated amount of time. The reaction was filtered, and the resin was
washed successively with with DMF (3 x 2 min), CH2Cl2 (3 x 2 min), 0.2 M sodium
diethyldithiocarbamate in DMF (3 x 30 min), MeOH (3 x 1 min), DMF (5 x 1 min) and
CH2Cl2 (3 x 1 min). *Note: resin changes from dark orange/brownish to yellowish/tan. The
resin was then subjected to a stated cleavage mixture for 30 minutes.
Product analysis was done directly (with no lyophilization) by analytical RP-HPLC-MS
using a Hypersil GOLD column (5 L, 150 x 4.6 mm) at a flow rate of 1 mL/min with stated
gradient and time.
Ammonia Cleavage of Peptides on Resin: The stated amount of the peptide on resin
(dry) was weighed out into a fritted reaction vial with an attached needle and rubber
stopper (suggested selection of SPPS vial: 10-40 mg of peptide on resin goes into the 2
mL reaction vial, 40-200 mg in the 5 mL reaction vial and ³200 mg goes into the 10 mL
reaction vial). The resin was swelled in DCM (500 µL – 4 mL) for 0.5-1 h. The MeDbz
linker was activated by a previously established protocol., Next, 500 µL of DMF was added
and the reaction vial was closed off with a septum (needle and stopper still attached at
the bottom). A double balloon was made and filled with ammonia. A hypodermic needle
was attached to the balloon and inserted into the septum and submerged into the DMF
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solution. The smallest (blue) gauge needle was placed into the septum to allow for the
slow exiting of gas. The ammonia gas was bubbled into DMF for 1.5 h. Then the solvent
was removed and collected. Additional rinsing was required to completely remove the
desired peptide from resin. DCM (3 x 1 mL) was used to rinse the resin, followed by MeCN
(3 x 1 mL), and lastly DCM (3 x 1 mL). The washes were combined with the initial DMF
solution, blown down with air, subjected to 1:1 MeCN:H2O, frozen (LN2), and lyophilized
to yield the crude product.
3.6.2 Experimental Procedures and Spectroscopic Data
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OH H

KCNTATCAT OH
SPG
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General Procedure for Table 3.1. The general procedure for Pd-DMSO cleavageoxidation was followed. The reaction mixture was agitated in a closed vial at room
temperature for 4 hours. After the wash, the dried resin was subjected to 300 µL of the
cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min. The filtrates were collected,
concentrated and analyzed by RP-HPLC-MS using an analytical Thermo Scientific
Hypersil Gold C8 column at a flow rate of 1 mL/min.

Entry 1. The IAPP1-9 with Cys(Trt) was used. The relevant quantities are: Resin 3.2.A (10
mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5% AcOH
(250 µL). The reaction was analyzed by RP-HPLC-MS using an analytical Thermo
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-90% MeCN/H2O
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gradient for 30 minutes. m/z ES calc’d for peptide 3.2.C [C108H135N11O16S2 + 1]+:
1907.45; observed: 1908.40. m/z ES calc’d for peptide 3.2.C-Trt [C89H121N11O16S2 + 1]+:
1665.13; observed: 1665.70.

Starting peptide (3.2.C); [(M+2)/2]+
Starting peptide-Trt; [(M+2)/2]+
Product (3.2.B); [(M+2)/2]+
PDA 214 nm

Figure 3.4 Analytical Column PDA for Table 3.1 – Entry 1

Entry 2. The IAPP1-9 with Cys(Mmt) was used. The relevant quantities are: Resin 3.2.A
(10 mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5%
AcOH (250 µL). The reaction was analyzed by RP-HPLC-MS using an analytical Thermo
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-80% MeCN/H2O
gradient for 30 minutes. m/z ES calc’d for peptide 3.2.C [C110H139N11O18S2 + 1]+:
1967.50; observed: 1968.40. m/z ES calc’d for peptide 3.2.C-Mmt [C90H123N11O17S2 +
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1]+: 1695.15; observed: 1695.75. m/z ES calc’d for peptide 3.2.B [(C70H105N11O16S2 +
2)/2]+: 711.40; observed: 711.25.

Starting peptide (3.2.C); [(M+2)/2]+
Starting peptide-Mmt; [(M+2)/2]+
Oxidized Product (3.2.B); [(M+2)/2]+
PDA 214 nm

Figure 3.5 Analytical Column PDA for Table 3.1 – Entry 2

Entry 3. The IAPP1-9 with Cys(Acm) was used. The relevant quantities are: Resin 3.2.A
(10 mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5%
AcOH (250 µL). The reaction was analyzed by analytical Thermo Scientific Hypersil Gold
C8 column at a flow rate of 1 mL/min with 50-80% MeCN/H2O gradient for 30 minutes.
m/z ES calc’d for peptide 3.2.C [(C76H117N13O18S2 + 2)/2]+: 783.48; observed: 783.20.
m/z ES calc’d for peptide 3.2.8 [(C70H105N11O16S2 + 2)/2]+: 711.40; observed: 711.20.
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Starting peptide (3.2.C); [(M+2)/2]+
Oxidized Product (3.2.B); [(M+2)/2]+
PDA 214 nm

Figure 3.6 Analytical Column PDA for Table 3.1 – Entry 2

Entry 4. The IAPP1-9 with Cys(tBu) was used. The relevant quantities are: Resin 3.2.A
(10 mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5%
AcOH (250 µL). The reaction was analyzed by RP-HPLC-MS using an analytical Thermo
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-90% MeCN/H2O
gradient for 30 minutes. m/z ES calc’d for peptide 4.X.B [C78H123N11O16S2 + 1]+: 1535.02;
observed: 1535.65. m/z ES calc’d for [(C78H123N11O16S2 + 2)/2]+: 768.51; observed:
768.25.
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Starting peptide (3.X.B); [M+1]+
Starting peptide (3.X.B); [(M+2)/2]+
Oxidized Product (4.X.C); [(M+2)/2]+
PDA, 214 nm

Figure 3.7 Analytical Column PDA for Table 3.1 – Entry 4
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Test Reaction (Scheme 3.2.B). The resin 3.3.A’ (10 mg, 2 µmol) was swelled in DMF
(300 µL). Then, a solution of NCS (0.5 mg, 4 µmol) in DMF (200 µL) was added and it
was agitated at room temperature for 15 min. The reaction solution was filtered and the
resin was rinsed with DMF (3 x 1 mL) and DCM (3 x 1 mL). The resulting resin was
subjected to 300 µL of the cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min. The
resulting solution was collected, concentrated and analyzed by RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 1050% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.3.A’
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[(C80H121N13O20S2 + 2)/2]+: 825.52; observed: 824.90. m/z ES calc’d for peptide 3.3.B’
[(C70H105N11O16S2 + 2)/2]+: 711.40; observed: 711.15.

Starting peptide (3.3.A’); [(M+2)/2]+
Oxidized Product (3.3.B’); [(M+2)/2]+
PDA 214 nm

Figure 3.8 Analytical Column PDA for Scheme 3.2 Reaction B
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SPPS of Peptide 3.5.A. The standard Fmoc-SPPS protocol was used to synthesize
peptide 3.5.A on CTC resin, except no HATU was used in the first amino acid coupling.
To analyze the peptide, 10 mg of the resin was subjected to 300 µL of the cleavage
mixture (1:1:8 TFE:AcOH:DCM) for 30 min. The filtrates were collected, concentrated
and analyzed by RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8
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column at a flow rate of 1 mL/min with 50-75-95% MeCN/H2O gradient for 30 minutes.
m/z ES calc’d for peptide 4.X.B [(C183H209N23O27S4 + 2)/2]+: 1645.23; observed: 1645.35.

Linear peptide (3.5.A); [(M+2)/2]+
PDA 214 nm

Figure 3.9 Analytical Column PDA for linear peptide 3.5.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 16.81 min

Figure 3.10 ES-MS spectrum for linear peptide 3.5.A at retention time 16.81 min
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General Procedure for Table 3.2. For each of the reaction, the general procedure for
Pd-DMSO cleavage-oxidation was followed using the peptide 3.5.A (10 mg, 4 µmol),
Pd(OAc)2 (1.4 mg, 6 µmol), NMM (15.0 µL, 68.4 µmol) and DMSO-5% AcOH (500 µL).
The reaction mixture was then agitated in a closed vial at room temperature for stated
amount of time. After the wash, the dried resin was subjected to 300 µL of the cleavage
mixture (1:1:8 TFE:AcOH:DCM) for 30 min. The filtrates were collected, concentrated
and analyzed by RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8
column at a flow rate of 1 mL/min with 50-75-95% MeCN/H2O gradient for 30 minutes.
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Entry 1. The reaction was agitated for 4 h. m/z ES calc’d for peptide 3.5.C
[(C183H209N23O27S4 + 2)/2]+: 1645.23; observed: 1646.00. m/z ES calc’d for peptide 3.5.B
[(C173H193N21O23S4 + 23 + 2)/2]+: 1543.41; observed: 1544.41

Starting peptide (3.5.C); [(M+2)/2]+
Product (3.5.B); [(M+2)/2]+
PDA 214 nm

Figure 3.11 Analytical Column PDA for determination of conversion; Table 3.2. Entry 1.
Gradient: 50-95% MeCN/H2O + 1% HCOOH over 40 min.
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Entry 2. The reaction was agitated for 6 h. m/z ES calc’d for peptide 3.5.B
[(C173H193N21O23S4 + 23 + 2)/2]+: 1532.41; observed: 1531.45

Starting peptide (3.5.C); [(M+2)/2]+
Product (3.5.B); [(M+2)/2]+
PDA 214 nm

Figure 3.12 Analytical Column PDA for determination of conversion; Table 3.2. Entry 2.
Gradient: 50-75-95% MeCN/H2O + 1% HCOOH over 30 min.
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Carboxy a4/7-Conotoxin LvIA (3.5.E). The resin 3.5.D (30 mg, 12 µmol) was swelled in
DMF (500 µL). Then, Iodine (24.4 mg, 96 µmol) in DCM (360 µL) was added and the
reaction mixture was agitated at room temperature for 1 hour. Next, the reaction mixture
was filtered out and few drops of saturated ascorbic acid in water was added until the
purple color of iodine disappeared. The resulting resin was washed with saturated
ascorbic acid in water. After that, 300 µL of the cleavage mixture (1:1:8 TFE:AcOH:DCM)
was introduced and kept for 2 x 15 min. The filtrates were collected, concentrated and
subjected to TFA:TIPS:H2O (95:2.5:2.5) cleavage mixture for 1 hour. Finally, the resulting
solution was concentrated under a constant stream of air, crashed out with cold diethyl
ether, centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in
5% MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 595% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.5.E
[(C66H97N21O23S4 + 2)/2]+: 841.44; observed: 840.90
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Carboxy a4/7-conotoxin LvIA (3.5.E); [(M+2)/2]+

PDA 214 nm

Figure 3.13 Analytical Column PDA for crude product 3.5.E; Gradient: 5-95% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 10.34 min

Figure 3.14 ES-MS spectrum for crude product 3.5.E at retention time 10.34 min
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MeDbz Linker-Gly-ChemMatrix Resin. The standard Fmoc-SPPS protocol described
was used to synthesize the linker on ChemMatrix resin. The loading of MeDbz linker: 0.3
mmol/g.
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Linear Peptide 3.6.A. The standard Fmoc-SPPS protocol described was used to
synthesize peptide 3.6.A on MeDbz linker-Gly-ChemMatrix resin. The peptide was
capped before the last coupling step. To analyze the peptide, 10 mg of the resin was
subjected general ammonia cleavage protocol and the resulting crude product was
dissolved in 50% MeCN:Water in presence of 0.05%TFA and analyzed via direct ES-MS.
Final loading of the resin: 0.01 mmol/g. m/z ES calc’d for peptide 3.6.A
[(C183H210N24O26S4 + 2)/2]+: 1646.04; observed: 1645.30.

Figure 3.15 ES-MS spectrum for linear peptide 3.6.A
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Mono Cyclic Peptide 3.6.C. The general procedure for Pd-DMSO cleavage-oxidation
was followed. The relevant quantities are: Resin 3.6.A 50 mg, 15 µmol), Pd(OAc)2 (5.1
mg, 22.5 µmol), NMM (56.5 µL, 513 µmol) and DMSO-5% AcOH (1.875 mL). The reaction
mixture was agitated in a closed vial at room temperature for 6 hours. To analyze the
peptide, first, 10 mg of the peptide (3 µmol) was treated with di-tert-butyl dicarbonate
(32.7 mg, 150 µmol) in DCM (300 µL). Then DIPEA (1.5 µL, 9 µmol) was added to the
reaction mixture and agitated for 12 hours. Thereafter, the resin was washed with DCM
(3 x 1 mL) and DMF (3 x 1 mL). After Boc protection step, the resulting peptide was
subjected to the general procedure for ammonia cleavage of peptide on resin. The
resulting crude product was then treated with TFA:TIPS:H2O (95:2.5.2.5) for 2 hours.
Finally, the TFA solution was concentrated under a constant stream of air, crashed out
with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. The peptide
was dissolved in 50% MeCN:Water in presence of 0.05%TFA and analyzed via RPHPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate
of 1 mL/min with 50-90% MeCN/H2O gradient for 30 minutes. Final loading of the resin:
0.01 mmol/g. m/z ES calc’d for peptide 3.6.C+Boc-Trt [(C159H188N22O24S4 + 2)/2]+:
1460.81;

observed:

1460.40.

m/z

ES

calc’d

for

[(C140H174N22O24S4 + 2)/2]+: 1339.65; observed: 1339.15.

peptide

3.6.C+Boc-2Trt
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Product (3.6.C) – Trt; [(M+2)/2]+
Product (3.6.C) - 2Trt; [(M+2)/2]+
PDA 214 nm

Figure 3.16 Analytical Column PDA for determination of conversion. Gradient: 50-90% MeCN/H2O + 1% HCOOH
over 30 min.
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a4/7-conotoxin LvIA 3.6.F. First, the peptide 3.6.C (50 mg, 15 µmol) was swelled in DMF

(500 µL). Then, Iodine (30.5 mg, 120 µmol) in DCM (400 µL) was added and the reaction
mixture was agitated at room temperature for 1 hour. Then, the reaction mixture was
filtered out and few drops of saturated ascorbic acid in water was added until the purple
color of iodine disappeared. The resulting resin was washed with saturated ascorbic acid
in water. Next, the peptide was treated with di-tert-butyl dicarbonate (163.5 mg, 750 µmol)
in DCM (1.5 mL). Then DIPEA (8.0 µL, 45 µmol) was added to the reaction mixture and
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agitated for 12 hours. After Boc protection step, the resulting peptide was subjected the
general procedure for ammonia cleavage of peptide on resin. The resulting crude product
was then treated with TFA:TIPS:H2O (95:2.5.2.5) for 2 hours. Finally, the TFA solution
was concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 50%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 2090% MeCN/H2O gradient for 30 minutes. Final loading of the resin: 0.01 mmol/g. m/z ES
calc’d for peptide 3.6.F+Boc [(C71H106N22O24S4 + 2)/2]+: 891.00; observed: 890.20. m/z
ES calc’d for [(C140H174N22O24S4 + 3)/3]+: 594.33; observed: 593.80.

a4/7-conotoxin LvIA (3.6.F); [(M+2)/2]+

PDA 214 nm

Figure 3.17 Analytical Column PDA for crude product 3.6.F; Gradient: 20-90% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 15.26 min
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Figure 3.18 ES-MS spectrum for crude product 3.6.F at retention time 15.26 min
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SPPS of Linear Peptide 3.8.A. The standard Fmoc-SPPS protocol described was used
to synthesize peptide 3.8.A on rink amide resin. The peptide was capped before the last
coupling step. To analyze the final peptide, 10 mg of the resin was subjected to cleavage
solution of TFA:TIPS:H2O (95:2.5.2.5) for 30 min. Finally, the TFA solution was
concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 1050% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.A
[(C80H124N24O26S5 +

2)/2]+: 1000.15; observed: 999.90. m/z ES calc’d for

[(C74H116N24O26S5 + 3)/3]+: 667.10; observed: 667.00.
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Linear peptide (3.8.A); [(M+3)/3]+
Linear peptide (3.8.A); [(M+3)/3]+
Linear peptide – 1Allocam; [(M+2)/2]+
PDA 214 nm

Figure 3.19 Analytical Column PDA for linear peptide 3.8.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 21.87 min

Figure 3.20 ES-MS spectrum for linear peptide 3.8.A at retention time 21.87 min
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1) X% HSCH2CH2OH in DMF, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
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General Procedure for Reaction Optimization Table 3.3. For each of the reactions, the
peptide 3.8.A (10 mg, 4 µmol) was first swelled in DMF (500 µL). Then, a solution of 20%
mercaptoethanol in DMF (1.0 mL) was added and agitated for stated amount of time either
at room temperature or at 60 ºC under microwave heating. The reaction solution was then
filtered and the resin was washed with DMF (5 x 1 mL). The resulting resin was subjected
to 300 µL of the cleavage mixture (95:2.5:2.5 TFA:TIPS:H2O) for 30 min. The resulting
TFA solution was collected, concentrated, and the peptide was crashed out with cold
diethyl ether. The precipitate was centrifuged, ether discarded, and the pellet was
dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed via
RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for
peptide 3.8.G [(C80H124N24O26S5 + 2)/2]+: 1000.15; observed: 999.80. m/z ES calc’d for
[(C80H124N24O26S5 + 3)/3]+: 667.10; observed: 666.95. m/z ES calc’d for peptide 3.8.F
[(C76H116N24O26S4 +

2)/2]+: 956.08; observed: 955.70. m/z ES calc’d for

[(C76H116N24O26S4 + 3)/3]+: 637.72; observed: 637.55.
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Entry 1. The reaction was agitated at room temperature for 3 hours.

Starting peptide (3.8.G); [(M+2)/2]+
Product (3.8.F); [(M+2)/2]+
PDA 214 nm

Figure 3.21 Analytical Column PDA for Table 3.3. Entry 1.

Entry 2. The reaction was agitated at room temperature for 6 hours.

Starting peptide (3.8.G); [(M+2)/2]+
Product (3.8.F); [(M+2)/2]+
PDA 214 nm

Figure 3.22 Analytical Column PDA for Table 3.3. Entry 2.
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Entry 3. The reaction was agitated at room temperature for 12 hours.

Starting peptide (3.8.G); [(M+2)/2]+
Product (3.8.F); [(M+2)/2]+
PDA 214 nm

Figure 3.23 Analytical Column PDA for Table 3.3. Entry 3.

Entry 4. The reaction was agitated in a microwave at 60 ºC for 2 hours.

Starting peptide (3.8.G); [(M+2)/2]+
Product (3.8.F); [(M+2)/2]+
PDA 214 nm

Figure 3.24 Analytical Column PDA for Table 3.3. Entry 4.
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Entry 5. The reaction was agitated in a microwave at 60 ºC for 3 hours.

Starting peptide (3.8.G); [(M+2)/2]+
Product (3.8.F); [(M+2)/2]+
Product – 1Allocam; [(M+2)/2]+
PDA 214 nm

Figure 3.25 Analytical Column PDA for Table 3.3. Entry 5.
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General Procedure for Reaction Optimization Table 3.4. For each of the reactions, the
resin 3.8.B (10 mg, 4 µmol) was first swelled in DMF (500 µL). Then, a solution of DTNP
(12.4 mg, 40 µmol) in DCM (1.0 mL) was added and allowed to agitate the stated amount
of time either at room temperature or at 60 ºC under microwave heating. The reaction
solution was filtered and the resin was washed with DCM (5 x 1 mL). The resulting resin
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was subjected to 300 µL of the cleavage mixture (95:2.5:2.5 TFA:TIPS:H2O) for 30 min.
The resulting TFA solution was collected, concentrated, and the peptide was crashed out
with cold diethyl ether. The precipitate was centrifuged, ether discarded, and the pellet
was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed
via RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for
peptide 3.8.H [(C76H116N24O26S4 + 2)/2]+: 956.08; observed: 955.75. m/z ES calc’d for
[(C76H116N24O26S4 + 3)/3]+: 637.72; observed: 637.45. m/z ES calc’d for peptide 3.8.I
[(C76H114N24O26S4 +

2)/2]+: 955.06; observed: 954.85. m/z ES calc’d for

[(C76H114N24O26S4 + 3)/3]+: 637.04; observed: 636.95.

Entry 1. The reaction was agitated at room temperature for 1 hour.

Starting peptide (3.8.I); [(M+3)/3]+
Product (3.8.H); [(M+2)/2]+
PDA 214 nm

Figure 3.26 Analytical Column PDA for Table 3.4. Entry 1.
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Entry 2. The reaction was agitated at room temperature for 3 hours.

Starting peptide (3.8.I); [(M+2)/2]+
Product (3.8.H); [(M+2)/2]+
PDA 214 nm

Figure 3.27 Analytical Column PDA for Table 3.4. Entry 2.

Entry 3. The reaction was agitated at room temperature for 6 hours.

Product (3.8.H); [(M+3)/3]+
Product isotope; [(M+3)/3]+
Product – 1Allocam; [(M+3)/3]+

PDA 214 nm

Figure 3.28. Analytical Column PDA for Table 3.4. Entry 3.
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Entry 4. The reaction was agitated in a microwave at 60 ºC for 1 hour.

Product (3.8.H); [(M+3)/3]+
Product isotope; [(M+3)/3]+
PDA 214 nm

Figure 3.29 Analytical Column PDA for Table 3.4. Entry
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SPPS of Peptide 3.8.J. The standard Fmoc-SPPS protocol described was used to
synthesize peptide 3.8.J on CTC resin, except no HATU was used in the first amino acid
coupling. To analyze the peptide, 10 mg of the resin was subjected to 300 µL of the
cleavage mixture (1:1:8 TFE:AcOH:DCM)

for 30 min. The filtrates were collected,

concentrated and analyzed via RP-HPLC-MS using an analytical Thermo Scientific
Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-75-95% MeCN/H2O gradient
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for 30 minutes. . m/z ES calc’d for peptide 3.X.B [(C169H206N24O27S5 + 2)/2]+: 1583.97;
observed: 1584.35. m/z ES calc’d for [(C169H206N24O27S5 + 3)/3]+: 1056.32; observed:
1056.55.

Figure 3.30 ES-MS spectrum for linear peptide 3.8.J
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General Procedure for Reaction Optimization Table 3.5. For each of the reactions, the
peptide 3.8.J (10 mg, 4 µmol) was first swelled in DCM (500 µL). A freshly prepared stated
percentage of TFA solution in DCM was added and the reaction mixture was agitated at
stated amount of time. About 2 – 3 drops of TIPS were added during the reaction until the
orange-yellow color disappeared in the reaction mixture. The resulting reaction solution
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was filtered in to a tube. The peptide was immediately crashed out with cold diethyl ether
and centrifuged, ether discarded, and the pellet was dissolved in 50% MeCN:Water in
presence of 0.05%TFA. This solution was analyzed directly by MS. m/z ES calc’d for
peptide 3.8.L [(C169H206N24O27S5 + 2)/2]+: 1583.97; observed: 1584.30. m/z ES calc’d
for peptide 3.8.K [(C149H190N24O26S5 + 2)/2]+: 1447.80; observed: 1448.05.

Entry 1. A freshly prepared solution of TFA:TIPS:DCM (2:5:93, 300 µL) was added and
the reaction mixture was agitated at room temperature for 30 min.

Figure 3.31 ES-MS spectrum for direct injection. Table 3.5. Entry 1

Entry 2. A freshly prepared solution of TFA:TIPS:DCM (2:5:93, 300 µL) was added and
the reaction mixture was agitated at room temperature for 60 min.

Figure 3.32 ES-MS spectrum for direct injection. Table 3.5. Entry 2
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Entry 3. A freshly prepared solution of TFA:TIPS:DCM (3:5:92, 300 µL) was added and
the reaction mixture was agitated at room temperature for 15 min.

Figure 3.33 ES-MS spectrum for direct injection. Table 3.5. Entry 3

Entry 4. A freshly prepared solution of TFA:TIPS:DCM (4:5:91, 300 µL) was added and
the reaction mixture was agitated at room temperature for 10 min.

Figure 3.34 MS spectrum for direct injection. Table 3.5. Entry 4
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Entry 5. A freshly prepared solution of TFA:TIPS:DCM (4:5:91, 300 µL) was added and
the reaction mixture was agitated at room temperature for 5 min.

Figure 3.35 ES-MS spectrum for direct injection. Table 3.5. Entry 5

Entry 6. A freshly prepared solution of TFA:TIPS:DCM (5:5:90, 300 µL) was added and
the reaction mixture was agitated at room temperature for 5 min.

Figure 3.36 ES-MS spectrum for direct injection. Table 3.5. Entry 5
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General Procedure for Reaction Optimization Table 3.6. For each of the reactions, the
general procedure for Pd-DMSO cleavage-oxidation was followed. The stated amount of
the resin 3.8.D was subjected to the stated amount of Pd(OAc)2 , NMM and DMSO-5%
AcOH. The reaction mixture was agitated in a 5 mL closed vial at room temperature for
stated amount of time. After the wash, the dried resin was subjected to 300 µL of the
cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 2 x 30 min. Finally, the TFA solution was
concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 1050% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.N
[(C76H114N24O26S4 + 3)/3]+: 637.04; observed: 637.20. m/z ES calc’d for peptide 3.8.O
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[(C71H107N23O24S4 + 3)/3]+: 599.54; observed: 598.50. m/z ES calc’d for peptide 3.8.M
[(C66H98N22O22S4 + 3)/3]+: 560.96; observed: 560.65.

Entry 1. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (3.0 mg,
13.5 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction
mixture was agitated at room temperature for 6 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.37 Analytical Column PDA for Table 3.6. Entry 1
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Entry 2. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (3.0 mg,
13.5 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction
mixture was agitated at room temperature for 12 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.38 Analytical Column PDA for Table 3.6. Entry 2
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Entry 3. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (6.1 mg,
27.0 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction
mixture was agitated at room temperature for 6 hours

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.39 Analytical Column PDA for Table 3.6. Entry 3
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Entry 4. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (14.1 mg,
63.0 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction
mixture was agitated at room temperature for 6 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.40 Analytical Column PDA for Table 3.6. Entry 4
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Entry 5. The relevant quantities are: Peptide 3.X.A (50 mg, 15 µmol), Pd(OAc)2 (10.1 mg,
45.0 µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction
mixture was agitated at 60 ºC in a microwave for 6 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.41 Analytical Column PDA for Table 3.6. Entry 5
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Entry 6. The relevant quantities are: Peptide 3.X.A (22 mg, 6.6 µmol), Pd(OAc)2 (4.4 mg,
19.8 µmol), NMM (25.0 µL, 225.72 µmol) and DMSO-5% AcOH (825 µL). The reaction
mixture was agitated at 60 ºC in a microwave for 6 hours. Next, the reaction solution was
then filtered and the resin was subjected again to Pd(OAc)2 (2.2 mg, 9.9 µmol), NMM
(25.0 µL, 225.72 µmol) and DMSO-5% AcOH (825 µL) and agitated again at 60 ºC in a
microwave for 3 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.42 Analytical Column PDA for Table 3.6. Entry 6
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Entry 7. The relevant quantities are: Peptide 3.X.A (50 mg, 15 µmol), Pd(OAc)2 (10.1 mg,
45.0 µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction
mixture was agitated at 60 ºC in a microwave for 7 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.43 Analytical Column PDA for Table 3.6. Entry 7
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Entry 8. The relevant quantities are: Resin (50 mg, 15 µmol), Pd(OAc)2 (10.1 mg, 45.0
µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction mixture
was agitated in a 10 mL closed vial at 60 ºC in a microwave for 6 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.44 Analytical Column PDA for Table 3.6. Entry 8
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Entry 9. The relevant quantities are: Peptide 3.X.A (50 mg, 15 µmol), Pd(OAc)2 (16.8 mg,
75.0 µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction
mixture was agitated at 60 ºC in a microwave for 6 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.45 Analytical Column PDA for Table 3.6. Entry 9
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General Procedure for Reaction Optimization Table 3.7. For each of the reactions, the
peptide 3.8.D (20 mg, 6 µmol) was first swelled in DMF (500 µL). Then, the sated amount
of NCS in DMF was added and allowed to agitate at room temperature for stated amount
of time. The reaction solution was filtered and the resin was washed with DMF (5 x 1 mL)
and DCM (5 x 1 mL). The resulting resin was subjected to 300 µL of the cleavage mixture
TFA:TIPS:H2O (95:2.5.2.5) for 2 x 30 min. Finally, the TFA solution was concentrated
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and
decanted to yield the crude peptide. The peptide was dissolved in 10% MeCN:Water in
presence of 0.05%TFA and analyzed via RP-HPLC-MS using an analytical Thermo
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O
gradient for 30 minutes. m/z ES calc’d for peptide 3.8.N [(C76H114N24O26S4 + 3)/3]+:
637.04; observed: 637.20. m/z ES calc’d for peptide 3.8.O [(C71H107N23O24S4 + 3)/3]+:
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599.54; observed: 598.50. m/z ES calc’d for peptide 3.8.M [(C66H98N22O22S4 + 3)/3]+:
560.96; observed: 560.65.

Entry 1. A solution of NCS (4.0 mg, 30 µmol) in DMF (400 µL) was added and the
reaction was allowed to agitate at room temperature for 6 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.46 Analytical Column PDA for Table 3.7. Entry 1
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Entry 2. A solution of NCS (4.0 mg, 30 µmol) in DMF (400 µL) was added and the reaction
was allowed to agitate at room temperature for 10 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.47 Analytical Column PDA for Table 3.7. Entry 2
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Entry 3. A solution of NCS (5.6 mg, 42 µmol) in DMF (400 µL) was added and the reaction
was allowed to agitate at room temperature for 6 hours.

Starting peptide (3.8.N); [(M+3)/3]+
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+
Product isotope (3.8.P); [(M+3)/3]+
Oxidized Product (3.8.M); [(M+3)/3]+
PDA 214 nm

Figure 3.48 Analytical Column PDA for Table 3.7. Entry 3
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GGG

Fmoc—Rink amide linker-Gly-Gly-Gly
ChemMatric Resin

Rink Amide Linker-Gly-Gly-Gly-ChemMatrix Resin 3.X.A. The standard Fmoc-SPPS
protocol described was used to synthesize Rink amide linker-Gly-Gly-Gly-ChemMatrix
Resin, except a special swelling method was performed to swell ChemMatrix resin before
coupling the first amino acid to get efficient loading. Here, First, MeOH (3 mL) was added
and agitated for 1 min at RT. The solvent was then removed and the treatment was
repeated with MeOH. In a similar manner, the resin was washed with DMF (2 x 1 min),
DCM (3 x 1 min), TFA-DCM (1:99) (3 x 1 min), DIEA-DCM (1:19) (3 x 1 min), DCM (3 x 1
min) and DMF (3 x 1 min). The linker was capped after the synthesis. Loading of the linker
on resin: 0.3 – 0.35 mmol/g

SMmt SStBu
tBu tBu
tBu

SPPS
FmocHN

RA Linker

GGG

CM

16

H

GCCSHPACNVDHPEIC

RA Linker

GGG

CM

Trt Trt Trt
SAllocam
SAllocam
3.9.A

SPPS of Peptide 3.9.A. The standard Fmoc-SPPS protocol described was used to
synthesize peptide 3.9.A on Rink amide linker-Gly-Gly-Gly-ChemMatrix resin. The
peptide was capped before the last coupling step. To analyze the final peptide, 10 mg of
the resin was subjected to cleavage solution of TFA:TIPS:H2O (95:2.5.2.5) for 30 min.
Finally, the TFA solution was concentrated under a constant stream of air, crashed out
with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. The peptide
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was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via RPHPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin:
0.14 mmol/g. m/z ES calc’d for peptide 3.9.A [(C80H124N24O26S5 + 2)/2]+: 1000.15;
observed: 999.80. m/z ES calc’d for [(C74H116N24O26S5 + 3)/3]+: 667.10; observed:
666.90.

Linear peptide (3.9.A); [(M+2/2]+
Linear peptide (3.9.A); [(M+3/3]+
PDA 214 nm

Figure 3.49 Analytical Column PDA for linear peptide 3.9.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 20.62 min

Figure 3.50 ES-MS spectrum for linear peptide 3.9.A at retention time 20.62 min
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tBu
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Trt Trt Trt
SAllocam
SAllocam
3.9.A
1) 30% HSCH2CH2OH in DMF
60 ºC MW, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
SH

SH

SH

SStBu

16

H
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16

NH2

SAllocam

H

GCCSHPACNVDHPEIC
SAllocam

3.9.B

NH2

SAllocam

3.9.C

General Procedure for Reaction Optimization Table 3.8. For each of the reactions, the
peptide 3.9.A (10 mg, 3 µmol) was first swelled in DMF (500 µL). Then, a solution of 30%
mercaptoethanol in DMF (1.0 mL) was added and agitated for stated amount of time. The
reaction solution was filtered and the resin was washed with DMF (5 x 1 mL). The resulting
resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5 TFA:TIPS:H2O) for 30
min. The resulting TFA solution was collected, concentrated, and the peptide was crashed
out with cold diethyl ether. The precipitate was centrifuged, ether discarded, and the pellet
was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed
via RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for
peptide 3.X.A [(C80H124N24O26S5 + 2)/2]+: 1000.15; observed: 999.80. m/z ES calc’d for
[(C74H116N24O26S5 + 3)/3]+: 667.10; observed: 666.95. m/z ES calc’d for peptide 3.X.C
[(C76H116N24O26S4 +

2)/2]+: 956.08; observed: 955.85. m/z ES calc’d for

[(C76H116N24O26S4 + 3)/3]+: 637.72; observed: 637.60.
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Entry 1. The reaction was agitated for 3 hours.

Starting peptide (3.9.C); [(M+3)/3]+
Product (3.9.B); [(M+3)/3]+
Product – 1Allocam; [(M+3)/3]+
Product – 2Allocam; [(M+3)/3]+
PDA 214 nm

Figure 3.51. Analytical Column PDA for Table 3.8. Entry 1

Entry 2. The reaction was agitated for 1.5 hours.

Starting peptide (3.9.C); [(M+3)/3]+
Product (3.9.B); [(M+3)/3]+
Product – 1Allocam; [(M+3)/3]+
Product – 2Allocam; [(M+3)/3]+
PDA 214 nm

Figure 3.52 Analytical Column PDA for Table 3.8. Entry 2
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Entry 3. The reaction was agitated for 1 hour.

Starting peptide (3.9.C); [(M+3)/3]+
Product (3.9.B); [(M+3)/3]+
Product – 1Allocam; [(M+3)/3]+
Product – 2Allocam; [(M+3)/3]+
PDA 214 nm

Figure 3.53 Analytical Column PDA for Table 3.8. Entry 3
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2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
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General Procedure for Reaction Optimization Table 3.9. For each of the reactions,
The resin 3.9.D (10 mg, 3 µmol) was first swelled in DMF (500 µL). Then, a solution of
DTNP (9.3 mg, 30 µmol) in DCM (1.0 mL) was added and allowed to stated amount of
time. The reaction solution was filtered and the resin was washed with DCM (5 x 1 mL).
The resulting resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5
TFA:TIPS:H2O) for 30 min. The resulting TFA solution was collected, concentrated, and
the peptide was crashed out with cold diethyl ether. The precipitate was centrifuged, ether
discarded, and the pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA.
This solution was analyzed via RP-HPLC-MS using an analytical Thermo Scientific
Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for
30 minutes. m/z ES calc’d for peptide 3.X.B [(C76H114N24O26S4 +

2)/2]+: 955.06;

observed: 954.90. m/z ES calc’d for [(C76H114N24O26S4 + 3)/3]+: 637.04; observed:
636.95.
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Entry 1. The reaction was agitated for 6 hour.

Product (3.9.E); [(M+3)/3]+
Product isotope; [(M+3)/3]+
PDA 214 nm

Figure 3.54 Analytical Column PDA for Table 3.9. Entry 1

Entry 2. The reaction was agitated for 3 hours.

Product (3.9.E); [(M+3)/3]+
Product isotope; [(M+3)/3]+
PDA 214 nm

Figure 3.55 Analytical Column PDA for Table 3.9. Entry 2
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Entry 3. The reaction was agitated for 1 hour.

Product (3.9.E); [(M+3)/3]+
Product isotope; [(M+3)/3]+
PDA 214 nm

Figure 3.56 Analytical Column PDA for Table 3.9. Entry 3
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Procedure for Table 3.10, Entry 1. The general procedure for Pd-DMSO cleavageoxidation was followed. The relevant quantities are: Resin 3.9.G (130 mg, 39 µmol),
Pd(OAc)2 (26.3 mg, 117.0 µmol), NMM (147.0 µL, 1333.8 µmol) and DMSO-5% AcOH
(4875 µL). The reaction mixture was agitated in a 10 mL closed vial at room temperature
for 6 hours. After the wash, the dried resin was subjected to 1 mL of the cleavage mixture
TFA:TIPS:H2O (95:2.5.2.5) for 2 x 3 hours. Finally, the TFA solutions were collected,
concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 1050% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.I
[(C76H114N24O26S4 + 3)/3]+: 637.04; observed: 637.20. m/z ES calc’d for peptide 3.8.J

146
[(C71H107N23O24S4 + 3)/3]+: 599.54; observed: 598.50. m/z ES calc’d for peptide 3.8.H
[(C66H98N22O22S4 + 3)/3]+: 560.96; observed: 560.65.

Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+
Reduced peptide (3.9.K); [(M+3)/3]+
Oxidized peptide (3.9.H); [(M+3)/3]+
PDA 214 nm

.
Figure 3.57 Analytical Column PDA for crude product 3.9.H. Table 3.10. Entry 1

The crude peptide was purified via RP-HPLC-MS using an analytical Thermo Scientific
Hypersil Gold C8 column at a flow rate of 1 mL/min to afford a4/7-conotoxin LvIA in 7%
yield (~1.6 mg).
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a4/7-conotoxin LvIA (3.9.H); [(M+3)/3]+
PDA 214 nm

Figure 3.58 Analytical Column PDA for pure product 3.9.H. Table 3.10. Entry 1
Gradient: 10-50% MeCN/H2O + 1% HCOOH over 15 min. Retention time 6.91 min

Figure 3.59 ES-MS spectrum for pure product 3.9.H at retention time 6.91 min. Table 3.10. Entry 1
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Procedure for Table 3.10, Entry 2. The resin 3.9.G (150 mg, 45 µmol) was first swelled
in DMF (3 mL). Then, a solution of NCS (30.0 mg, 225 µmol) in DMF (1.0 mL) was added
and allowed to agitate in a 10-mL closed vial at room temperature for 5 hours. The
reaction solution was filtered and the resin was washed with DMF (5 x 3 mL) and DCM
(5 x 3 mL).

The resulting resin was subjected to 1 mL of the cleavage mixture

TFA:TIPS:H2O (95:2.5.2.5) for 2 x 3 hours. Finally, the TFA solutions were collected,
concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 1050% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.H
[(C66H98N22O22S4 + 3)/3]+: 560.96; observed: 560.65.

Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+
Reduced peptide (3.9.K); [(M+3)/3]+
Oxidized peptide (3.9.H); [(M+3)/3]+
PDA 214 nm

Figure 3.60 Analytical Column PDA for crude product 3.9.H. Table 3.10. Entry 2
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Procedure for Table 3.10, Entry 3. The resin 3.9.G (20 mg, 6 µmol) was first swelled in
DMF (500 µL). Then, a solution of iodine (7.6 mg, 30 µmol) in DCM (400 µL) was added
and allowed to agitate in a 2 mL vial at room temperature for 5 hours. The reaction solution
was filtered and the resin was washed with DMF (10 x 1 mL) and DCM (10 x 1 mL). The
resulting resin was subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O
(95:2.5.2.5) for 2 x 30 min. Finally, the TFA solutions were collected, concentrated under
a constant stream of air, crashed out with cold diethyl ether, centrifuged, and decanted to
yield the crude peptide. The peptide was dissolved in 10% MeCN:Water in presence of
0.05%TFA and analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil
Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30
minutes. m/z ES calc’d for peptide 3.8.H [(C66H98N22O22S4 + 3)/3]+: 560.96; observed:
560.65. m/z ES calc’d for peptide 3.8.K [(C66H100N22O22S4 + 3)/3]+: 561.96; observed:
561.40.

Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+
Reduced peptide (3.9.K); [(M+3)/3]+
Oxidized peptide (3.9.H); [(M+3)/3]+
PDA 214 nm

Figure 3.61 Analytical Column PDA for Table 3.10. Entry 3
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Procedure for Table 3.10, Entry 4. The resin 3.9.G (150 mg, 45 µmol) was first swelled
in DMF (3 mL). Then, a solution of iodine (91.3 mg, 360 µmol) in DCM (2 mL) was added
and allowed to agitate in a 10-mL closed vial at room temperature for 5 hours. The
reaction solution was filtered and the resin was washed with DMF (10 x 3 mL) and DCM
(10 x 3 mL).

The resulting resin was subjected to 1 mL of the cleavage mixture

TFA:TIPS:H2O (95:2.5.2.5) for 2 x 3 hours. Finally, the TFA solutions were collected,
concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 1050% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.X.B
[(C66H98N22O22S4 +

2)/2]+:

840.94;

observed:

840.70.

m/z

ES calc’d

[(C66H98N22O22S4 + 3)/3]+: 560.96; observed: 560.80.

Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+
Reduced peptide (3.9.K); [(M+3)/3]+
Oxidized peptide (3.9.H); [(M+3)/3]+
PDA 214 nm

Figure 3.62 Analytical Column PDA for crude product 3.9.H. Table 3.10. Entry 4

for
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The crude peptide was purified via RP-HPLC-MS using an analytical Thermo Scientific
Hypersil Gold C8 column at a flow rate of 1 mL/min to afford a4/7-conotoxin LvIA in 18%
yield (4.2 mg).

a4/7-conotoxin LvIA (3.9.H); [(M+3)/3]+
PDA 214 nm

Figure 3.63 Analytical Column PDA for pure product 3.9.H. Table 3.10. Entry 4
Gradient: 10-50% MeCN/H2O + 1% HCOOH over 15 min. Retention time 6.97 min

Figure 3.64 ES-MS spectrum for pure product 3.9.H at retention time 6.97 min.
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CHAPTER 4: ELLMAN’S REAGENT
AS A COLORIMETRIC AND MILD OXIDIZING AGENT FOR ON-RESIN FOLDING OF
CYSTEINE CONTAINING PEPTIDES

4.1 Introduction
Ellman’s reagent has been the most popular reagent for spectrometric
measurement of protein sulfhydryls for over four decades. It is then been adapted
successfully in to a solid phase mode to mediate intramolecular disulfide bond formation
in solution. However, there were no reports for its potential as a solution phase oxidizing
agent to form on-resin disulfide bonds in peptides. In this chapter we are introducing a
new application of Ellman’s reagent, which can mediate on-resin disulfide bond formation
while offering colorimetric method to monitor the reaction.
4.2 Ellman’s Reagent for Free Thiol Analysis
The compound 5,5'-dithiobis-(2-nitrobenzoic acid) which is known as Ellman’s
reagent or DTNB was introduced in 1959 by George L. Ellman to quantify the amount and
concentration of thiols groups in a sample under physiological conditions.158,159 Since
then it has been widely used in both qualitative and quantitative assays to measure
protein sulfhydryls. Reaction between a thiol group and 5,5'-dithiobis-(2-nitrobenzoic acid)
cleaves off the homo-disulfide bond in DTNB to give a mixed disulfide (R-S-TNB) and
release one equivalent of 5-thio-2-nitrobenzoic acid (TNB) (Scheme 4.1).
Scheme 4.1 Reaction of Ellman’s reagent with thiol groups
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The resulting TNB ionizes to the TNB2− dianion at neutral to alkaline pH and generate a
yellow color as a result of intense light absorption at 412 nm. Base on this phenomena,
the standard procedure for colorimetric analysis of thiols is done using a dilute solution of
Ellman’s reagent in basic aqueous buffer (pH 8). The measurement of absorbance values
at 412 nm allows to quantify the concentration of thiols using Beer-lambert law. The
method has been used to analyze sulfhydryl group content in wide range of substrates
such as cereal proteins,160 blood samples, urine, tissues, purified proteins, etc159. and
slight modifications in the standard procedure has been done based on stability, solubility
and pH of the substrate.
With rapid development in the solid-phase peptide synthesis, simple laboratory
methods for analysis of on-resin functionality needed to be developed. Most importantly
a readily accessible method for on-resin thiol group analysis. Steel and coworkers have
reported their investigation of adopting Ellman’s reagent to analyze resin bound thiol
groups.161 According to their findings, for highly-crosslinked polystyrene resins which are
compatible with range of aqueous and non-aqueous solvent systems, standard thiol
analysis conditions with aqueous solution of the Ellman’s reagent failed to give
reproducible results. For peptides on polystyrene based resins, Ellman’s reagent in
methanol, basified with DIPEA, gave excellent results. TentaGel resins, which can
tolerate aqueous-organic solvent systems, react efficiently with Ellman’s reagent in a
THF:methanol (1:1) solvent mixture, basified with DIPEA. This is a simple and cheap
method to analyze free macroporous or PEG graft resin bound thiols. Further
enhancement to the procedure can be done by retreating the resin with dithiothreitol to
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cleave the disulfide bond which releases a second equivalent of TNB. Colorimetric
analysis of the second TNB allows to get a duplicate value for the same sample.161
4.3 Supported Ellman’s Reagent for Cysteine Disulfide Formation
As discussed in Section 4.2, Ellman’s reagent was originally developed for a
colorimetric method to measure free thiol concentration under physiological conditions. It
is then found to be an effective mild oxidizing agent to generate disulfides, when bound
to a suitable solid support.85 Solid supports such as polyethylene glycol-polystyrene
(PEG-PS), modified Sephadex supports, controlled-pore glass (CPG) and Cross-Linked
Ethoxylate Acrylate Resin (CLEAR) can be used to attach Ellman’s reagent through two
sites and promote cysteine disulfide bond formation in solution.86 In the oxidation process
(Scheme 4.2), first, one of the peptidyl-thiol groups 4.1.A react with the solid-supported
oxidant to generate solid-bound activated intermediate 4.1.B.
Scheme 4.2 Proposed mechanism for resin-bound Ellman’s reagent mediated intramolecular disulfide
formation
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Then, the intermediate 4.1.B undergoes intramolecular nucleophilic attack by the other
peptidyl-thiol group to form the desired disulfide linkage, detached from the solid support
and release the oxidized product 4.1.C back in to the solution. Simple filtration allows the
isolation of desired disulfide products and the solid support reagent can be recycled and
reused.162 Resin-bound Ellman’s oxidation offers a quick and straightforward tool to
obtain disulfide bonds in peptides. Most significantly, it can function at a wide range of pH
values and give relatively higher yields and purity over other solution phase oxidation
methods such as Glutathione-based oxidation and DMSO mediated oxidation.162
Furthermore, it can be used in orthogonal synthesis schemes (see Chapter 1) and offers
high selectivity.163 The major drawback of this system is covalent binding of the substrate
to the solid support, which diminish the overall yield of the product obtained in solution.
However, the byproduct, the covalently bound peptide can be separated from the product
easily by filtration at the end of oxidation, along with the resin-bound reduced reagent.
The covalently bound peptide can be then released from the solid support by treatment
with dithiothreitol to give the reduced from of the peptide.162,164
4.4 Potential of Ellman’s Reagent as Mild Oxidizing Agent for On-Resin Cysteine Disulfide
Formation
After understanding the potential of resin bound Ellman’s reagent as an oxidant to
facilitate cysteine disulfide formation in solution, we were curious to examine its oxidation
potential to form on-resin cysteine disulfide bonds when Ellman’s reagent is used as a
solution. Preliminary test reactions were done using the model peptide IAPP1-9 (Table
4.1).
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Table 4.1 On-resin disulfide formation on model peptide IAPP1-9 using Ellman’s reagent
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0
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Figure 4.1 Color change of the resin during on-resin Ellman’s reagent-mediated oxidation in DMF

A
t = 0 min

B
t = 5-10 min

C
t = 50 min

D
t = 60 min

For these experiments, linear synthesis of IAPP1-9 4.2.A was done on TGT resin using
StBu as the cysteine protecting group. First, Deprotection of Cys(StBu) was done under
microwave conditions at 60 ºC with 30% mercaptoethanol for an hour to get IAPP1-9 with
reduced cysteines. Next, 1.0 equivalence of Ellman’s reagent in DMF was added to the
on-resin reduced peptide and allowed to agitate in an open vial at room temperature. An
interesting color changing effect was observed during this reaction. At the beginning when
the resin was treated with Ellman’s reagent, the resin color turned to dark peach-orange
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color (B. Figure 4.1). With time, intensity of the peach-orange color decreased (C. Figure
4.1) and eventually the resin color turned to yellow (D. Figure 4.1). For our curiosity, the
peptide was cleaved from the resin at different time interval related to each color change
and the peptide was analyzed by RP-HPLC-MS to evaluate the status of the reaction at
each time interval (Table 4.1). After 10 min, when the resin color is still dark peachorange, about 45% starting peptide 4.2.A was observed with 65% oxidized product 4.2.D
(entry 1). At 50 min, when the initial resin color get faded to light peach color, hardly any
starting peptide 4.2.A was observed and formation of a S-Sthionitrobenzoic double
adduct on peptide 4.2.E was observed along with oxidized peptide 4.2.D (entry 2). When
the resin color changed to yellow, at 60 min reaction time, fully oxidized product 4.2.D
was observed as the major product with 30% of the peptide adduct 4.2.E (entry 3). with
S-Sthionitrobenzoic double adduct. This is an interesting observation which demonstrate
the colorimetric behavior of Ellman’s reagent to indicate on-resin cysteine disulfide bond
formation while acting as the mild oxidant for the reaction.
The mechanism of Ellman’s reagent-mediated on-resin disulfide formation can be
related to that of solid-bound Ellman’s reagent-mediated solution phase oxidation
described in Section 4.3 (Scheme 4.3). In this method the peptide containing reduced
cysteines is attached to a resin instead of the oxidant been attached to a solid support.
When the resin-bound peptide 4.3.A is treated with a solution of Ellman’s reagent in DMF,
one of the peptidyl-thiol groups react with Ellman’s reagent and break the homo S-S bond
to generate solid-bound activated intermediate 4.3.B.
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Scheme 4.3 Suggested mechanism for on-resin intramolecular disulfide formation via Ellman’s reagent
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This result release of one equivalent of 5-thio-2-nitrobenzoic acid, which gives a yellow
color to the reaction system. Formation of the intermediate 4.3.B may be indicated by
the intense peach-orange color during the reaction, which diminishes the yellow
coloration of 5-thio-2-nitrobenzoic acid in the reaction solution. As the peptide is attached
to a resin, due the pseudo-dilution effect, an intramolecular disulfide bond formation is
favored by the nucleophilic attack of other peptidyl-thiol group. The intramolecular
reaction breaks the hetero-disulfide bond in the on-resin activated intermediate 4.3.B,
which may results the disappearance of initial intense peach-orange color. The
intramolecular reaction facilitates release of another 5-thio-2-nitrobenzoic acid. Hence,
when the reaction goes to completion, the yellow color of 5-thio-2-nitrobenzoic acid
becomes the dominant color in the reaction. Beside an intramolecular reaction, the
second free thiol group of solid-bound activated intermediate can react with another
molecule of Ellman’s reagent to form S-Sthionitrobenzoic double adduct on peptide
(Scheme 4.4). This competitive intermolecular reaction forms a byproduct 4.3.D which
can diminish the yield of the final folded product. Therefore, this Ellman’s reagent-
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mediated on-resin disulfide formation reaction needed to be optimized for minimum
intermolecular byproduct formation.
Scheme 4.4 Proposed mechanism for formation of S-Sthionitrobenzoic double adduct on peptide
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In order to minimize the byproduct formation, a test experiment was performed using
reduced IAPP1-9 4.4.A with different loadings of Ellman’s reagent in DMF (Table 4.2).
Table 4.2 Optimization for Ellman’s reagent loading to minimize byproduct formation
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Each test reaction was run until the color of the resin changed from dark peach-orange
to yellow. A relationship was observed between the loading of Ellman’s reagent and the
amount of byproduct 4.4.C formed. As the loading of Ellman’s reagent is lowered a
decrement in the byproduct 4.4.C formation was observed along with an increment in the
reaction time (entry 1 – entry 3). For IAPP1-9 4.4.A, 0.25 equivalent of Ellman’s reagent
gave the oxidized product with zero byproduct in 3 hours (entry 3).
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Sensitive amino acid side chains of Met, Typ and Tyr can undergo various
modifications in presence of an oxidant.164,165,166 Therefore a test reaction to determine
the stability of methionine towards Ellman’s reagent oxidation was evaluated. For the test
reaction, methionine incorporated model peptide IAPP1-9 4.5.A was used as the substrate
(Scheme 4.5). The resin-bound peptide 4.5.A was subjected to Ellman’s reagent in DMF
and the reaction was run until the color of the resin changes from dark peach-orange to
yellow. The reaction was analyzed by analytical RP-HPLC and neither sulfoxide nor
sulfone byproducts was observed. The desired oxidized product 4.5.B was observed with
clean analytical trace.
Scheme 4.5 Determination of Met stability toward Ellman’s reagent oxidation condition
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The stability of Typ and Tyr amino acids towards Ellman’s oxidation were also evaluated
and the results will be discussed later in this chapter.
4.5 On-Resin Disulfide Bond Formation in Peptides using Ellman’s Reagent in DMF
4.5.1 On-Resin Synthesis of Oxytocin
After evaluating the potential of Ellman’s reagent to oxidize resin-bound free thiols
in a model peptide, we wanted to apply this method to a real system. One of the common
targets, oxytocin, was chosen and the peptide folding was achieved using Ellman’s
reagent in DMF on rink amide resin (Scheme 4.6). The linear synthesis of the peptide
4.6.A was done on rink amide resin via Fmoc-SPPS and it was subjected to 5% TFA in
DCM in presence of TIPS to deprotect Cys(Trt) group. The resulting reduced peptide was
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then treated with 0.25 equivalent of Ellman’s reagent to access the disulfide bond in
oxytocin 4.6.B. The color change of the resin was used to monitor the reaction.
Scheme 4.6 On-resin synthesis of oxytocin
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No byproduct of S-Sthionitrobenzoic double adduct on peptide was observed during the
reaction. Moreover, the Tyr group has not been affected by Ellman’s reagent-mediated
oxidation condition. The reaction was clean according to the analytical RP-HPLC-MS
data.
4.5.2 On-Resin Synthesis of a-Conotoxin ImI
The success in the synthesis of oxytocin, which contains single disulfide linkage,
led us to evaluate the Ellman’s reagent – mediated oxidation method for more advanced
systems. One of such systems we selected was the C-terminal carboxamide a-conotoxin
ImI, a sub-type selective nicotinic acetylcholine receptor antagonist167,168,169 isolated from
the venom of Conus imperialis marine snails.170,171,172 It has two disulfide linkages lie
between Cys2-Cys8 and Cys3-Cys12 (Figure 4.3)173.
Figure 4.2 A. Structure of α-conotoxin ImI B. Graphical represtation of α-conotoxin ImI structure
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The on-resin synthetic pathway for a-conotoxin ImI was designed in two steps using
Cys(Acm) and Cys(Trt) groups (Scheme 4.7). The linear synthesis of the starting peptide
4.7.A was done on rink amide linker-Gly-Gly-Gly-ChemMatric resin. The synthesis
protocol for a-conotoxin ImI was designed such that the larger loop between Cys3-Cys12
is made first followed by the small loop between Cys2-Cys8. To achieve the larger loop,
first, Cys(Trt) deprotection can be done with 5% TFA in DCM in presence of TIPS as the
scavenger. The resulting free thiol can then be oxidized using Ellman’s reagent in DMF.
Scheme 4.7 Synthetic design for on-resin synthesis of α-Conotoxin ImI
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Before start the synthesis, the loading of Ellman’s reagent was optimized to get zero
byproduct during reaction (Table 4.3).
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Table 4.3 Optimization of the loading of Ellman’s reagent for minimum byproduct formation
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Entry

X equiv. of
Ellman’s R.

1.

:

4.7.E

The loadings of Ellman’s reagent was varied from 1.0 equivalent to 0.125 equivalent and
each of the reactions were run until the color of the resin changes from dark peach-orange
to yellow. With 1.0 equivalent of Ellman’s reagent, 70% conversion of the desired product
4.7.D was observed in 3 hours with 30% conversion of the byproduct 4.7.E (entry 1).
About 90% conversion of the desired oxidized product was observed in 12 hours when
the loading of Ellman’s reagent was 0.25 equivalent (entry 2). For the larger loop of aconotoxin ImI, zero byproduct formation can be achieved with 0.125 equivalent of
Ellman’s reagent in DMF in 24 hours (entry 3). Hence, the first step of the synthesis was
scaled up using the optimized condition for Ellman’s reagent in DMF. Then, the resulting
mono cyclized peptide 4.7.B was treated with 8 equivalent of iodine in DCM for 2 hours
to remove Acm group and oxidize the free thiol groups, which result the fully folded
peptide 4.7.C on resin. The a-conotoxin ImI has Trp amino acid residue and no side chain
modification was observed during the Ellman’s reagent-mediated oxidation process. Only
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the fully folded product with desired disulfide bond pattern was observed in 59% overall
yield.
4.5.3 On-Resin Synthesis of a4/7-conotoxin LvIA
One of the suggested synthetic routes to access a4/7-conotoxin LvIA (see Chapter
03) was use Cys(Trt) to form small loop first, either by iodine oxidation or NCS oxidation,
followed by Cys(Allocam) deprotection and oxidation with Pd-DMSO based cleavageoxidation condition to fold the larger loop (Scheme 4.8). Sensitivity of the Allocam group
towards both iodine oxidation and NCS oxidation failed this synthetic path (4.8.A – 4.8.B)
and we had to select another method to access first disulfide bond formation, which
described in chapter 03.
Scheme 4.8 Suggested on-resin synthesis of α4/7-Conotoxin LvIA with
Cys(Trt) and Cys(Allocam)
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After the discovery of Ellman’s reagent as a mild oxidant for on-resin cysteine disulfide
bond formation, we wanted to revisit the synthesis of a4/7-conotoxin LvIA using Ellman’s
reagent to form the first S-S bond.
After the linear synthesis of the peptide 4.8.A, it was subjected to screening the
best loading condition for Ellman’s reagent to get 100% conversion of the desired mono
cyclic product 4.8.B. with zero byproduct formation (Table 4.4).
Table 4.4 Optimization of the loading of Ellman’s reagent for minimum byproduct formation
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From the optimization data, it was found that 0.125 equivalent of Ellman’s reagent is the
best condition for this target peptide to form its first disulfide linkage without any byproduct
made during the oxidation step (entry 3). With the optimized data in hand, the reaction
was scaled up. Next, the resulting mono cyclic peptide 4.8.B was subjected to I2 oxidation
for simultaneous Allocam removal and oxidize to get the bicyclic peptide 4.8.C with
desired disulfide pattern (Scheme 4.9). From chapter 03, it was identified that iodine
oxidation gives better conversion with good yield compared to Pd-DMSO based Allocam
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removal and oxidation condition. Therefore, in this synthesis protocol, iodine oxidation
was chosen over the Pd-DMSO based Allocam removal and oxidation condition to make
the second disulfide bond. From this method, we were able to synthesize a4/7-conotoxin
LvIA in 24% overall yield.
Scheme 4.9 On-resin synthesis of α4/7-Conotoxin LvIA with Cys(Trt)
and Cys(Allocam)
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Interestingly, Ellman’s reagent-mediated oxidation of on-resin free thiols give access to
combine Allocam with Trt as the cysteine protecting group to generate disulfides in
peptides in either order, which was not possible before. This permits the formation of
disulfides on-resin in either order from a single linear sequence/substrate 4.9.A (Scheme
4.10). This strategic flexibility can be applied to any peptide containing two disulfide
linkages.
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Scheme 4.10 Strategic flexibility in the controlled folding of α4/7-Conotoxin LVIA.
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4.6 On-Resin Folding of Peptides using Ellman’s Reagent as the Only Oxidizing Agent
After investigating the potential of Ellman’s reagent as a colorimetric and mild
oxidizing agent, we were curious to take advantage of its potential to form all the disulfide
bonds in a peptide selectively using Ellman’s reagent as the only oxidizing agent. As we
have seen in previous synthetic procedures, Ellman’s reagent react on free thiols and
oxidize them to S-S bonds. Therefore, in order to perform oxidation with Ellman’s reagent,
the cysteine pairs in the target peptide needed to be protected with protecting groups
which have deprotecting condition to get free thiol groups. Examples for such protecting
groups are StBu, which can be cleaved with mercaptoethanol to get free thiol, Trt and
Mmt, which result the reduced cysteine with mild TFA conditions. To evaluate the method,
a4/7-conotoxin LvIA was chosen as the target.
4.6.1 Synthesis of a4/7-Conotoxin LvIA using Ellman’s Reagent in DMF
For the synthesis of a4/7-conotoxin LvIA using Ellman’s reagent as the only
oxidant, StBu and Trt were chosen to protect each pair of cysteines in the peptide. The
linear synthesis of the peptide 4.10.A was first done on rink amide linker-Gly-Gly-Gly-
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Chemmatrix resin using Cys(StBu) and Cys(Trt). Selective folding methods were then
proceeded on the linear peptide to get the desired folding pattern (Scheme 4.11). The
linear peptide was first treated with 30% mercaptoethanol for 3 hours under microwave
heating at 60 ºC to remove StBu groups.
Scheme 4.11 On-resin formation of disulfide bonds in α4/7-Conotoxin LvIA
using Ellman’s Reagent in DMF
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The resulting free thiols in the peptide 4.10.B was then oxidized using previously
optimized condition (see Table 4.4) for Ellman’s reagent – mediated oxidation. The
reaction was run until the color of the resin changes from dark peach-orange to yellow.
This step formed the small loop selectively. Next, Cys(Trt) deprotection of the mono cyclic
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peptide 4.10.C was done using 5% TFA in DCM in presence of TIPS for 5 x 1 min. The
resulting free thiol was then oxidized again with Ellman’s reagent in DMF and the reaction
was monitored by the color change of the resin. It took about 28 hours to form the larger
loop of the peptide in DMF. The 5% TFA treatment was done several times followed by
addition of Ellman’s reagent during the reaction in order to ensure completion of the
reaction (see experimental procedures for more details). When no color change was
observed after addition of Ellman’s reagent, the reaction was terminated by filtering off
the solution of Ellman’s reagent followed by several DMF wash. The total deprotection
and resin cleavage was done to collect the resulting peptide and analytical RP-HPLC was
performed to confirm the product 4.10.D formation. Surprisingly in the analytical HPLC
trace the fully folded product 4.10.D was observed in very minor amount whereas the
mono-cyclic peptide 4.10.C was observed as the major product. The last step of the
synthesis was revisited with longer TFA treatment with 10% TFA in DCM for 10 x 2 min,
followed by Ellman’s reagent – mediated oxidation. The resulting peptide was cleaved
after color change of the resin and analyzed again via analytical RP-HPLC. This slight
modification in the last step of the synthesis facilitated formation of the desired fully folded
product 4.10.D. This experiment illustrates that removal of Trt group from the mono cyclic
system is difficult and longer exposer time or higher TFA concentration is needed to
improve the synthesis.
4.6.2 Synthesis of a4/7-Conotoxin LvIA using Ellman’s Reagent in NMP
When considering all the synthesis protocols we performed using Ellman’s reagent
in DMF to form disulfide bonds, the only drawback is longer reaction time. In addition to
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DMF as the solvent, the reaction was done with 1.0 equivalent of Ellman’s reagent in
methanol, DMSO and NMP to evaluate their colorimetric behavior. The test experiments
were done using reduced IAPP1-9 as the model peptide. The color of the resin changed
to intense yellow color with the addition of Ellman’s reagent in methanol (A. Figure 4.3)
whereas with DMSO (B. Figure 4.3) and NMP (C. Figure 4.3), the color of the resin
changed to dark peach-orange color similar to that in DMF. The reactions were then eft
for few hours to observe any other changes. Even after two hours, no color change was
observed in the reactions with methanol and DMSO. Interestingly, in the reaction with
NMP, the color of the resin changed from dark peach-orange to yellow in 20 min instead
of an hour with DMF. Analytical RP-HPLC-MS analysis were performed for all of the
peptides and it confirmed disulfide bond formation during the reaction. In the reaction with
NMP, no S-Sthionitrobenzoic double adduct on peptide was observed, which was
significant in the reaction with DMF.
Figure 4.3 Color of the resin with Ellman’s reagent in different solvents

A
Ellman’s in MeOH

B
Ellman’s in DMSO

C
Ellman’s in NMP

After investigation of faster reaction rates in NMP solvent, the method described in section
4.6.2 was revisited with Cys(StBu) and Cys(Mmt) to synthesize a4/7-conotoxin LvIA using
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Ellman’s reagent in NMP (Scheme 4.12). First, the linear peptide 4.10.A was subjected
to 30% mercaptoethanol for 3 hours under microwave heating at 60 ºC to deprotect
Cys(StBu). Then, the resulting reduced peptide 4.10.B was treated with Ellman’s reagent
in NMP.
Scheme 4.12 On-resin formation of disulfide bonds in α4/7-Conotoxin LvIA
using Ellman’s Reagent in NMP
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Completion of the first disulfide bond formation was monitored by color change of the
resin and it required only 30 min. The resulting mono cyclic peptide 4.10.C was treated
with 5% TFA in DCM in presence of TIPS as a scavenger for 5 x 1 min to ensure Mmt
group removal in the system. Another solution of Ellman’s reagent in NMP was added to
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the resin with free thiols at Cys3 and Cys16 to form the second disulfide bond. Color
changed from dark orange to yellow in 90 min for this step. Finally, Ellman’s reagent was
filtered off and the resin was washed thoroughly with NMP. Analytical RP-HPLC-MS was
performed to the cleaved peptide and ES-MS confirmed the fully folded peptide 4.2.D.
After purification, a4/7-conotoxin LvIA was isolated in 76% overall yield. Disulfide bond
formation using Ellman’s reagent in NMP shows greater improvement in reaction rates
compared to that of in DMF.
4.7 Summary
We demonstrated the potential of Ellman’s reagent as a colorimetric and mild
oxidizing agent to form on-resin disulfide bonds in peptides. The reaction procedure is
simple, no complex time consuming reaction set up is needed. Most importantly, the
reaction can be monitored easily by observing the color change of the resin, which is
advantageous over time consuming lengthy reaction analysis protocols. The colorimetric
behavior of Ellman’s reagent can be seen both in DMF and NMP. Ellman’s reagent –
mediated disulfide bond formation in DMF is relatively slower and the yield-diminishing
intermolecular side reaction involving formation of S-Sthionitrobenzoic double adduct on
peptide can be addressed by optimizing the loading of Ellman’s reagent for each
substrate. Therefore, DMF is best in formation of smaller disulfide linkages in peptides.
In contrast, Ellman’s reagent – mediated disulfide bond formation in NMP has faster
reaction rates and no S-Sthionitrobenzoic double adduct on peptide was observed even
with 1.0 equivalent of Ellman’s reagent. The insight of colorimetric behavior of Ellman’s
reagent in disulfide bond formation process needed to be further investigated. However,
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on-resin disulfide bond formation using Ellman’s reagent introduces a simple and an
efficient synthetic route to access disulfide rich bioactive peptides.
4.8 Methods and Material
4.8.1 General Information
Unless otherwise specified, all commercially available reagents were purchased from
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF,
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial
solvent purification system (2 columns of alumina) and used without further drying.
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL,
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room
temperature. All yields refer to chromatographically and spectroscopically pure products.
All HPLC analyses and purifications were performed on a Custom Reverse Phase
Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle
between analytical and semi-preparative columns. This instrument has a photodiode
array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O)
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific
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Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based
on the final loading.
SPPS General Information. Solid-phase peptide synthesis was executed on a Biotage
Isolera+ semi-automated synthesizer with microwave heating.
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL)
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The
solvent was then removed over 1 m followed by two DMF washes (DMF was added
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of
solvent (over 2 m)).
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv)
in DMF was made immediately prior to addition to the reaction vial containing the
resin. Once the solution was added, the suspension was heated to 75 ºC (except for
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed
with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m).
•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF.
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF
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washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200
RPM for 1 m, solvent removal was at a rate of 2 m).
•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times.
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL).
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the
lyophilizer overnight for drying.
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF
(5 x 3 mL).
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed
based on amount of Fmoc group.
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min,
the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF
was added to it and allowed to vortex in the peptide synthesizer at room temperature for
10 min. The resulting filtrate was collected to the same tube and the deprotected resin
was washed with DMF (4 x 1.75 ml).
Sample preparation for UV analysis – From the collected ”deprotection solution” above,
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF.
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The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF
blank using a UV spectrometer with 1 cm cuvette.
4.8.2 Experimental Procedures and Spectroscopic Data
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4.2.A

SH

SH

4.4.A

Reduced IAPP1-9 4.4.A. The resin 4.2.A (60 mg, 12 µmol) was first swelled in DMF (500
µL). Then, a solution of 30% mercaptoethanol in DMF (1.0 mL) was added and agitated
at 60 ºC under microwave condition for 1 hour. The reaction solution was filtered and the
resin was washed with DMF (5 x 1 mL). To analyze the reaction 5 mg of the resulting
resin was subjected to 300 µL of the cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min.
The resulting solution was filtered, concentrated and analyzed via MS, direct injections at
a flow rate of 0.4 mL/min with 50% MeCN/H2O for 1.5 minutes. m/z ES calc’d for peptide
4.4.A [(C70H107N11O16S2)+1]+: 1422.81; observed: 1423.55; m/z ES calc’d for
[(C70H107N11O16S2 + 2)/2]+: 712.41; observed: 712.00.

Reduced pdt (4.4.A); [(M+3)/3]+
Reduced (4.4.A); [(M+2)/2]+
PDA 214 nm

Figure 4.4 Analytical Column PDA for reduced IAPP1-9 4.4.A
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General Procedure for Table 4.2. For each of the test reactions, the resin 4.4.A (10 mg,
2 µmol) was first swelled in DMF (500 µL). Then, the stated amount of Ellman’s reagent
in DMF (1.0 mL) was added and agitated for the stated amount of time. The reaction
solution was filtered and the resin was washed with DMF (5 x 1 mL). The resulting resin
was subjected to 300 µL of the cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min. The
resulting solution was filtered, concentrated and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 1050% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 4.4.B
[C70H107N11O16S2

+

1]+:

1420.79;

observed:

1421.85.

m/z

ES

calc’d

for

[(C70H107N11O16S2 + 2)/2]+: 711.39; observed: 711.20. m/z ES calc’d for peptide 4.4.C
[C84H113N13O24S4

+

1]+:

1817.14;

observed:

1817.15.

[(C84H113N13O24S4 + 2)/2]+: 909.57; observed: 909.30.

m/z

ES

calc’d

for
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Entry 1. A solution of Ellman’s reagent (0.8 mg, 2 µmol) in DMF (1.0 mL) was added and
the reaction was agitated for 1 hour.

Oxidized pdt (4.4.B); [(M+2)/2]+
Byproduct (4.4.C); [(M+2)/2]+
PDA 214 nm

Figure 4.5 Analytical Column PDA for Table 4.2 – Entry 1

Entry 2. A solution of Ellman’s reagent (0.4 mg, 1 µmol) in DMF (1.0 mL) was added and
the reaction was agitated for 2.5 hours.

Oxidized pdt (4.4.B); [(M+2)/2]+
Byproduct (4.4.C); [(M+2)/2]+

PDA 214 nm

Figure 4.6 Analytical Column PDA for Table 4.2 – Entry 2
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Entry 3. A solution of Ellman’s reagent (0.2 mg, 0.5 µmol) in DMF (1.0 mL) was added
and the reaction was agitated for 3 hours.

Oxidized pdt (4.4.B); [(M+2)/2]+
Byproduct (4.4.C); [(M+2)/2]+

PDA 214 nm

Figure 4.7. Analytical Column PDA for Table 4.2 – Entry 3
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Fmoc-Rink Amide linker-Gly-Gly-Gly
ChemMatrix Resin

4.7.A

SPPS of Linear Peptide 4.7.A. The standard Fmoc-SPPS protocol described was used
to synthesize peptide 4.7.A on Rink Amide linker-Gly-Gly-Gly-ChemMatrix resin. The
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the
resin was subjected general ammonia cleavage protocol and the resulting crude product
was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via Rp-
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HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin:
0.15 mmol/g. m/z ES calc’d for peptide 4.X.B [(C58H92N22O17S4 + 2)/2]+: 749.87;
observed: 746.60. m/z ES calc’d for [(C58H92N22O17S4 + 3)/3]+: 500.25; observed: 500.05.

Linear Peptide (4.7.A); [(M+2)/2]+
Linear Peptide (4.7.A); [(M+3)/3]+
PDA 254 nm

Figure 4.8 Analytical Column PDA for linear peptide 4.7.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 14.02 min

Figure 4.9 ES-MS spectrum for linear peptide 4.7.A at retention time 14.02 min
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General Procedure for Table 4.3. For each of the test reactions, the resin 4.7.A (10 mg,
4 µmol) was first swelled in DMF (500 µL). Then, a freshly prepared solution of
TFA:TIPS:DCM (5:5:90) was added and the reaction mixture was agitated at room
temperature for 5 x 2 min. About 1 – 2 drops of more TIPS were added during the reaction
until the orange-yellow color disappeared in the reaction mixture. The resulting TFA
solution was filtered and the resin was washed with DCM (3 x 1 mL). After that, the resin
was subjected to the stated amount of Ellman’s Reagent in DMF for the stated amount of
time until the resin color changed from peach to yellow. Finally, the reaction solution was
filtered and the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). In order to
confirmed the total Trt group removal, the resulting peptide was retreated with a solution
of TFA:TIPS:DCM (5:5:90) for 5 x 1 min and re-subjected to the stated amount of Ellman’s
Reagent in DMF. If the resin color changes to peach-orange color upon addition of
Ellman’s reagent, the reaction was agitated further until the resin color changed from
peach to yellow. This procedure was repeated until no color change was observed. When
no color change was observed, the solution of Ellman’s reagent added was filtered and
the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). The resulting resin was
subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 3 hours. The
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resulting the TFA solutions were collected, concentrated under a constant stream of air,
crashed out with cold diethyl ether, centrifuged, and decanted to yield the crude peptide.
The resulting pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This
solution was analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil
Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30
minutes. m/z ES calc’d for peptide 4.7.D [(C58H90N22O17S4 + 2)/2]+: 748.87; observed:
748.75. m/z ES calc’d for [(C58H90N22O17S4 + 3)/3]+: 499.58; observed: 499.40. m/z ES
calc’d for peptide 4.7.E [(C72H98N24O25S6+ 2)/2]+: 947.04; observed: 946.75. m/z ES
calc’d for [(C72H98N24O25S6+ 3)/3]+: 631.69; observed: 631.50

Entry 1. A solution of Ellman’s reagent (1.6 mg, 4 µmol) in DMF (1.0 mL) was added and
the reaction was agitated for 3 hours.

Oxidized pdt (4.7.D); [(M+2)/2]+
Byproduct (4.7.E); [(M+2)/2]+
PDA 254 nm

Figure 4.10 Analytical Column PDA for reaction optimization; Table 4.3 – Entry 1
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Entry 2. A solution of Ellman’s reagent (0.4 mg, 1 µmol) in DMF (1.0 mL) was added and
the reaction was agitated for 12 hours

Oxidized pdt (4.7.D); [(M+2)/2]+
Byproduct (4.7.E); [(M+2)/2]+
PDA 254 nm

Figure 4.11 Analytical Column PDA for reaction optimization; Table 4.3 – Entry 2

Entry 3. A solution of Ellman’s reagent (0.2 mg, 0.5 µmol) in DMF (1.0 mL) was added
and th reaction was agitated for 24 hours.

Oxidized pdt (4.7.D); [(M+2)/2]+
Byproduct (4.7.E); [(M+2)/2]+
PDA 254 nm

Figure 4.12 Analytical Column PDA for reaction optimization; Table 4.3 – Entry 3
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Synthesis of a-conotoxin ImI 4.7.F. The peptide 4.7.B (100 mg, 40 µmol) was first
swelled in DCM (3 mL). Then, a solution of iodine (81.2 mg, 320 µmol) in DCM (3 mL)
was added and allowed to agitate in a 10 mL vial at room temperature for 2 hours. The
reaction solution was filtered and the resin was washed with DMF (10 x 1 mL) and DCM
(10 x 1 mL). The resulting resin was subjected to 300 µL of the cleavage mixture
TFA:TIPS:H2O (95:2.5.2.5) for 3 hours. Finally, the TFA solutions were collected,
concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The resulting pellet was dissolved
in 10% MeCN:Water in presence of 0.05%TFA and purified via RP-HPLC-MS using a
Semi-Preparative Thermo Scientific Hypersil Gold C8 column at a flow rate of 5 mL/min
with 5–40% MeCN/H2O gradient for 15 minutes to yield the pure peptide in 59% overall
yield (11.9 mg). m/z ES calc’d for peptide 4.7.F [(C52H78N20O15S4 + 2)/2]+: 676.78;
observed: 676.60. m/z ES calc’d for [(C52H78N20O15S4 + 3)/3]+: 451.52; observed: 451.35.
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a-conotoxin ImI (4.7.F); [(M+3)/3]+
PDA 254 nm

Figure 4.13 Analytical Column PDA of crude a-conotoxin ImI 4.7.F. Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min.

PDA 254 nm

a-conotoxin ImI (4.7.F); [(M+3)/3]+
Figure 4.14 Analytical Column PDA of pure a-conotoxin ImI 4.7.F. Gradient: 5-40% MeCN/H2O + 1% HCOOH
over 15 min. Retention time 10.01 min
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Figure 4.15 ES-MS spectrum for pure a-conotoxin ImI 4.7.F at retention time 10.01 min
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SPPS of Linear Peptide 4.8.A. The standard Fmoc-SPPS protocol described was used
to synthesize peptide 4.8.A on Rink Amide linker-Gly-Gly-Gly-ChemMatrix resin. The
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the
resin was subjected general ammonia cleavage protocol and the resulting crude product
was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via RpHPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin:
0.10 mmol/g. m/z ES calc’d for peptide 4.8.B [(C76H116N24O26S4 + 2)/2]+: 956.07;
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observed: 955.80. m/z ES calc’d for [(C76H116N24O26S4 + 3)/3]+: 637.72; observed:
637.60.

Linear peptide (4.8.A); [(M+3)/3]+
Linear peptide-1Allocam; [(M+3)/3]+
Linear peptide-2Allocam; [(M+3)/3]+
PDA 214 nm

Figure 4.16 Analytical Column PDA for linear peptide 4.8.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 17.35 min

Figure 4.17 ES-MS spectrum for linear peptide 4.8.A at retention time 17.35 min
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General Procedure for Table 4.4. For each of the test reactions, the resin 4.8.A (10 mg,
3 µmol) was first swelled in DMF (500 µL). Then, a freshly prepared solution of
TFA:TIPS:DCM (5:5:90) was added and the reaction mixture was agitated at room
temperature for 5 x 1 min. About 1 – 2 drops of more TIPS were added during the reaction
until the orange-yellow color disappeared in the reaction mixture. The resulting TFA
solution was filtered and the resin was washed with DCM (3 x 1 mL). After that, the resin
was subjected to the stated amount of Ellman’s Reagent in DMF for the stated amount of
time until the resin color changed from peach to yellow. Finally, the reaction solution was
filtered and the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). In order to
confirmed the total Trt group removal, the resulting peptide was retreated with a solution
of TFA:TIPS:DCM (5:5:90) for 5 x 1 min and re-subjected to the stated amount of Ellman’s
Reagent in DMF. If the resin color changes to peach-orange color upon addition of
Ellman’s reagent, the reaction was agitated further until the resin color changed from
peach to yellow. This procedure was repeated until no color change was observed. When
no color change was observed, the solution of Ellman’s reagent added was filtered and
the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). The resulting resin was
subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 1 hour. The
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resulting the TFA solutions were collected, concentrated under a constant stream of air,
crashed out with cold diethyl ether, centrifuged, and decanted to yield the crude peptide.
The resulting pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This
solution was analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil
Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30
minutes. . m/z ES calc’d for peptide 4.8.D [(C76H114N24O26S4 + 2)/2]+: 955.06; observed:
954.85. m/z ES calc’d for [(C76H114N24O26S4 + 3)/3]+: 637.04; observed: 636.95. m/z ES
calc’d for peptide 4.8.E [(C90H122N26O34S6+ 3)/3]+: 769.16; observed: 769.00.

Entry 1. A solution of Ellman’s reagent (1.2 mg, 3 µmol) in DMF (1.0 mL) was added and
the reaction was agitated for 2 hours

Oxidized pdt (4.8.D); [(M+3)/3]+
Oxidized pdt – 1Allocam; [(M+3)/3]+
Oxidized pdt – 2Allocam; [(M+3)/3]+
Byproduct (4.8.E); [(M+3)/3]+

PDA 214 nm

Figure 4.18 Analytical Column PDA for reaction optimization; Table 4.4 – Entry 1
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Entry 2. A solution of Ellman’s reagent (0.3 mg, 0.75 µmol) in DMF (1.0 mL) was added
and the reaction was agitated for 10 hours.

Oxidized pdt (4.8.D); [(M+3)/3]+
Oxidized pdt – 1Allocam; [(M+3)/3]+
Oxidized pdt – 2Allocam; [(M+3)/3]+
Byproduct (4.8.E); [(M+3)/3]+
PDA 214 nm

Figure 4.19 Analytical Column PDA for reaction optimization; Table 4.4 – Entry 2

Entry 3. A solution of Ellman’s reagent (0.15 mg, 0.375 µmol) in DMF (1.0 mL) was added
and the reaction was agitated for 16 hours.

Oxidized pdt (4.8.D); [(M+3)/3]+
Oxidized pdt – 1Allocam; [(M+3)/3]+
Oxidized pdt – 2Allocam; [(M+3)/3]+
Byproduct (4.8.E); [(M+3)/3]+
PDA 214 nm
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Figure 4.20 Analytical Column PDA for reaction optimization; Table 4.4 – Entry 3
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Synthesis of a4/7-conotoxin LvIA 4.8.F. The resin 4.8.B (100 mg, 30 µmol) was first
swelled in DCM (3 mL). Then, a solution of iodine (60.9 mg, 240 µmol) in DCM (400 µL)
was added and allowed to agitate in a 10 mL vial at room temperature for 6 hours. The
reaction solution was filtered and the resin was washed with DMF (10 x 1 mL) and DCM
(10 x 1 mL). The resulting resin was subjected to 300 µL of the cleavage mixture
TFA:TIPS:H2O (95:2.5.2.5) for 2 hours. Finally, the TFA solutions were collected,
concentrated under a constant stream of air, crashed out with cold diethyl ether,
centrifuged, and decanted to yield the crude peptide. The resulting pellet was dissolved
in 10% MeCN:Water in presence of 0.05%TFA and purified via RP- HPLC-MS using a
Semi-Preparative Thermo Scientific Hypersil Gold C8 column at a flow rate of 5 mL/min
with 10–50% MeCN/H2O gradient for 15 minutes to yield the pure peptide in 24% overall
yield (5.6 mg). m/z ES calc’d for a4/7-conotoxin LvIA [(C66H98N22O22S4 + 2)/2]+: 840.94;
observed: 840.80; m/z ES calc’d for [(C66H98N22O22S4 + 3)/3]+: 560.96; observed: 560.85
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a4/7-conotoxin LvIA (4.8.F); [(M+3)/3]+
PDA 214 nm

Figure 4.21 Analytical Column PDA of pure a-conotoxin LvIA 4.8.F. Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 15 min. Retention time 6.97 min

Figure 4.22 ES-MS spectrum for pure a-conotoxin LvIA 4.8.F at retention time 6.97 min
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SPPS of Linear Peptide 4.10.A. The standard Fmoc-SPPS protocol described was used
to synthesize resin 4.10.A on Rink Amide linker-Gly-Gly-Gly-ChemMatrix resin. The
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the
resin was subjected general ammonia cleavage protocol and the resulting crude product
was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via RpHPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin:
0.13 mmol/g. m/z ES calc’d for peptide 4.X.B [(C74H118N22O22S6 + 2)/2]+: 931.13;
observed: 930.85. m/z ES calc’d for [(C74H118N22O22S6 + 3)/3]+: 621.08; observed:
620.95.

Linear Peptide (4.10.B); [(M+3)/3]+
PDA 214 nm

Figure 4.23 Analytical Column PDA for linear peptide 4.10.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 21.01 min
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Figure 4.24 ES-MS spectrum for linear peptide 4.10.A at retention time 21.01 min
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Synthesis of Peptide 4.10.B. The resin 4.10.A (60 mg, 18 µmol) was first swelled in
DMF (500 µL). Then, a solution of 30% mercaptoethanol in DMF (1.0 mL) was added and
agitated at 60 ºC under microwave condition for 3 hour. The reaction solution was filtered
and the resin was washed with DMF (5 x 1 mL). To analyze the reaction 10 mg of the
resulting resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5
TFA:TIPS:H2O) for 1 hour. The resulting TFA solutions were collected, concentrated
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and
decanted to yield the crude peptide. The resulting pellet was dissolved in 10%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10–
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 4.10.B
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[(C66H102N22O22S4

+

2)/2]+:

842.96;

observed:

842.60.

m/z

ES

calc’d

for

[(C66H102N22O22S4 + 3)/3]+: 561.97; observed: 562.05.

Reduced Peptide (4.10.B); [(M+3)/3]+
PDA, 214 nm

Figure 4.25 Analytical Column PDA for Scheme 4.11 – Step 1
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Synthesis of Peptide 4.10.C. The peptide 4.10.B (50 mg, 15 µmol) was first swelled in
NMP (1 mL). Then it was subjected to a solution of Ellman’s Reagent (6.0 mg, 15 µnol)
in NMP for 30 min until the resin color changed from peach to yellow. Finally, the reaction
solution was filtered and the resin was washed with NMP (6 x 1 mL) and DCM (6 x 1 mL).
To analyze the reaction 10 mg of the resulting resin was subjected to 300 µL of the
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cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 1 hour. The resulting the TFA solutions
were collected, concentrated under a constant stream of air, crashed out with cold diethyl
ether, centrifuged, and decanted to yield the crude peptide. The resulting pellet was
dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed via
RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for
peptide 4.10.C [C66H100N22O22S4 + 1]+: 1681.90; observed: 1682.60. m/z ES calc’d for
[(C66H100N22O22S4

+

2)/2]+:

841.95;

observed:

841.75.

m/z

ES

calc’d

[(C66H100N22O22S4 + 3)/3]+: 561.63; observed: 561.50.

Monocyclic Peptide (4.10.C); [(M+3)/3]+
Monocyclic Peptide (4.10.C); [(M+2)/2]+
PDA, 214 nm

Figure 4.26 Analytical Column PDA for Scheme 4.11 – Step 2
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Synthesis of a4/7-Conotoxin LvIA 4.10.D. The resin 4.10.C (40 mg, 12 µmol) was first
swelled in DCM (1 mL). Then, a freshly prepared solution of TFA:TIPS:DCM (5:5:90) was
added and the reaction mixture was agitated at room temperature for 3 x 5 min. About 1
– 2 drops of more TIPS were added during the reaction until the orange-yellow color
disappeared in the reaction mixture. The resulting TFA solution was filtered and the resin
was washed with DCM (3 x 1 mL). After that, the resin was subjected to a solution of
Ellman’s Reagent (5.0 mg, 12 µmol) in DMF (1.5 mL) for 90 min until the resin color
changed from peach to yellow. Finally, the reaction solution was filtered and the resin was
washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). In order to confirmed the total Trt group
removal, the resulting peptide was retreated with a solution of TFA:TIPS:DCM (5:5:90)
for 2 x 5 min and re-subjected to the stated amount of Ellman’s Reagent in NMP. If the
resin color changes to peach-orange color upon addition of Ellman’s reagent, the reaction
was agitated further until the resin color changed from peach to yellow. This procedure
was repeated until no color change was observed. When no color change was observed,
the solution of Ellman’s reagent added was filtered and the resin was washed with DMF
(6 x 1 mL) and DCM (6 x 1 mL). The resulting resin was subjected to 300 µL of the
cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 2 hours. The resulting the TFA solutions
were collected, concentrated under a constant stream of air, crashed out with cold diethyl
ether, centrifuged, and decanted to yield the crude peptide. The resulting pellet was
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dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via RP- HPLCMS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1
mL/min with 10-50% MeCN/H2O gradient for 15 minutes. m/z ES calc’d for peptide 4.10.D
[C66H98N22O22S4 + 1]+: 1679.88; observed: 1682.00. m/z ES calc’d for [(C66H98N22O22S4
+ 2)/2]+: 840.94; observed: 840.75. m/z ES calc’d for [(C66H98N22O22S4 + 3)/3]+: 560.96;
observed: 560.80.

a-conotoxin LvIA (4.10.D); [(M+3)/3]+
a-conotoxin LvIA (4.10.D); [(M+2)/2]+

PDA, 214 nm

Figure 4.27 Analytical Column PDA of pure a-conotoxin LvIA 4.10.D. Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 15 min. Retention time 7.18 min

Figure 4.28 ES-MS spectrum for pure a-conotoxin LvIA 4.10.D at retention time 7.18 min
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CHAPTER 5: ON RESIN CONTROLLED FOLDING OF LINACLOTIDE

5.1 Introduction
A majority of cysteine-rich bioactive peptides contain three or more disulfide bonds.
They have higher potential as a valuable tool in biomedical and pharmaceutical research.
Duo to their small size, chemical synthesis has become the method of choice over
recombinant expression. Although there are several on-resin folding methods have been
developed to synthesize one or two disulfide bonds in peptides, successful regioselective
formation of three or more disulfide bonds with resin-bound peptides has not been
reported. This chapter details the progress towards on-resin regioselective disulfide bond
formation to access linaclotide, which contains three disulfide linkages. The synthetic
procedure demonstrates utility of Allocam group as a cysteine protecting group and
applicability of new Allocam cleavage - oxidation method and Ellman’s reagent - mediated
on-resin disulfide bond formation method to access peptides with three disulfide bonds
5.2. Linaclotide
5.2.1 Linaclotide: Structure and Bioactivity
Linaclotide is a cyclic peptide consists of 14-amino acid residues. It derived from
heat-stable enterotoxins, produced by various Escherichia coli strains which are a
frequent cause of diarrhea.174 It is a small peptide with 43% cysteine residues in the
sequence, and have three disulfide bonds in a constrained conformation. The disulfide
bonds are lies between Cys1-Cys6, Cys2-Cys10 and Cys5-Cys13 (Figure 5.1). Linaclotide
was approved by FDA in 2012 as a drug, marketed under the trade name Linzess in the
US and Mexico, and as Constella in Canada. It can be used for the treatment of
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gastrointestinal diseases such as chronic constipation (CC) and irritable bowel syndrome
(IBS) in adults.175 The drug provides well tolerated relief in patients and acts by binding
to guanylate cyclase C on the surface of intestinal epithelial cells.176,177,178 Activation of
the cyclase triggers a signaling pathway that leads to chloride and fluid secretions into
the lumen, increasing colonic transit. The location of this target in the intestine allows for
linaclotide to be orally administered.179
Figure 5.1 A. Structure of Linaclotide B. Graphical representation of Linaclotide structure
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5.2.2 Reported Chemical Synthesis of Linaclotide
Albericio and co-workers have reported synthesis studies of linaclotide.180 The
study illustrated 14 available strategies and only 2 were successful to give correctly-linked
product as the major product. The two succeeded strategies have Trt protection of all
cysteines, or Trt protection of all cysteines except StBu protection of Cys1 and Cys6 in the
sequence (Scheme 5.1). The linear peptide 5.1.A was synthesized on CTC resin and all
six cysteine residues were incorporated with Trt protecting group for the random folding
strategy (A. Scheme 5.1). First, the protected peptide was cleaved from the resin by 1%
TFA in DCM in presence of TIPS and then, it was subjected to 95% TFA condition for
total side group deprotection.
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Scheme 5.1 (A) Random folding strategy for synthesis of Linaclotide Cys(Trt)
(B) Semi-directed folding strategy for synthesis of Linaclotide Cys(StBu) and Cys(Trt)
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The resulting reduced peptide 5.1.B was oxidized by three different in-solution folding
conditions. An air oxidation was done by dissolving the peptide in buffer A (100 mM
sodium phosphate, 2 M guanidine hydrochloride, pH 7.0) and stirred under open
atmosphere at 25 ºC for 12 hours. Using the same buffer conditions, DMSO-mediated
oxidation was done with 5% DMSO and the reaction was stirred under open atmosphere
at 25 ºC for 12 hours. As the third method, the peptide was subjected to a mixture of
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buffer A:2-propanol (1:1) and 2 mM glutathione and the solution stirred at 25 ºC for 12
hours under open atmosphere. In this strategy all the oxidation procedures gave
completely oxidized peptide 5.1.C with desired disulfide bonds. A semi-regioselective
strategy was done by protecting Cys1 and Cys6 residues with StBu group (B. Scheme
5.1). After linear synthesis of the peptide 5.2.A on CTC resin, it was first treated with 20%
mercaptoethanol and 0.1 M N-methylmorpholine in DMF on resin. The resulting peptide
5.2.B was then cleaved from the resin with 1% TFA in DCM. The cleavage mixture was
poured over H2O and the organic phase was evaporated under N2 prevent an increase in
concentration of TFA, which prevent premature cleavage of Trt groups. The peptide 5.2.C
is then lyophilized and subjected to DMSO oxidation form first disulfide bond. After
purifying the mono cyclic peptide 5.2.D, it was re-subjected to DMSO oxidation to form
two remaining disulfide bonds randomly in solution. This strategy also gave fully oxidized
product 5.2.E with correct disulfide bond conformation.
5.3 Synthesis of Linaclotide using On-resin Regioselective Folding Method
After analyzing both random and semi-regioselective strategies reported for
linaclotide synthesis, we evaluated few on-resin regioselective folding methods to access
correct disulfide bond pattern in for linaclotide. The findings form Albericio’s work,7 such
as order of Cys residue pairing, best protecting group positioning for cysteine protection
were applied to design our synthesis pathways.
5.3.1 Synthesis of Linaclotide using Cys(StBu), Cys(Mmt), Cys(Allocam) and Cys(Trt)
The synthesis of a-conotoxin LvIA by the combination of a displacement method
and simultaneous Allocam removal and oxidation (see Chapter 02) inspired this design
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of synthesis for linaclotide (Scheme 5.2). The linear synthesis of linaclotide 5.3.A was
done on Wang resin and StBu, Mmt, Allcam and Trt was used to protect cysteine
residues.
Scheme 5.2. On-resin synthesis of Linaclotide using Cys(StBu),
Cys(Mmt), Cys(Allocam) and Cys(Trt)
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As described in Chaper 01 and Chapter 02, StBu and Mmt groups were used to form the
first disulfide bond vis a displacement method. Deprotection of Cys(StBu) was achieved
with 20% mercaptoethanol, 0.1 NMM in DMF at room temperature, after 18 hours.
Microwave heating was also tried to remove StBu group with 30% mercaptoethanol, but
significant peptide cleavage was observed. The free thiol group resulting from Cys(StBu)
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deprotection was activated with 5-Npys group by treating the peptide with excess DTNP.
To form the first disulfide bond, Mmt group needed to be removed in present of Trt group.
This was a very challenging step since both the group have slightly different TFA
tolerance. The general 1% TFA cleavage condition didn’t work for removal of Mmt group
in this substrate. When higher TFA conditions were used, Trt group was started to cleave
together with Mmt group. Therefore, we couldn’t continue the synthetic steps as planned.
Failure to remove Mmt group in presence of Trt group made this proposed synthetic route
a challenge.
5.3.2 Synthesis of Linaclotide using Cys(Allocam), Cys(Trt) and Cys(Acm)
A synthetic route using Cys(Allocam), Cys(Trt) and Cys(Acm) was designed to
access correct disulfide bonds in linaclotide (Scheme 5.3). Allocam group was used to
form the first disulfide bond by NCS oxidation. Neither Pd-DMSO based simultaneous
Allocam removal and oxidation conditions nor iodine oxidation can be used in this step.
Because from our previous studies in Chapter 02, we observed that Acm group is
sensitive to Pd-DMSO based simultaneous Allocam removal and oxidation conditions and
both Acm and Trt groups are not stable to iodine oxidation. Therefore, the choice of
oxidation method was NCS-mediated oxidation. The linear peptide 5.4.A was subjected
to NCS in DMF and it caused cleavage of not only Allocam group, but also other two
cysteine protecting group. This illustrated the sensitivity of both Trt and Acm groups
toward NCS oxidation. There was no other method for Allocam cleavage and oxidation in
presence of Trt and Acm groups, and therefore, this proposed synthetic design also failed
to access desired selectivity in disulfide bond formation .
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Scheme 5.3. On-resin synthesis of Linaclotide using Cys(Allocam),
Cys(Trt) and Cys(Acm)
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5.3.3 Synthesis of Linaclotide using Cys(StBu), Cys(Allocam) and Cys(Trt)
After the discovery of Ellman’s reagent as a mild oxidant to form on-resin disulfide
bonds in reduced peptides (see chapter 04), a new synthetic route was designed using
combination of Cys(StBu), Cys(Allocam) and Cys(Trt) groups (Scheme 5.4). Linear
synthesis of the peptide 5.5.A was done on Wang resin using StBu, Allocam and Trt to
protect cysteine residues. First, optimized Cys(StBu) deprotection condition reported in
Albericio and co-workers’ studies,7 was applied to remove StBu groups in the peptide.
The peptide was treated with 20% mercaptoethanol, 0.1 NMM in DMF for 18 hours and
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the resulting free thiols in the peptide 5.5.B were subjected to 1.0 equivalent of Ellman’s
reagent in DMF to form the first disulfide bond.
Scheme 5.4. On-resin regioselective synthesis of Linaclotide using Cys(StBu),
Cys(Trt) and Cys(Allocam)
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The reaction was monitors by color change of the resin, from dark peach-orange to yellow.
After 3 hours, when the resin color changed to yellow, reagents were filtered off and the
resin was washed thoroughly with DMF and DCM. With 1.0 equivalent of Ellman’s reagent
the mono-cyclic peptide 5.5.C was obtained with zero by products. Next, the mono-cyclic
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peptide 5.5.C was subjected to Pd-DMSO based simultaneous Allocam removal and
oxidation conditions and the second disulfide bond formation 5.5.D was observed in 7
hours. Thereafter, the Cys(Trt) deprotection was done with 5% TFA in DCM using TIPS
as the scavenger to get free cysteine residues. Finally, another Ellman’s reagent-based
on-resin oxidation was done to get the fully folded product 5.5.E. In this last step, 1.0
equivalent of Ellman’s reagent in DMF was used and the reaction was run for 5 hours
until the resin color changes from dark peach-orange to yellow.
5.4 Summary and Future Directions
Different on-resin regioselective methods to access three disulfide bonds in
peptides were evaluated using linaclotide as a target peptide. Out of the three proposed
synthetic designs, orthogonal combination of StBu, Allocam and Trt groups allowed
regioselective disulfide bond formation to access desired disulfide pattern. To our
knowledge, this is the first on-resin regioselective synthesis of a peptide with more than
two bonds.
Several modifications could be done to improve this on-resin regioselective
synthesis of linaclotide. As iodine-mediated simultaneous Allocam removal and oxidation
is more effective (see chapter 03) than Pd-DMSO mediated Allocam removal and
oxidation, the Allocam-mediated disulfide bond formation step (Step 3) in linaclotide
synthesis could be done using iodine oxidation. In order to perform an iodine oxidation on
Allocam group, change in the positioning of cysteine protecting groups should be done in
the synthetic design. As Allocam group is sensitive to iodine oxidation, Trt group removal
with 5% TFA in DCM followed by Ellman’s oxidation should be done to form the second
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disulfide bond. Allocam protection should be done for Cys5-Cys13 residues and iodinemediated simultaneous Allocam removal and oxidation could be done to form the final
disulfide bond. In addition, Ellman’s oxidation could be done in NMP to increase the rate
of disulfide formation (see chapter 4). The higher density of both cysteine residues and
side-chain protecting groups in linaclotide made the on-resin synthesis a very challenging
process. In order to have higher swelling power of the resin, which increases the reactivity
of peptide (see chapter 2 and 3), the synthesis could be rerun on ChemMatric resin with
Wang linker. Moreover, to increase the flexibility of peptide backbone and get effective
folding of the peptide, a long linker could be introduce between the resin and the peptide,
similar to the modification done in the synthesis of a4/7-conotoxin LvIA (see chapter 3).
5.5 Methods and Material
5.5.1 General Information
Unless otherwise specified, all commercially available reagents were purchased from
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF,
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial
solvent purification system (2 columns of alumina) and used without further drying.
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL,
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room
temperature. All yields refer to chromatographically and spectroscopically pure products.
All HPLC analyses and purifications were performed on a Custom Reverse Phase
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Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle
between analytical and semi-preparative columns. This instrument has a photodiode
array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O)
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific
Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based
on the final loading.
SPPS General Information. Solid-phase peptide synthesis was executed on a Biotage
Isolera+ semi-automated synthesizer with microwave heating.
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL)
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The
solvent was then removed over 1 m followed by two DMF washes (DMF was added
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of
solvent (over 2 m)).
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv)
in DMF was made immediately prior to addition to the reaction vial containing the
resin. Once the solution was added, the suspension was heated to 75 ºC (except for
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed
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with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m).
•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF.
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF
washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200
RPM for 1 m, solvent removal was at a rate of 2 m).
•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times.
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL).
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the
lyophilizer overnight for drying.
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF
(5 x 3 mL).
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed
based on amount of Fmoc group.
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min,
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the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF
was added to it and allowed to vortex in the peptide synthesizer at room temperature for
10 min. The resulting filtrate was collected to the same tube and the deprotected resin
was washed with DMF (4 x 1.75 ml).
Sample preparation for UV analysis – From the collected ”deprotection solution” above,
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF.
The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF
blank using a UV spectrometer with 1 cm cuvette.
5.5.2 Experimental Procedures and Spectroscopic Data
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SPPS of Linear Peptide 5.5.A. The standard Fmoc-SPPS protocol described was used
to synthesize peptide 5.5.A on pre-loaded Wang resin 5.5 A’ (500 mg, 0.15 mmol). The
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the
resin was subjected 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 3
hours. The resulting the TFA solutions were collected, concentrated under a constant
stream of air, crashed out with cold diethyl ether, centrifuged, and decanted to yield the
crude peptide. The resulting pellet was dissolved in 10% MeCN:Water in presence of
0.05%TFA. This solution was analyzed via RP-HPLC-MS using an analytical Thermo
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O
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gradient for 30 minutes. Final loading of the resin: 0.10 mmol/g. m/z ES calc’d for peptide
5.5.A [(C77H115N17O25S8 + 1]+: 1935.34; observed: 1936.50. m/z ES calc’d for
[(C77H115N17O25S8 + 2)/2]+: 968.67; observed: 968.45.

Linear Peptide (5.5.A); [(M+2)/2]+
Linear Peptide – 1Allocam; [(M+2)/2]+
PDA 214 nm

Figure 5.2. Analytical Column PDA for linear peptide 5.5.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH
over 30 min. Retention time 25.34 min

Figure 5.3. ES-MS spectrum for linear peptide 5.5.A at retention time 25.34 min
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tBu tBu
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Wang

Trt
STrt
STrt
SAllocam SAllocam

5.5.A

5.5.B

Synthesis of Reduced Peptide 5.5.B. The peptide 5.5.A (200 mg, 60 µmol) was first
swelled in DMF (3 mL). Then, a solution of 20% mercaptoethanol, 0.1 M NMM in DMF
(5.0 mL) was added and agitated at room temperature for 18 hours. The reaction solution
was filtered and the resin was washed with DMF (5 x 3 mL). To analyze the reaction 10
mg of the resulting resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5
TFA:TIPS:H2O) for 1 hour. The resulting TFA solutions were collected, concentrated
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and
decanted to yield the crude peptide. The resulting pellet was dissolved in 10%
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10–
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 5.5.B
[(C69H99N17O25S6

+

1]+:

1759.01

observed:

1759.80.

[(C69H99N17O25S6 + 2)/2]+: 880.50; observed: 880.20.

m/z

ES

calc’d

for

214

Product (5.5.B); [(M+2)/2]+
Product – 1Allocam; [(M+2)/2]+
PDA 214 nm

Figure 5.4. Analytical Column PDA for Scheme 5.4. Step 01
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1.0 equiv. Ellman’s Reagent
in DMF, 3 h
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tBu tBu
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CCEYCCNPACTGCY

Wang

Trt
STrt
STrt
SAllocam SAllocam
5.5.C

Synthesis of Mono Cyclic Peptide 5.5.C. The peptide 5.5.B (200 mg, 60 µmol) was first
swelled in DMF (3 mL). Then it was subjected to a solution of Ellman’s Reagent (23.70
mg, 60 µmol) in DMF (3 mL) for 16 hours until the resin color changed from dark peachorange to yellow. Finally, the reaction solution was filtered and the resin was washed with
DMF (6 x 3 mL) and DCM (6 x 3 mL). To analyze the reaction 10 mg of the resulting resin
was subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 3 hours.
The resulting the TFA solutions were collected, concentrated under a constant stream of
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air, crashed out with cold diethyl ether, centrifuged, and decanted to yield the crude
peptide. The resulting pellet was dissolved in 10% MeCN:Water in presence of
0.05%TFA. This solution was analyzed via RP-HPLC-MS using an analytical Thermo
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O
gradient for 30 minutes. m/z ES calc’d for peptide 5.5.C [(C69H97N17O25S6 + 2)/2]+:
879.49; observed: 879.30.

Product (5.5.C); [(M+2)/2]+
Product – 1Allocam; [(M+2)/2]+
PDA 214 nm

Figure 5.5. Analytical Column PDA for Scheme 5.4. Step 02
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Wang
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Synthesis of Bicyclic Peptide 5.5.D. First, the resin 5.5.C (100 mg, 30 µmol) was
swelled in DMF (3 mL). A solution of Pd(OAc)2 (20.2 mg, 90 µmol) in 5% AcOH/DMSO
(3.75 mL) solution was added, and then the NMM (113 µL) was added. The cartridge/vial
was capped on the top, attached to a magnetic stir bar retriever using a rubber band, and
agitated for 7 hours. The reaction was filtered, and the resin was washed successively
with with DMF (3 x 2 min), CH2Cl2 (3 x 2 min), 0.2 M sodium diethyldithiocarbamate in
DMF (3 x 30 min), MeOH (3 x 1 min), DMF (5 x 1 min) and CH2Cl2 (3 x 1 min). *Note:
resin changes from dark orange/brownish to yellowish/tan. To analyze the reaction 10 mg
of the resulting resin was subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O
(95:2.5.2.5) for 3 hours. The resulting the TFA solutions were collected, concentrated
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and
decanted to yield the crude peptide. The resulting pellet was dissolved in 10%
MeCN:Water in presence of 0.05%TFA. This solution was analyzed via RP-HPLC-MS
using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min
with 10-40% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 5.5.D
[C59H81N15O21S6

+

1]+:

1528.74;

observed:

1528.45.

[(C59H81N15O21S6 + 2)/2]+: 765.37; observed: 765.20.

m/z

ES

calc’d

for

217

Bicyclic Product (5.5.D); [(M+2)/2]+
PDA 214 nm

Figure 5.6 Analytical Column PDA for Scheme 5.4. Step 03

S
tBu
tBu

S
H

tBu tBu
14

CCEYCCNPACTGCY
S

Trt
STrt

S
5.5.D

STrt

Wang
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3) TFA:TIPS:H2O (95:2.5:2.5), 3 h
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Synthesis of Linaclotide 5.5.F. The resin 5.5.E (90 mg, 27 µmol) was first swelled in
DMF (3 mL). Then, a freshly prepared solution (500 µL) of TFA:TIPS:DCM (5:5:90) was
added and the reaction mixture was agitated at room temperature for 5 x 1 min. About 1
– 2 drops of more TIPS were added during the reaction until the orange-yellow color
disappeared in the reaction mixture. The resulting TFA solution was filtered and the resin
was washed with DCM (3 x 5 mL). After that, the resin was subjected to Ellman’s Reagent
(10.8 mg, 27 µmol) in DMF (2 mL) for 5 hours until the resin color changed from peach to
yellow. Finally, the reaction solution was filtered and the resin was washed with DMF (6
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x 3 mL) and DCM (6 x 3 mL). In order to confirmed the total Trt group removal, the
resulting peptide was retreated with a solution (500 µL) of TFA:TIPS:DCM (5:5:90) for 5
x 1 min and re-subjected to the same amount of Ellman’s Reagent in DMF. No color
change was observed, the solution of Ellman’s reagent added was filtered and the resin
was washed with DMF (6 x 3 mL) and DCM (6 x 3 mL). The resulting resin was subjected
to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 1 hour. The resulting the
TFA solutions were collected, concentrated under a constant stream of air, crashed out
with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. The resulting
pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was
analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8
column at a flow rate of 1 mL/min with 15-45% MeCN/H2O gradient for 20 minutes. m/z
ES calc’d for peptide 5.5.E [(C59H79N15O21S6 + 2)/2]+: 764.37; observed: 764.20.

Product isotope; [(M+2)/2]+
Fully folded Linaclotide (5.X.E); [(M+2)/2]+
PDA, 214 nm

Figure 5.7 Analytical Column PDA for crude Linaclotide 5.5.E; Gradient: 15-45% MeCN/H2O + 1% HCOOH
over 20 min. Retention time 11.89 min
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Figure 5.8 ES-MS spectrum for linear peptide 5.5.E at retention time 11.89 min
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CHAPTER 6: SUMMARY
Peptide – based pharmaceuticals are becoming increasingly important over
traditional small molecule pharmaceuticals. This is mainly because of the greater
specificity, potency and lower toxicity profile of the disulfide-rich mini proteins. Disulfide
linkages play an important role to improve the thermal, chemical, and enzymatic stability
of these polypeptides. The synthesis of disulfide – containing mini-peptides become a
challenge in field of peptide chemistry, and hence, there is a demand for broadly
applicable methods to construct correct disulfide connectivity in bioactive peptides. This
dissertation detailed development of efficient deprotection methods for Allocam group and
utility of Allocam as cysteine protecting group to form on-resin disulfide bonds in more
complex peptides. In addition, oxidation potential of Ellman’s reagent to access on-resin
disulfide bonds was evaluated along with its interesting colorimetric behavior.
First, little-used Allocam group was studied for better p-allyl deprotection
conditions to overcome limitations which prevent its general use in the field. A one-pot
approach with Pd-mediated deprotection-oxidation was developed to form disulfide bonds
on resin. As an on-resin method, it minimizes the number of time consuming purification
steps and the reaction can be done with bench-stable reagents. The utility of the method
was evaluated by solid phase synthesis and folding of the carboxy-oxytocin. However,
detailed investigations into the mechanism of Pd-DMSO mediated simultaneous Allocam
removal and oxidation needed to be done.
In addition to oxytocin, a4/7-conotoxin LvIA was synthesized to demonstrated the
applicability of novel Pd-DMSO mediated simultaneous Allocam removal and oxidation
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condition to access more complex disulfide – rich peptides. Two routes were introduced
based on position of the Allocam protected cysteines and selection of compatible other
cysteine protecting groups for each of the synthetic routes. In addition to Pd-DMSO based
simultaneous on-resin Allocam removal and oxidation condition, both I2 oxidation and
NCS oxidation can be used in on-resin Allocam removal and oxidation. Selection of the
best method is highly depend on design of synthetic protocol.
The potential of Ellman’s reagent as a colorimetric and mild oxidizing agent to form
on-resin disulfide bonds in peptides was evaluated. The reaction procedure is simple, no
complex time consuming reaction set up is needed and the reaction can be monitored
easily by observing the color change of the resin. The colorimetric behavior of Ellman’s
reagent can be seen both in DMF and NMP. Ellman’s reagent – mediated disulfide bond
formation in DMF is relatively slower while it shows faster reaction rates in NMP. The
insight of colorimetric behavior of Ellman’s reagent in disulfide bond formation process
needed to be further investigated.
The new Allocam cleavage - oxidation method and Ellman’s reagent - mediated
on-resin disulfide bond formation method was carefully combined in a synthetic protocol
to access linaclotide, which contains three disulfide bonds. For best of our knowledge,
this is the first on-resin synthesis of three disulfide linkages.
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ABSTRACT
PROGRESS TOWARD CONTROLLED DISULFIDE FORMATION TO ACCESS
NEUROACTIVE CONOTOXINS
by
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Advisor: Dr. Jennifer L. Stockdill
Major: Chemistry (Organic)
Degree: Doctor of Philosophy
Conotoxins are mini proteins isolated from marine snails of the Conus family. They
have shown activity in the selective inhibition of various ion channels. Therefore, they
present an opportunity as possible therapy for a myriad of neurological ailments. The
synthesis of conotoxins would enable both biological studies and evaluation of these
structures as lead targets for therapeutics. However, establishing a reliable method to
consistently folding disulfide rich proteins, including conotoxin, into their native structure
has been challenging over few decades. In this research project, it is shown the progress
towards a mild, efficient, and broadly applicable methods to generate the desired pattern
of disulfide linkages in synthetic polypeptides.
p-allyl chemistry mediated deprotection conditions for Allocam group was optimized
to overcome the limitations which prevent its general use in the field. A one-pot approach
with Pd-mediated deprotection-oxidation was developed to form disulfide bonds on resin.
The utility of the method was evaluated by solid phase synthesis and folding of the
carboxy-oxytocin. In addition, a4/7-conotoxin LvIA was synthesized to demonstrate the
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applicability of novel Pd-DMSO mediated simultaneous Allocam removal and oxidation
condition to access more complex disulfide – rich peptides. Two routes were introduced
based on position of the Allocam protected cysteines and selection of compatible other
cysteine protecting groups for each of the synthetic routes.
The potential of Ellman’s reagent as a colorimetric and mild oxidizing agent to form
on-resin disulfide bonds in peptides was evaluated. The reaction procedure is simple, no
complex time consuming reaction set up is needed and the reaction can be monitored
easily by observing the color change of the resin. The colorimetric behavior of Ellman’s
reagent in different solvents were examined. Ellman’s reagent – mediated disulfide bond
formation in DMF is relatively slower while it shows faster reaction rates in NMP. This new
colorimetric method was utilized in the synthesis of a4/7-conotoxin LvIA and a-conotoxin
ImI and obtained excellent overall yields.
For the first time, a regioselective on-resin synthesis of three disulfide linkages was
achieved by synthesizing linaclotide with careful orthogonal combination of the new
Allocam cleavage - oxidation method and Ellman’s reagent - mediated on-resin disulfide
bond formation method.
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